pioglitazone has been researched along with Insulin Resistance in 665 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 9.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| "Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function." | 9.41 | In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. ( Bell, DSH; Jerkins, T, 2023) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 9.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| "In the Insulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo." | 9.27 | Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. ( Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Tanne, D; Viscoli, CM; Young, LH, 2018) |
| "The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack." | 9.27 | Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( Conwit, R; Dearborn, J; Furie, KL; Gorman, M; Inzucchi, SE; Kamel, H; Kasner, SE; Kernan, WN; Lovejoy, AM; Viscoli, CM; Yaghi, S; Young, LH, 2018) |
| "The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients." | 9.27 | Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, A; Pfau, SE; Schwartz, GG; Spatz, ES; Viscoli, CM; Young, LH, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To determine whether, among patients with an ischemic stroke or transient ischemic attack and insulin resistance, those at higher risk for future stroke or myocardial infarction (MI) derive more benefit from the insulin-sensitizing drug pioglitazone hydrochloride compared with patients at lower risk." | 9.24 | Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. ( Conwit, R; Dearborn, JL; Fayad, P; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kent, DM; Kernan, WN; Stuart, A; Viscoli, CM; Young, LH, 2017) |
| "Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event." | 9.24 | Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, AM; Pfau, SE; Schwartz, GG; Viscoli, CM; Young, LH, 2017) |
| "Pioglitazone (Pio) is known to improve insulin sensitivity in skeletal muscle." | 9.24 | Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function. ( Bajpeyi, S; Conley, KE; Gamboa, C; Jubrias, SA; Murray, K; Newcomer, BR; Pasarica, M; Sereda, O; Smith, SR; Sparks, LM, 2017) |
| "Efficacy [myocardial infarction (MI) or recurrent stroke] new-onset diabetes) and adverse outcomes (oedema, weight gain, heart failure and bone fracture) were examined for subjects assigned to pioglitazone or placebo within strata defined by mode dose of study drug taken (i." | 9.22 | Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. ( Abdul-Ghani, M; Dandona, P; DeFronzo, R; Furie, K; Inzucchi, SE; Kernan, WN; Spence, JD; Viscoli, C; Young, LH, 2022) |
| " The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease." | 9.22 | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. ( Adams, HP; Berger, L; Brass, LM; Carolei, A; Clark, W; Conwit, R; Coull, B; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Kleindorfer, D; Lovejoy, AM; O'Leary, JR; Parsons, MW; Peduzzi, PN; Ringleb, P; Schwartz, GG; Sen, S; Spence, JD; Tanne, D; Viscoli, CM; Wang, D; Winder, TR; Young, LH, 2016) |
| "The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone." | 9.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| "The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA)." | 9.22 | Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. ( Dagogo-Jack, S; Furie, KL; Gorman, M; Inzucchi, SE; Ismail-Beigi, F; Kernan, WN; Korytkowski, MT; Lovejoy, AM; Pratley, RE; Schwartz, GG; Viscoli, CM; Young, LH, 2016) |
| "Pioglitazone in individuals with MetS induces a potent decrease in plasma ceramides, and some of the changes correlate with changes in insulin resistance and adiponectin levels." | 9.20 | Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. ( Anuwe, E; Blankfard, MB; Gordillo, R; Hicks, J; Holland, WL; Lingvay, I; Lopez, X; Scherer, PE; Warshauer, JT, 2015) |
| "While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes." | 9.20 | Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. ( Furukawa, Y; Hattori, N; Kawamori, R; Miyamoto, N; Nakahara, T; Nakamura, S; Okuma, Y; Shimura, H; Tanaka, R; Tanaka, Y; Tomizawa, Y; Ueno, Y; Urabe, T; Watada, H; Yamashiro, K, 2015) |
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 9.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 9.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 9.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| " Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA." | 9.19 | Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. ( Brass, LM; Carolei, A; Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Parsons, MW; Peduzzi, PN; Ringleb, PA; Schwartz, GG; Spence, JD; Tanne, D; Viscoli, CM; Young, LH, 2014) |
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 9.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone." | 9.16 | Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012) |
| "Pioglitazone has been shown to reduce the occurrence of fatal and nonfatal myocardial infarction (MI) in type 2 diabetes mellitus (DM)." | 9.16 | Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus. ( Iwasaka, T; Miyasaka, Y; Murakawa, K; Sugiura, T; Tsujimoto, S; Yokoe, H; Yoshida, S; Yuasa, F; Yuyama, R, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 9.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 9.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| " We evaluated whether the peroxisome proliferator-activated receptor-γ agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity." | 9.15 | Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. ( Bopp, C; Cade, WT; Hubert, S; Laciny, E; Lassa-Claxton, S; Mondy, KE; Overton, ET; Reeds, DN; Yarasheski, KE, 2011) |
| "Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance." | 9.15 | Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011) |
| "We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance." | 9.15 | Pioglitazone for diabetes prevention in impaired glucose tolerance. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D; Williams, K, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 9.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| "Insulin sensitivity indices (SI indices) were obtained by analyzing fasting glucose and insulin concentration with homeostasis model assessment (HOMA), the glucose and insulin profiles after 75 g dextrose oral glucose tolerance tests (OGTT, Matsuda-Index) and euglycemic hyperinsulinemic clamp (m-value) in a double-blind placebo-controlled study in 60 patients with arterial hypertension before and after 4 months treatment with Pioglitazone 45 mg (PIO45)." | 9.14 | Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. ( Bär, F; Franke, S; Konrad, T; Schneider, F; Vossler, S, 2009) |
| "To assess insulin sensitivity in CAH patients and the effect of pioglitazone treatment on insulin sensitivity in CAH patients." | 9.14 | Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. ( Hermus, AR; Kroese, JM; Mooij, CF; Tack, CJ; van der Graaf, M, 2009) |
| "The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes." | 9.14 | Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. ( Cha, BS; Choi, SH; Han, SJ; Hur, KY; Kang, ES; Kim, DJ; Kim, MS; Kim, SI; Kim, YS; Kwak, JY; Lee, HC, 2010) |
| " The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study." | 9.14 | Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010) |
| "Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease." | 9.14 | Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010) |
| "Insulin sensitivity, GH, adiponectin, and IGF-I significantly increased during pioglitazone treatment, whereas alloTHF/THF levels significantly decreased." | 9.14 | A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. ( Andersen, M; Bennett, P; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Jensen, LT, 2009) |
| " The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites." | 9.13 | Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. ( Andersen, NR; Beck-Nielsen, H; Glintborg, D; Hansen, BF; Højlund, K; Wojtaszewski, JF, 2008) |
| "We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)." | 9.13 | Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008) |
| "Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus." | 9.13 | Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 9.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| " Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3." | 9.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn)." | 9.12 | Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. ( Bloedon, LT; Chittams, J; Duffy, D; Rader, DJ; Reilly, MP; Samaha, FF; Soffer, D; Szapary, PO; Wolfe, ML, 2006) |
| "We compared the effects of diet/exercise induce weight loss versus pioglitazone on lipoprotein particle characteristics in non-diabetic, insulin resistant adults to determine whether the responses and potential mechanisms for improvement are similar between these two insulin sensitizing regimens." | 9.12 | Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size. ( Jensen, MD; LaForge, R; Otvos, JD; Shadid, S, 2006) |
| " Thus, the aim of our study was to investigate the effect of pioglitazone on endothelial dysfunction, insulin sensitivity, and glucose control in newly detected type 2 diabetic patients with CAD." | 9.12 | Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. ( Sourij, H; Wascher, TC; Zweiker, R, 2006) |
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 9.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| "We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo." | 9.12 | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006) |
| "We investigated the effect of pioglitazone in comparison with and in combination with simvastatin on insulin resistance, plasma adiponectin, postprandial plasma glucose, insulin, and intact proinsulin levels in a nondiabetic population at cardiovascular risk." | 9.12 | Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. ( Baurecht, W; Forst, T; Hanefeld, M; Hohberg, C; Karagiannis, E; Koehler, C; Lübben, G; Marx, N; Pfützner, A; Weber, M, 2007) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 9.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| " We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 9.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
| " This work examines the effect of pioglitazone on 24-hour ambulatory BP monitoring in patients with type 2 diabetes and difficult-to-control hypertension." | 9.12 | Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. ( de Rivas, B; Fernández, C; Fernández-Cruz, A; Luque, M; Martell, N, 2007) |
| "Pioglitazone treatment significantly reduced the insulin response to OGTT and improved the insulin sensitivity indices (P < 0." | 9.11 | Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. ( Apa, R; Costantini, B; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Suriano, R, 2004) |
| "To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000)." | 9.11 | Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. ( Gilmore, KJ; Glazer, NB; Johns, D; Tan, MH; Widel, M, 2004) |
| "The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year." | 9.11 | Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004) |
| "This study compared the effects of 52 weeks' treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes." | 9.11 | Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. ( Clausen, J; Eriksson, JW; Halse, J; Herz, M; Johns, D; Konkoy, CS; Madsbad, S; Strand, J; Tan, MH, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "Short-term treatment with pioglitazone improved insulin sensitivity in the absence of any changes in circulating NEFA or lipid levels." | 9.11 | Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. ( Gogg, S; Hammarstedt, A; Jansson, PA; Smith, U; Sopasakis, VR, 2005) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 9.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "Despite their comparable glycaemic effects in patients with Type 2 diabetes mellitus (T2DM), pioglitazone and metformin may have different effects on insulin sensitivity because they have different mechanisms of action." | 9.11 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. ( Johns, D; Laakso, M; Mariz, S; Richardson, C; Roden, M; Tan, MH; Urquhart, R; Widel, M, 2005) |
| "The present findings demonstrate that pioglitazone improves LV diastolic function without LV mass regression in hypertensive patients in proportion to the amelioration of insulin resistance." | 9.11 | Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. ( Funahashi, T; Hiuge, A; Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Kihara, S; Suzuki, K; Suzuki, M; Takamisawa, I; Takiuchi, S; Yoshimasa, Y, 2005) |
| " Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion." | 9.11 | Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. ( Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Støving, RK; Veldhuis, JD, 2005) |
| "The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia." | 9.11 | Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. ( Hiuge, A; Horio, T; Kawano, Y; Suzuki, K; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2005) |
| "Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts its effect primarily by decreasing hepatic glucose output." | 9.10 | Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. ( Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT, 2003) |
| "The aim of this study was to determine the effectiveness of pioglitazone compared with placebo for improving insulin sensitivity among nondiabetic patients with a recent transient ischemic attack (TIA) or nondisabling ischemic stroke and impaired insulin sensitivity." | 9.10 | Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. ( Brass, LM; Bravata, DM; Horwitz, RI; Inzucchi, SE; Kernan, WN; McVeety, JC; Shulman, GI; Viscoli, CM, 2003) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 9.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 9.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| " We assessed the effects of pioglitazone versus diet and exercise on fat distribution and the relationship between fat distribution and insulin sensitivity in upper body obesity." | 9.10 | Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. ( Jensen, MD; Shadid, S, 2003) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| " Use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio 0." | 8.95 | Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. ( Lee, M; Liao, HW; Lin, CH; Ovbiagele, B; Saver, JL, 2017) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 8.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 8.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| "We explored the cascade effects of a high fat-carbohydrate diet (HFCD) and pioglitazone (an anti-diabetic therapy used to treat type 2 diabetes mellitus (T2DM)) on lipid profiles, oxidative stress/antioxidant, insulin, and inflammatory biomarkers in a rat model of insulin resistance." | 8.02 | The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance. ( Al-Muzafar, HM; Alshehri, FS; Amin, KA, 2021) |
| "The results showed significant improvement in the insulin sensitivity of pioglitazone-treated mice as manifested by significant reduction in the insulin resistance index." | 8.02 | Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. ( El-Fayoumi, S; Fahmy, A; Ibrahim, I; Mahmoud, A; Mansour, R, 2021) |
| "Our study aimed to investigate the effect of pioglitazone (PIO) on the obesity-associated metabolic effects and whether this effect is associated with modulation of catechol O-methyl transferase (COMT) expression in the high fat diet (HFD) induced obese rats." | 7.96 | Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats. ( Abd Elaziz, AI; Abulsoud, AI; El-Shafey, M; Elsadek, BEM; Hegazy, M; Salama, SA, 2020) |
| "This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients." | 7.96 | Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. ( Sun, Y; Xie, J; Yu, Q, 2020) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 7.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| " Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has been applied to enhance insulin sensitivity." | 7.88 | Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis. ( Chen, IC; Chen, LW; Fu, MH; Hung, CY; Liu, WC; Tain, YL; Wu, CW; Wu, KLH, 2018) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 7.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "The findings suggest that LPS challenge exacerbates IR in db/db mice by altering the expression of genes in WAT involved in adipogenesis and inflammation, which is effectively controlled by pioglitazone treatment." | 7.85 | Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. ( Chatterjee, A; Jain, MR; Malik, U; Mohapatra, J; Nagar, J; Ramachandran, B; Sharma, M, 2017) |
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 7.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| "In this study, the cellular model of insulin resistance was used to investigate the mechanisms involved in the endothelial protective effects of pioglitazone in a vascular endothelial cell damage model." | 7.80 | The endothelial protective effects of pioglitazone on insulin resistance in endothelial cells. ( Jin, J; Kong, J; Yang, O; Zeng, H, 2014) |
| "It is insinuated that VAT is associated with late phase obesity CIDEC decrease and insulin resistance, while pioglitazone enhances CIDEC through activation of PPAR-γ, increases its expression, and decreases lipolysis, hence preventing an increase of blood sugar in mice exposed to HFD." | 7.80 | Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice. ( Ma, C; Naqvi, S; Shamsi, BH; Xiao, Y, 2014) |
| " We investigated the effect of cafeteria diet and pioglitazone on body weight, insulin resistance, and adiponectin/ghrelin levels in an experimental study on male Wistar rats." | 7.78 | A study on the short-term effect of cafeteria diet and pioglitazone on insulin resistance and serum levels of adiponectin and ghrelin. ( Bazzo, ML; Colombo, G; Colombo, MD; d'Acampora, AJ; Nogueira, CL; Schiavon, LL, 2012) |
| "To explore the adipose tissue endocrine mechanism of pioglitazone and its possible prophylactic role in insulin resistance." | 7.78 | The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance. ( Gong, Y; Li, C; Li, J; Liu, Y; Mu, Y; Pan, C; Tian, H; Xiao, Y, 2012) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 7.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 7.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| " To test this hypothesis, we analyzed long-term metabolic effects of pioglitazone and the activation of nPKC-epsilon and -theta isoforms in an animal model of the metabolic syndrome, the spontaneously hypertensive rat (a congenic SHR strain with wild type Cd36 gene) fed a diet with 60 % sucrose from the age of 4 to 8 months." | 7.76 | Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats. ( Kazdová, L; Marková, I; Mlejnek, P; Musilová, A; Pravenec, M; Šimáková, M; Zídek, V, 2010) |
| " We investigated the effects of curcumin on fructose-induced hypertriglyceridemia and liver steatosis and explored its preventive mechanisms in rats." | 7.76 | Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. ( Hu, QH; Kong, LD; Li, JM; Li, YC, 2010) |
| "The aim of this study was to evaluate the efficacy of pioglitazone on metabolic parameters in drug-naïve Japanese type 2 diabetic patients with (Diabetes Mellitus Metabolic Syndrome [DMMS] group, n = 36) and without (Diabetes Mellitus non-Metabolic Sundrome [DMNMS] group, n = 36) metabolic syndrome." | 7.76 | Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome. ( Kutoh, E, 2010) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 7.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "05) were higher on the IL/H study day than on the glycerol study day, indicating persistence of NEFA-induced insulin resistance." | 7.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| "The change in peripheral insulin sensitivity after treatment with pioglitazone and during the infusion of the lipid emulsion was the main outcome measure." | 7.74 | Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. ( Ackermans, MT; Aerts, JM; Allick, G; Groener, JE; Heijligenberg, R; Meijer, AJ; Sauerwein, HP; Serlie, MJ; Voermans, BC, 2007) |
| " Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology." | 7.74 | Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007) |
| " PPAR-gamma agonists like pioglitazone decrease insulin resistance and have been shown to reduce neointimal hyperplasia in the short-term." | 7.74 | Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. ( Desouza, CV; Gerety, M; Hamel, FG, 2007) |
| "Pioglitazone is widely used for the treatment of diabetic patients with insulin resistance." | 7.74 | Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. ( Bukhari, A; Fujisaka, S; Haruta, T; Ishizuka, K; Kanatani, Y; Kishimoto, T; Kobayashi, M; Naka, T; Urakaze, M; Usui, I, 2007) |
| "To evaluate the effects of pioglitazone on menstruation and the metabolic parameters of non-obese women of reproductive age with polycystic ovary syndrome (PCOS) and compare the effects among different subgroups of PCOS patients with different clinical presentations." | 7.74 | Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. ( Choi, D; Koo, YA; Shin, SY; Yoon, BK, 2007) |
| "Pioglitazone improved insulin sensitivity after 4 weeks combined with lower glucose and insulin levels without any change in BMI." | 7.74 | High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects. ( Graham, TE; Hammarstedt, A; Kahn, BB; Kainulainen, S; Laakso, M; Pihlajamäki, J; Smith, U, 2008) |
| "Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels." | 7.74 | Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. ( DeFronzo, RA; Miyazaki, Y, 2008) |
| "In 6- and 10-week-old obesity-prone (fa/fa) Zucker diabetic fatty (ZDF) rats, effects of prevention and intervention therapies, respectively, were compared between PPARalpha/gamma agonist, ragaglitazar (RAGA) and separate PPARgamma and alpha agonists, pioglitazone (PIO) and bezafibrate (BF)." | 7.73 | The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. ( Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP, 2005) |
| "The data suggest that treatment with pioglitazone improves insulin sensitivity in low-dose STZ and high sucrose-fat diet induced obese rats." | 7.73 | Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. ( Chen, YT; Ding, SY; Liu, Q; Shen, ZF; Sun, SJ; Xie, MZ, 2005) |
| "We report beneficial effects of pioglitazone on insulin resistance in diabetes mellitus accompanied with myotonic dystrophy (DM1)." | 7.73 | [Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone]. ( Isobe, T; Kawai, M; Ogata, K; Ogawa, M; Oya, Y; Shirafuji, T; Yamamoto, T, 2005) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 7.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| "We have evaluated the effects of a 2 week treatment with pioglitazone (Pio, 4mg/kg x d) on hepatic and peripheral insulin sensitivity, plasma adiponectin, and resistin concentrations in lipid-infused rats." | 7.73 | Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. ( Boden, G; Li, L; Tang, Y; Yang, G, 2006) |
| "To determine the effects of pioglitazone (30 mg once daily for 16 weeks) on insulin sensitivity, insulin-mediated vasodilation, vascular inflammatory markers, fat distribution and lipids in Asian Indians and Caucasians of European ancestry." | 7.73 | Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. ( Gerhard-Herman, MD; O'connor, ME; Raji, A; Simonson, DC; Williams, JS, 2006) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats." | 7.73 | Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. ( Li, YM; Xu, GY; Xu, L; Xu, P; Yu, CH; Zhang, XG, 2006) |
| " Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 7.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
| "To investigate the ameliorations of pioglitazone, a member of the thiazolidinedione group of antidiabetic agents, on insulin resistance in spontaneous OLETF rats with impaired glucose tolerance (IGT-OLETF)." | 7.72 | [Ameliorations of pioglitazone on insulin resistance in spontaneous IGT-OLETF rats]. ( Chen, YT; Ding, SY; Shen, ZF; Xie, MZ, 2004) |
| "We examined the effect of pioglitazone on abdominal fat distribution to elucidate the mechanisms via which pioglitazone improves insulin resistance in patients with type 2 diabetes mellitus." | 7.71 | Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. ( Cusi, K; DeFronzo, RA; Hardies, J; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y, 2002) |
| " Therefore, the effect of BRX-220 on insulin sensitivity was compared with the action of pioglitazone (PGZ) in high fat (HF) diet-induced insulin resistance (IR) of rats." | 7.71 | Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance. ( Demcáková, E; Klimes, I; Koranyi, L; Kürthy, M; Mogyorosi, T; Nagy, K; Seböková, E; Ukropec, J, 2002) |
| " The objective of this investigation was to determine if a novel antidiabetic agent, pioglitazone, ameliorated hepatic insulin resistance in KKA(y) mice and to identify any alterations in PIP2-phospholipase C activity of liver plasma membranes that may accompany changes in insulin sensitivity." | 7.68 | Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity. ( Bleasdale, JE; Swanson, ML, 1993) |
| "Effects of pioglitazone (5-[4-[2-(5-etyl-2-pyridyl)ethoxy] benzyl]-2,4-thiazolidinedione, AD-4833, also known as U-72, 107E) on peripheral and hepatic insulin resistance were examined using genetically obese-hyperglycemic rats, Wistar fatty." | 7.68 | Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. ( Ikeda, H; Shimura, Y; Sugiyama, Y, 1990) |
| "Insulin resistance is associated with blunted sympathetic nervous system (SNS) response to carbohydrate ingestion which may contribute to postprandial hypotension and impaired body weight homeostasis." | 6.80 | Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome. ( Dixon, JB; Eikelis, N; Grima, MT; Lambert, EA; Lambert, GW; Nestel, PJ; Richards, K; Sari, CI; Schlaich, MP; Straznicky, NE, 2015) |
| ": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment." | 6.79 | Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 6.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 6.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels." | 6.75 | Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Ishihara, K; Kitagawa, Y; Nakamura, N; Nakano, K; Obayashi, H; Ogata, M; Ohta, M; Takashima, T; Yamasaki, M, 2010) |
| "With pioglitazone treatment, E(2) responses to r-hFSH remained unchanged during low-dose insulin infusion, whereas a highly significant (P < 0." | 6.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Pioglitazone was well tolerated; the main side effects were weight gain (averaging 4%) and an increase in total body adiposity." | 6.71 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. ( Doo, E; Freedman, RJ; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Lutchman, G; Park, Y; Premkumar, A; Promrat, K; Soza, A; Uwaifo, GI; Yanovski, JA, 2004) |
| "Isohumulone treatment did not result in significant body weight gain, although pioglitazone treatment did increase body weight (10." | 6.71 | Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. ( Ezaki, O; Fujiwara, D; Ikeshima, E; Kanaya, T; Kondo, K; Odai, H; Oikawa, S; Shiraki, M; Tsuboyama-Kasaoka, N; Yajima, H, 2004) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 6.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 6.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Twenty NIDDM subjects (mean age 58." | 6.68 | Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. ( Baba, S; Eguchi, H; Hozumi, T; Ikeda, M; Ishida, Y; Kaneko, T; Kawamori, R; Kubota, M; Omori, Y; Sasaki, H; Sato, A; Shichiri, M; Tominaga, M; Uehara, M; Wasada, T; Yamasaki, Y, 1997) |
| "Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients." | 6.47 | Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. ( Forst, T; Pfützner, A, 2011) |
| "Pioglitazone has favorable effects on important components of metabolic syndrome including blood pressure." | 6.44 | [Pioglitazone effects on blood pressure in patients with metabolic syndrome]. ( Kushiro, T; Takahashi, A, 2008) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 6.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Insulin resistance has a complex etiology, with multiple manifestations across the organ systems involved in glucose homeostasis." | 6.43 | Metformin and pioglitazone: Effectively treating insulin resistance. ( Staels, B, 2006) |
| "Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported." | 6.41 | [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. ( Ikeda, H; Sugiyama, Y, 2001) |
| "Metformin was used as a positive control." | 5.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "The combined treatment with INS 18 U/kg + PIO 5 mg/kg was more effective in preventing advanced cachexia in TB rats than each treatment alone, emerging as the best approach, considering the lower dosage and higher efficacy." | 5.91 | Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity. ( Bazotte, RB; Bertolini, GL; Biazi, GR; Cassolla, P; de Souza Galia, WB; de Souza, HM; Diaz, BF; Ferraz, LS; Frasson, IG; Kurauti, MA; Mareze-Costa, CE; Marmentini, C; Miksza, DR; Peres, SB, 2023) |
| " Pioglitazone improves insulin sensitivity and it may have potential for treating CKD-related FGF23 overactivity." | 5.69 | Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial. ( Nata, N; Satirapoj, B; Supasyndh, O; Triwatana, W, 2023) |
| "Type 2 diabetes was induced in male Sprague-Dawley rats by combination of high fat diet and low dose streptozotocin (35mg/kg)." | 5.48 | Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. ( Abdel-Rahman, N; Eissa, LA; Eraky, SM, 2018) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 5.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 5.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| "Treatment with pioglitazone ameliorated Aβ42 deposition in the hippocampus by increasing IDE and PPARγ expression." | 5.46 | Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. ( Cao, M; Chen, Z; Li, R; Wang, Z; Yang, S; Zhang, M, 2017) |
| "Treatment with pioglitazone or nicorandil either alone or in combination successfully ameliorated the deleterious effects of HFD on the all previous parameters." | 5.42 | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. ( Elshazly, SM, 2015) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 5.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| " Pioglitazone was associated with increased peripheral insulin sensitivity (+23%-72%, standardized mean difference of 0." | 5.41 | Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review. ( Davies, TW; Fowler, AJ; McClelland, TJ; Pearse, R; Prowle, J; Puthucheary, Z, 2023) |
| "Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function." | 5.41 | In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. ( Bell, DSH; Jerkins, T, 2023) |
| " Referring to the lower surface under the cumulative ranking curves (SUCRA) and the league matrix table, exenatide and liraglutide, which are also glucagon-like peptide-1 receptor agonists (GLP-1RAs), showed excellent potential to reduce liver fat content, control glycemia, reduce body weight, and improve liver function and insulin resistance." | 5.41 | Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials. ( Ba, Y; Deng, M; Fan, H; Fan, Y; Lu, Q; Ren, L; Wang, H; Wang, Z; Wen, Y; Yan, J; Zhang, R, 2023) |
| "One-year treatment with pioglitazone even at low dosage significantly improved liver steatosis and inflammation, systemic and adipose tissue insulin resistance in patients with T2D." | 5.41 | Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. ( Bozzetto, L; Carli, F; Della Pepa, G; Gastaldelli, A; Masulli, M; Riccardi, G; Rivellese, AA; Russo, M; Vaccaro, O; Vetrani, C; Vitale, M, 2021) |
| "Pioglitazone treatment increased the cross-sectional area of adipocytes by 18% (p = 0." | 5.40 | Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. ( Adu, A; Finlin, BS; Kern, PA; Peterson, CA; Rasouli, N; Shipp, LR; Spencer, M; Yang, L; Zhu, B, 2014) |
| "A rat model of type 2 diabetes (T2D) was established with streptozotocin (STZ)." | 5.39 | Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. ( Hu, SH; Jiang, T; Yang, SS; Yang, Y, 2013) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12 weeks of the 16-week period." | 5.37 | Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. ( Dong, C; Hou, L; Hou, X; Liu, X; Luo, D; Wang, M; Xu, S, 2011) |
| "A total of 101 patients with type 2 diabetes were treated for 12 weeks with pioglitazone (15 mg/day)." | 5.37 | Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. ( Azarpira, N; Dabbaghmanesh, MH; Namvaran, F; Rahimi-Moghaddam, P, 2011) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12weeks of the 16-week period." | 5.36 | Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. ( Hao, Y; Hou, L; Liu, X; Luo, D; Zhang, S; Zheng, M, 2010) |
| "Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0." | 5.35 | Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. ( Beck-Nielsen, H; Glintborg, D; Højlund, K; Jensen, T; Knudsen, S; Kruse, TA; Skov, V; Tan, Q, 2008) |
| "Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin." | 5.35 | The ratio of leptin to adiponectin can be used as an index of insulin resistance. ( Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y, 2008) |
| " In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression." | 5.34 | Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. ( Aroda, V; Ciaraldi, TP; Dagon, Y; Henry, RR; Heo, JI; Hong, SH; Huang, H; Hwang, WM; Kang, MC; Kim, MS; Kim, SS; Kim, YB; Lee, SH; Lima, IS; Park, KS; Pereira de Moura, L; Seo, JA; Uner, A; Vijyakumar, A; Willnow, TE; Yang, WM, 2020) |
| " IRIS was a randomized, placebo controlled, double-blind trial testing pioglitazone to prevent stroke or myocardial infarction in patients with a recent ischemic stroke or transient ischemic attack." | 5.34 | Adherence to study drug in a stroke prevention trial"?>. ( Furie, KL; Gorman, M; Kernan, WN; Kiran, A; Viscoli, CM, 2020) |
| "Insulin resistance is related to the atherosclerotic process." | 5.34 | Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. ( Harano, Y; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2007) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 5.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Pioglitazone abolished the CCK-8-evoked hyperinsulinemia (P < 0." | 5.34 | Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders? ( DiMagno, MJ; Gangireddy, SR; Hao, Y; Lee, SH; Owyang, C; Reddy, RC, 2007) |
| "Pioglitazone (10 mg/kg) was then administered by gavage daily for 11 weeks to the pioglitazone group." | 5.33 | [The impact of pioglitazone on plasma homocysteine high-fat diet-induced insulin resistance in rats]. ( Liu, HF; Lu, JM; Ma, FL; Pan, CY; Yang, GQ; Zou, XM, 2005) |
| "A patient with type 2 diabetes and hypothalamic damage due to a suprasellar tumor developed impaired glycemic control and central obesity." | 5.33 | Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. ( Goto, T; Igaki, N; Tanaka, M, 2005) |
| "In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration." | 5.32 | Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. ( Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Piper, P; Pratipanawatr, T; Suraamornkul, S, 2004) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 5.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 5.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| "Pioglitazone treatment prevented the development of hypertension and reduced plasma insulin concentration by 70% and 37% in rats fed a high-fat or glucose diet, respectively (P < ." | 5.29 | Pioglitazone attenuates diet-induced hypertension in rats. ( DeGrange, LM; Kaufman, LN; Peterson, MM, 1995) |
| "Insulin sensitivity was increased by pioglitazone hydrochloride (P = 0." | 5.29 | Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. ( Baum, ST; Bergman, RN; Elson, DF; Kemnitz, JW; Meglasson, MD; Roecker, EB, 1994) |
| "Pioglitazone treatment did not change insulin binding in Wistar fatty rats but increased insulin-stimulated autophosphorylation of insulin receptors to 78% over the level in the control but not the basal state." | 5.28 | Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. ( Egawa, K; Iwanishi, M; Kobayashi, M; Shigeta, Y, 1992) |
| "In the Insulin Resistance Intervention after Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) were randomised to pioglitazone (target 45 mg daily) or placebo." | 5.27 | Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. ( Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Tanne, D; Viscoli, CM; Young, LH, 2018) |
| "The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack." | 5.27 | Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). ( Conwit, R; Dearborn, J; Furie, KL; Gorman, M; Inzucchi, SE; Kamel, H; Kasner, SE; Kernan, WN; Lovejoy, AM; Viscoli, CM; Yaghi, S; Young, LH, 2018) |
| "The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients." | 5.27 | Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, A; Pfau, SE; Schwartz, GG; Spatz, ES; Viscoli, CM; Young, LH, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To determine whether, among patients with an ischemic stroke or transient ischemic attack and insulin resistance, those at higher risk for future stroke or myocardial infarction (MI) derive more benefit from the insulin-sensitizing drug pioglitazone hydrochloride compared with patients at lower risk." | 5.24 | Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. ( Conwit, R; Dearborn, JL; Fayad, P; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kent, DM; Kernan, WN; Stuart, A; Viscoli, CM; Young, LH, 2017) |
| "Patients were 3876 nondiabetic participants in the Insulin Resistance Intervention after Stroke trial randomized to pioglitazone or placebo and followed for a median of 4." | 5.24 | Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. ( Conwit, R; Furie, KL; Gorman, M; Insogna, KL; Inzucchi, SE; Kelly, MA; Kernan, WN; Lovejoy, AM; Viscoli, CM; Young, LH, 2017) |
| "Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event." | 5.24 | Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. ( Abbott, JD; Conwit, R; Curtis, JP; Furie, KL; Gorman, MJ; Inzucchi, SE; Jacoby, DL; Kernan, WN; Kolansky, DM; Ling, FS; Lovejoy, AM; Pfau, SE; Schwartz, GG; Viscoli, CM; Young, LH, 2017) |
| "Pioglitazone (Pio) is known to improve insulin sensitivity in skeletal muscle." | 5.24 | Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function. ( Bajpeyi, S; Conley, KE; Gamboa, C; Jubrias, SA; Murray, K; Newcomer, BR; Pasarica, M; Sereda, O; Smith, SR; Sparks, LM, 2017) |
| " A significant reduction in homoeostatic model assessment of insulin resistance (HOMA-IR) was seen with exenatide versus metformin (MD: -0." | 5.22 | Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. ( Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N, 2022) |
| "Efficacy [myocardial infarction (MI) or recurrent stroke] new-onset diabetes) and adverse outcomes (oedema, weight gain, heart failure and bone fracture) were examined for subjects assigned to pioglitazone or placebo within strata defined by mode dose of study drug taken (i." | 5.22 | Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. ( Abdul-Ghani, M; Dandona, P; DeFronzo, R; Furie, K; Inzucchi, SE; Kernan, WN; Spence, JD; Viscoli, C; Young, LH, 2022) |
| "Participants were enrolled in the Insulin Resistance Intervention after Stroke trial, which examined the insulin sensitiser, pioglitazone versus placebo for prevention of stroke and myocardial infarction after ischaemic stroke or transient ischaemic attack." | 5.22 | Taking care of volunteers in a stroke trial: a new assisted-management strategy. ( Cote, R; Ford, GA; Furie, KL; Inzucchi, SE; Kernan, WN; Sico, JJ; Spence, JD; Stuart, AC; Tanne, D; Tayal, AH; Viscoli, CM, 2016) |
| " The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease." | 5.22 | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. ( Adams, HP; Berger, L; Brass, LM; Carolei, A; Clark, W; Conwit, R; Coull, B; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Kleindorfer, D; Lovejoy, AM; O'Leary, JR; Parsons, MW; Peduzzi, PN; Ringleb, P; Schwartz, GG; Sen, S; Spence, JD; Tanne, D; Viscoli, CM; Wang, D; Winder, TR; Young, LH, 2016) |
| "The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone." | 5.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| "The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA)." | 5.22 | Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. ( Dagogo-Jack, S; Furie, KL; Gorman, M; Inzucchi, SE; Ismail-Beigi, F; Kernan, WN; Korytkowski, MT; Lovejoy, AM; Pratley, RE; Schwartz, GG; Viscoli, CM; Young, LH, 2016) |
| "Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period." | 5.22 | Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study. ( Abbasi, F; Ariel, D; Cardell, J; Grove, K; Kim, SH; Kushida, CA; Lamendola, C; Liu, A; Mojaddidi, H; Patel, S; Reaven, GM; Tomasso, V; Tsao, PS; Xu, S, 2016) |
| "Participants were 428 of the total of 602 ACT NOW impaired glucose tolerance (IGT) subjects randomized to pioglitazone (45 mg/d) or placebo and followed for 2." | 5.20 | A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. ( Adam, KP; Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; Cobb, JE; DeFronzo, RA; Ferrannini, E; Gall, W; George, T; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D, 2015) |
| "Pioglitazone in individuals with MetS induces a potent decrease in plasma ceramides, and some of the changes correlate with changes in insulin resistance and adiponectin levels." | 5.20 | Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. ( Anuwe, E; Blankfard, MB; Gordillo, R; Hicks, J; Holland, WL; Lingvay, I; Lopez, X; Scherer, PE; Warshauer, JT, 2015) |
| "While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes." | 5.20 | Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. ( Furukawa, Y; Hattori, N; Kawamori, R; Miyamoto, N; Nakahara, T; Nakamura, S; Okuma, Y; Shimura, H; Tanaka, R; Tanaka, Y; Tomizawa, Y; Ueno, Y; Urabe, T; Watada, H; Yamashiro, K, 2015) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-α that has been clinically used to treat dyslipidemia and insulin resistance." | 5.19 | Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue. ( Chen, M; Deng, D; Fang, Z; Hu, H; Luo, L; Wang, Y; Xu, M, 2014) |
| " We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status." | 5.19 | Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Gastaldelli, A; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D, 2014) |
| "Patients (n = 34) with bipolar disorder (I, II, or not otherwise specified) and metabolic syndrome/insulin resistance who were currently depressed (Quick Inventory of Depressive Symptoms [QIDS] total score ≥11) despite an adequate trial of a mood stabilizer received open-label, adjunctive treatment with the PPAR-γ agonist pioglitazone (15-30 mg/day) for 8 weeks." | 5.19 | PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. ( Calabrese, JR; Conroy, C; Ganocy, SJ; Gao, K; Ismail-Beigi, F; Kemp, DE; Schinagle, M, 2014) |
| "Pioglitazone suppresses RAGE expression and increases circulating sRAGE/esRAGE, and those activities are not necessarily dependent on plasma glucose or insulin resistance levels." | 5.19 | Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). ( Emoto, M; Fujii, H; Fukui, M; Fukumoto, S; Inaba, M; Koyama, H; Monden, M; Mori, K; Morioka, T; Nishizawa, Y; Shoji, T; Tanaka, S, 2014) |
| "In non-diabetic patients with hypertension or hypercholesterolemia, pioglitazone improves insulin sensitivity, lipid profile, and inflammation but does not affect endothelin activity." | 5.19 | PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia. ( Campia, U; Cardillo, C; Matuskey, LA; Panza, JA; Tesauro, M, 2014) |
| " PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 5.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
| "A total of 441 individuals with impaired glucose tolerance (IGT) from ACT NOW received an oral glucose tolerance test and were randomized to pioglitazone or placebo for 2." | 5.19 | The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone. ( Abdul-Ghani, M; DeFronzo, RA; Gastaldelli, A; Musi, N; Tripathy, D, 2014) |
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 5.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| " The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity." | 5.19 | Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study. ( Bertrand, PC; Bortolotti, M; Burnier, M; Gauthier, T; Halabi, G; Lê, KA; Mathieu, C; Tappy, L; Teta, D; Theumann, N; Tremblay, S; Zanchi, A, 2014) |
| " Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA." | 5.19 | Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. ( Brass, LM; Carolei, A; Conwit, R; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Parsons, MW; Peduzzi, PN; Ringleb, PA; Schwartz, GG; Spence, JD; Tanne, D; Viscoli, CM; Young, LH, 2014) |
| " Here, we examined whether pioglitazone plus nateglinide (PIO) interferes with hepatocellular lipid (HCL) content and/or improves insulin sensitivity in well-controlled non-obese patients with type 2 diabetes mellitus (T2DM)." | 5.17 | Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. ( Anderwald, CH; Bernroider, E; Brehm, A; Krebs, M; Krssak, M; Nowotny, P; Phielix, E; Roden, M; Schmid, AI, 2013) |
| "Addition of pioglitazone to RA therapy improves insulin resistance and modestly reduces RA disease activity measured by DAS28-CRP and two of its components, including patient-reported global health and CRP, but not DAS28-ESR or ESR." | 5.17 | Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. ( Bian, A; Cunningham, A; Oeser, AM; Ormseth, MJ; Shintani, A; Solus, J; Stein, CM; Tanner, S, 2013) |
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 5.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| "Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo." | 5.17 | Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. ( Carey, M; Esterson, YB; Hawkins, M; Kehlenbrink, S; Kishore, P; Koppaka, S; Maginley, SR; Raghavan, P; Zhang, K, 2013) |
| "Pioglitazone decreased blood glucose and TG, increased insulin sensitivity, and ameliorated endothelial dysfunction of IGR subjects among the first-degree relatives of T2DM patients." | 5.17 | Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients. ( Chen, P; Wang, H; Yu, X; Zhu, T, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone." | 5.16 | Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012) |
| "Pioglitazone has been shown to reduce the occurrence of fatal and nonfatal myocardial infarction (MI) in type 2 diabetes mellitus (DM)." | 5.16 | Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus. ( Iwasaka, T; Miyasaka, Y; Murakawa, K; Sugiura, T; Tsujimoto, S; Yokoe, H; Yoshida, S; Yuasa, F; Yuyama, R, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 5.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 5.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| " We evaluated whether the peroxisome proliferator-activated receptor-γ agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity." | 5.15 | Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. ( Bopp, C; Cade, WT; Hubert, S; Laciny, E; Lassa-Claxton, S; Mondy, KE; Overton, ET; Reeds, DN; Yarasheski, KE, 2011) |
| "Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance." | 5.15 | Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011) |
| "We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance." | 5.15 | Pioglitazone for diabetes prevention in impaired glucose tolerance. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D; Williams, K, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To study the clinical, metabolic and adverse effects of pioglitazone over a period of 6 months in obese adolescent and young adults with polycystic ovary syndrome." | 5.14 | Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. ( Jacob, JJ; Narsing Rao, L; Paul, TV; Rajarathinam, S; Seshadri, MS; Thomas, N, 2009) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "Insulin sensitivity indices (SI indices) were obtained by analyzing fasting glucose and insulin concentration with homeostasis model assessment (HOMA), the glucose and insulin profiles after 75 g dextrose oral glucose tolerance tests (OGTT, Matsuda-Index) and euglycemic hyperinsulinemic clamp (m-value) in a double-blind placebo-controlled study in 60 patients with arterial hypertension before and after 4 months treatment with Pioglitazone 45 mg (PIO45)." | 5.14 | Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. ( Bär, F; Franke, S; Konrad, T; Schneider, F; Vossler, S, 2009) |
| "To assess insulin sensitivity in CAH patients and the effect of pioglitazone treatment on insulin sensitivity in CAH patients." | 5.14 | Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. ( Hermus, AR; Kroese, JM; Mooij, CF; Tack, CJ; van der Graaf, M, 2009) |
| "After both placebo and pioglitazone treatment, insulin sensitivity was determined by hyperinsulinemic euglycemic clamp and abdominal sc adipose tissue was obtained to measure adipocyte cell surface and expression of genes involved in glucose uptake and inflammation." | 5.14 | Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. ( de Graaf, J; Hermus, AR; Koenen, TB; Kroese, JM; Stalenhoef, AF; Stienstra, R; Sweep, FC; Tack, CJ; van der Laak, J; van Tits, LJ, 2009) |
| "The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes." | 5.14 | Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. ( Cha, BS; Choi, SH; Han, SJ; Hur, KY; Kang, ES; Kim, DJ; Kim, MS; Kim, SI; Kim, YS; Kwak, JY; Lee, HC, 2010) |
| " The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naïve patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study." | 5.14 | Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. ( Abdelaleem, A; Atef, R; Emad, M; Eslam, M; Hamdy, L; Khattab, M; Shaker, Y, 2010) |
| "The aim of the study was to compare the effects of the addition of sitagliptin or metformin to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state parameters." | 5.14 | Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "The objectives of the investigation were to study MMP-9 regulation by insulin resistance and pioglitazone treatment in impaired glucose tolerant subjects using adipose tissue biopsies and study the mechanism of MMP-9 regulation by pioglitazone in adipocyte cultures." | 5.14 | Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. ( Kern, PA; Labbate, C; Ranganathan, G; Rasouli, N; Unal, R; Varma, V; Yao-Borengasser, A, 2010) |
| "Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake." | 5.14 | Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. ( Burnier, M; Deleaval, P; Jornayvaz, FR; Maillard, M; Nussberger, J; Pechere-Bertschi, A; Vinciguerra, M; Zanchi, A, 2010) |
| "Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease." | 5.14 | Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. ( Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K; Soma, M, 2010) |
| "The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM)." | 5.14 | Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. ( Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level." | 5.14 | Withdrawal of pioglitazone in patients with type 2 diabetes mellitus. ( Asano, T; Hiramatsu, S; Iida, M; Iwase, M; Ogo, A; Sakai, Y; Sasaki, N; Yoshizumi, H, 2010) |
| "In asymptomatic DM2 patients with LVDD, the addition of pioglitazone to oral conventional treatment for 6 months does not induce any adverse or favorable changes in LV diastolic or systolic function despite improvements in glycaemic control, insulin sensitivity, lipid profile, and blood pressure." | 5.14 | Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papamichael, ND; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2010) |
| "Insulin sensitivity, GH, adiponectin, and IGF-I significantly increased during pioglitazone treatment, whereas alloTHF/THF levels significantly decreased." | 5.14 | A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. ( Andersen, M; Bennett, P; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Jensen, LT, 2009) |
| " The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites." | 5.13 | Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. ( Andersen, NR; Beck-Nielsen, H; Glintborg, D; Hansen, BF; Højlund, K; Wojtaszewski, JF, 2008) |
| "We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study)." | 5.13 | Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. ( Genné, D; Golay, A; Negro, F; Overbeck, K, 2008) |
| "Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus." | 5.13 | Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. ( Horibata, Y; Matsuzawa, Y; Nozaki, T; Ogawa, H; Sugamura, K; Sugiyama, S, 2008) |
| "Despite improvements in insulin sensitivity and glycemic regulation, either pioglitazone or metformin treatment did not result in any effect on blood visfatin levels in patients with treatment naïve T2DM." | 5.13 | The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. ( Bozoglu, E; Dogru, T; Ercin, CN; Erdem, G; Muhsiroglu, O; Sonmez, A; Tapan, S; Tasci, I, 2008) |
| " In this study, we evaluated the clinical efficacy of pioglitazone in the treatment of diabetic patients with hypertension undergoing hemodialysis (HD)." | 5.13 | Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. ( Abe, M; Kikuchi, F; Matsumoto, K; Okada, K, 2008) |
| " pioglitazone on measures of beta-cell function and insulin sensitivity as well as cardiac load." | 5.13 | Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? ( Dorkhan, M; Frid, A; Groop, L, 2008) |
| "Treatment with pioglitazone was associated with significant improvements of lipid and glycemic parameters that are linked to insulin resistance and cardiovascular risk in patients with T2DM in their routine clinical care." | 5.13 | [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus]. ( Mesa, J; Polavieja, P; Reviriego, J; Rodríguez, A, 2008) |
| " Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3." | 5.13 | Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Handberg, A; Henriksen, JE; Højlund, K, 2008) |
| "The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn)." | 5.12 | Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. ( Bloedon, LT; Chittams, J; Duffy, D; Rader, DJ; Reilly, MP; Samaha, FF; Soffer, D; Szapary, PO; Wolfe, ML, 2006) |
| "We compared the effects of diet/exercise induce weight loss versus pioglitazone on lipoprotein particle characteristics in non-diabetic, insulin resistant adults to determine whether the responses and potential mechanisms for improvement are similar between these two insulin sensitizing regimens." | 5.12 | Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size. ( Jensen, MD; LaForge, R; Otvos, JD; Shadid, S, 2006) |
| " We hypothesized that pioglitazone treatment of FCH patients might increase insulin sensitivity, but may also improve serum lipid levels, body fat distribution, intramyocellular lipids (IMCL) and endothelial function." | 5.12 | Effects of pioglitazone in familial combined hyperlipidaemia. ( Abbink, EJ; De Graaf, J; De Haan, JH; Heerschap, A; Stalenhoef, AF; Tack, CJ, 2006) |
| "The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate beta-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study." | 5.12 | Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. ( Buchanan, TA; Goico, J; Kawakubo, M; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2006) |
| "To investigate the relationship between insulin resistance, postprandial hyperglycemia, postprandial hyperlipidemia, and oxidative stress in type 2 diabetes, changes in postprandial glucose, triglyceride, and nitrotyrosine levels vs baseline after diet loading were examined in type 2 diabetic patients given pioglitazone (PG) or glibenclamide (GB)." | 5.12 | Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. ( Itoh, Y; Mori, Y; Obata, T; Tajima, N, 2006) |
| " Thus, the aim of our study was to investigate the effect of pioglitazone on endothelial dysfunction, insulin sensitivity, and glucose control in newly detected type 2 diabetic patients with CAD." | 5.12 | Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. ( Sourij, H; Wascher, TC; Zweiker, R, 2006) |
| "To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism." | 5.12 | Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. ( Andersen, M; Beck-Nielsen, H; Glintborg, D; Hagen, C; Henriksen, JE; Hermann, AP; Veldhuis, JD, 2006) |
| " We assessed the relationship among plasma adipokine concentrations and their relationship with insulin sensitivity and body composition in obese adults before and after insulin sensitization accomplished using diet/exercise or pioglitazone." | 5.12 | Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. ( Jensen, MD; Shadid, S; Stehouwer, CD, 2006) |
| "Pioglitazone therapy appears to be better in achieving glycaemic control and increasing plasma adiponectin and insulin sensitivity in newly detected type 2 diabetics." | 5.12 | Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. ( Bhansali, A; Malhotra, S; Pandhi, P; Sharma, PK; Sialy, R, 2006) |
| "We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo." | 5.12 | A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006) |
| "To determine whether the addition of the thiazoladinedione, pioglitazone, to standard therapy improves metabolic control in adolescents with type 1 diabetes (T1D) and clinical evidence of insulin resistance." | 5.12 | Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. ( Cummings, EA; Daneman, D; Hamilton, JK; Zdravkovic, V, 2006) |
| "We investigated the effect of pioglitazone in comparison with and in combination with simvastatin on insulin resistance, plasma adiponectin, postprandial plasma glucose, insulin, and intact proinsulin levels in a nondiabetic population at cardiovascular risk." | 5.12 | Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. ( Baurecht, W; Forst, T; Hanefeld, M; Hohberg, C; Karagiannis, E; Koehler, C; Lübben, G; Marx, N; Pfützner, A; Weber, M, 2007) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 5.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| " We studied the effects of pioglitazone (PIO) and rosiglitazone (ROSI) treatments on serum lipoprotein particle concentrations and sizes in type 2 diabetic patients with dyslipidemia." | 5.12 | Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. ( Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Tan, MH; Zagar, AJ, 2007) |
| " This work examines the effect of pioglitazone on 24-hour ambulatory BP monitoring in patients with type 2 diabetes and difficult-to-control hypertension." | 5.12 | Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. ( de Rivas, B; Fernández, C; Fernández-Cruz, A; Luque, M; Martell, N, 2007) |
| "Pioglitazone treatment significantly reduced the insulin response to OGTT and improved the insulin sensitivity indices (P < 0." | 5.11 | Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. ( Apa, R; Costantini, B; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Suriano, R, 2004) |
| "To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000)." | 5.11 | Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. ( Gilmore, KJ; Glazer, NB; Johns, D; Tan, MH; Widel, M, 2004) |
| "The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year." | 5.11 | Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. ( Antúnez, O; Fabián, G; Flores-Lozano, F; Garza, E; González Gálvez, G; Herz, M; Johns, D; Konkoy, C; Morales, H; Tan, M; Zúñiga Guajardo, S, 2004) |
| "This study compared the effects of 52 weeks' treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes." | 5.11 | Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. ( Clausen, J; Eriksson, JW; Halse, J; Herz, M; Johns, D; Konkoy, CS; Madsbad, S; Strand, J; Tan, MH, 2004) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "Short-term treatment with pioglitazone improved insulin sensitivity in the absence of any changes in circulating NEFA or lipid levels." | 5.11 | Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. ( Gogg, S; Hammarstedt, A; Jansson, PA; Smith, U; Sopasakis, VR, 2005) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 5.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| " Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also." | 5.11 | Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. ( Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V, 2004) |
| "Despite their comparable glycaemic effects in patients with Type 2 diabetes mellitus (T2DM), pioglitazone and metformin may have different effects on insulin sensitivity because they have different mechanisms of action." | 5.11 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. ( Johns, D; Laakso, M; Mariz, S; Richardson, C; Roden, M; Tan, MH; Urquhart, R; Widel, M, 2005) |
| "The present findings demonstrate that pioglitazone improves LV diastolic function without LV mass regression in hypertensive patients in proportion to the amelioration of insulin resistance." | 5.11 | Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. ( Funahashi, T; Hiuge, A; Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Kihara, S; Suzuki, K; Suzuki, M; Takamisawa, I; Takiuchi, S; Yoshimasa, Y, 2005) |
| " Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion." | 5.11 | Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. ( Andersen, M; Flyvbjerg, A; Frystyk, J; Glintborg, D; Hagen, C; Hermann, AP; Støving, RK; Veldhuis, JD, 2005) |
| "The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia." | 5.11 | Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. ( Hiuge, A; Horio, T; Kawano, Y; Suzuki, K; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2005) |
| "Pioglitazone is considered to reduce insulin resistance." | 5.10 | Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. ( Hayashi, Y; Imaeda, K; Itoh, M; Kamiya, F; Kato, T; Miyachi, N; Okayama, N; Shimizu, M; Takeuchi, T; Takeuchi, Y, 2003) |
| "Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts its effect primarily by decreasing hepatic glucose output." | 5.10 | Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. ( Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT, 2003) |
| "The aim of this study was to determine the effectiveness of pioglitazone compared with placebo for improving insulin sensitivity among nondiabetic patients with a recent transient ischemic attack (TIA) or nondisabling ischemic stroke and impaired insulin sensitivity." | 5.10 | Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. ( Brass, LM; Bravata, DM; Horwitz, RI; Inzucchi, SE; Kernan, WN; McVeety, JC; Shulman, GI; Viscoli, CM, 2003) |
| "To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 5.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
| "The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes." | 5.10 | Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. ( Baumstark, MW; Destani, R; Friedrich, I; Füllert, S; Konrad, T; Krebs, K; März, W; Wieland, H; Winkler, K, 2003) |
| " We assessed the effects of pioglitazone versus diet and exercise on fat distribution and the relationship between fat distribution and insulin sensitivity in upper body obesity." | 5.10 | Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. ( Jensen, MD; Shadid, S, 2003) |
| "Six months of pioglitazone treatment decreased insulin resistance and improved glycemic control to a significantly greater extent than acarbose treatment." | 5.10 | Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. ( Göke, B, 2002) |
| "Pioglitazone improved insulin resistance and glycemic control, as well as Tg and HDL-C - which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes." | 5.09 | The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. ( Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S, 2001) |
| "To evaluate the effect of pioglitazone on insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) patients, a double-blind placebo-controlled trial was carried out with 30 NIDDM patients." | 5.08 | Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. ( Arisaka, T; Ikebuchi, M; Ikeda, M; Kanda, T; Kawamori, R; Kinoshita, J; Kubota, M; Matsuhisa, M; Mochizuki, K; Niwa, M; Tohdo, R; Wada, M; Yamasaki, Y, 1998) |
| " Pioglitazone (an oral hypoglycemic agent of the thiazolidinedione drug class) was shown in the IRIS trial to reduce the risk of recurrent stroke in patients with impaired glucose tolerance who had not developed type 2 diabetes mellitus." | 4.98 | Updates in Stroke Treatment. ( Mac Grory, B; Yaghi, S, 2018) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| " Use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio 0." | 4.95 | Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. ( Lee, M; Liao, HW; Lin, CH; Ovbiagele, B; Saver, JL, 2017) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 4.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| " Reversal of lipotoxicity with pioglitazone is associated with significant histological improvement, which occurs within 6 months and persists with continued treatment (or for at least 3 years) in patients with prediabetes or type 2 diabetes, holding potential to modify the natural history of the disease." | 4.93 | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. ( Cusi, K, 2016) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| " The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women." | 4.89 | [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| " Current treatment strategies aim to improve insulin resistance via weight loss and exercise, improve insulin sensitivity by the use of insulin-sensitizing agents (for example, pioglitazone) and reduce oxidative stress by the use of antioxidants, such as vitamin E." | 4.87 | Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. ( Adams, LA; Smith, BW, 2011) |
| "Treatment with pioglitazone in T2DM was shown to improve insulin resistance and blood glucose levels without increasing the risk of hypoglycemia." | 4.87 | Review of approved pioglitazone combinations for type 2 diabetes. ( Forst, T; Hanefeld, M; Pfützner, A, 2011) |
| "Pioglitazone has diverse multiple effects on metabolic and inflammatory processes that have the potential to influence cardiovascular disease pathophysiology at various points in the disease process, including atherogenesis, plaque inflammation, plaque rupture, haemostatic disturbances and microangiopathy." | 4.86 | Pioglitazone and mechanisms of CV protection. ( Erdmann, E; Wilcox, R, 2010) |
| "Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles." | 4.86 | Pioglitazone: beyond glucose control. ( de Pablos-Velasco, P, 2010) |
| " In particular, Food and Drug Administration of the United States Department of Health and Human Service (FDA) noted that rosiglitazone and pioglitazone, PPAR gamma agonists, have an increased risk of bone fractures." | 4.85 | [Relationship between insulin resistance and bone metabolism]. ( Hamada, Y, 2009) |
| "Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake." | 4.83 | Pioglitazone: a review of its use in type 2 diabetes mellitus. ( Easthope, S; Keating, GM; Plosker, GL; Robinson, DM; Waugh, J, 2006) |
| "The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance." | 4.83 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006) |
| " Search terms used were insulin resistance, diabetes, insulin sensitivity, obesity, cardiovascular disease, metformin, thiazolidinediones, pioglitazone, rosiglitazone, and troglitazone." | 4.82 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. ( Henry, RR, 2003) |
| " Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis." | 4.82 | The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005) |
| "Ciglitazone was the first insulin sensitizer with a thiazolidinedione structure to reduce insulin resistance and hyperglycemia and many thiazolidinedione derivatives (TZDs) have since been reported as insulin sensitizers." | 4.80 | [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects]. ( Ikeda, H; Murase, K; Sugiyama, Y, 2000) |
| " Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
| "To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) and measures of diastolic function and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)." | 4.31 | Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. ( Abdul-Ghani, M; Cersosimo, E; Chilton, RJ; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Iozzo, P; Merovci, A; Molina-Wilkins, M; Moody, AJ; Solis-Herrera, C, 2023) |
| "In T2D patients with ischemic stroke, lobeglitazone reduced the risk of cardiovascular complications similar to that of pioglitazone without an increased risk of HF." | 4.31 | Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study. ( Baik, M; Jeon, J; Kim, J; Yoo, J, 2023) |
| " Ob/ob mice are deficient of leptin and develop obesity with hyperphagia and hyperinsulinemia." | 4.12 | Role of insulin resistance and the gut microbiome on urine oxalate excretion in ob/ob mice. ( Chen, H; Dodd, D; Liu, Y; Pao, AC; Xiang, H, 2022) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "We explored the cascade effects of a high fat-carbohydrate diet (HFCD) and pioglitazone (an anti-diabetic therapy used to treat type 2 diabetes mellitus (T2DM)) on lipid profiles, oxidative stress/antioxidant, insulin, and inflammatory biomarkers in a rat model of insulin resistance." | 4.02 | The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance. ( Al-Muzafar, HM; Alshehri, FS; Amin, KA, 2021) |
| "The results showed significant improvement in the insulin sensitivity of pioglitazone-treated mice as manifested by significant reduction in the insulin resistance index." | 4.02 | Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. ( El-Fayoumi, S; Fahmy, A; Ibrahim, I; Mahmoud, A; Mansour, R, 2021) |
| "Pioglitazone belongs to the class of drugs thiazolidinediones (TZDs) and is an oral hypoglycemic drug, used in the treatment of type 2 diabetes, which improves insulin sensitivity in target tissues." | 3.96 | MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice. ( Araújo Dos Santos, B; Araújo, HN; da Paixão, AO; de Mendonça, M; de Sousa, É; Imamura de Lima, T; Murata, GM; Passos Simões Fróes Guimarães, DS; Rodrigues, AC; Roveratti Spagnol, A; Silveira, LR, 2020) |
| "Our study aimed to investigate the effect of pioglitazone (PIO) on the obesity-associated metabolic effects and whether this effect is associated with modulation of catechol O-methyl transferase (COMT) expression in the high fat diet (HFD) induced obese rats." | 3.96 | Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats. ( Abd Elaziz, AI; Abulsoud, AI; El-Shafey, M; Elsadek, BEM; Hegazy, M; Salama, SA, 2020) |
| "This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients." | 3.96 | Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. ( Sun, Y; Xie, J; Yu, Q, 2020) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 3.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| " Free fatty acid receptor 1 (FFA1) has been recognized to mediate insulin secretion, and pioglitazone has direct effects on glucose-stimulated insulin secretion in addition to the reversion of insulin resistance." | 3.91 | Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells. ( An, L; Lin, Y; Ma, G; Mu, G; Qian, L; Ren, L; Zhu, K, 2019) |
| " Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has been applied to enhance insulin sensitivity." | 3.88 | Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis. ( Chen, IC; Chen, LW; Fu, MH; Hung, CY; Liu, WC; Tain, YL; Wu, CW; Wu, KLH, 2018) |
| "Pioglitazone is effective in improving insulin resistance and liver histology in patients with nonalcoholic steatohepatitis (NASH)." | 3.88 | Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. ( Abdo, K; Andrews, P; Bril, F; Cusi, K; Frye, RF; Garrett, TJ; Guingab, J; Jose, D; Kalavalapalli, S; Koelmel, JP; Li, WY; Sunny, NE; Yost, RA, 2018) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 3.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "The findings suggest that LPS challenge exacerbates IR in db/db mice by altering the expression of genes in WAT involved in adipogenesis and inflammation, which is effectively controlled by pioglitazone treatment." | 3.85 | Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice. ( Chatterjee, A; Jain, MR; Malik, U; Mohapatra, J; Nagar, J; Ramachandran, B; Sharma, M, 2017) |
| " Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA." | 3.85 | Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea. ( Abbasi, F; Ariel, D; Cardell, J; Grove, K; Kim, SH; Kushida, CA; Lamendola, C; Liu, A; Mojaddidi, H; Patel, S; Reaven, GM; Tomasso, V; Tsao, PS; Xu, S, 2017) |
| " Mice with diet-induced obesity were treated with the PPARγ or PPARα agonist, pioglitazone or fenofibrate, respectively." | 3.83 | Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver. ( Jia, WP; Wang, C; Zhang, ML; Zhong, Y; Zhu, YX, 2016) |
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 3.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| " Our previous study demonstrated that a combination of fish oil, which is rich with EPA and DHA, and pioglitazone exerts beneficial effects on obesity and diabetes through their actions on the liver and adipose tissue." | 3.83 | Protective effects of fish oil and pioglitazone on pancreatic tissue in obese KK mice with type 2 diabetes. ( Hirako, S; Iizuka, Y; Izawa, T; Kim, H; Matsumoto, A; Sakurai, K; Wada, M, 2016) |
| "Pioglitazone treatment significantly decreased serum RBP4 levels in obese rats, which was correlated with reduced body weight and increased insulin sensitivity." | 3.81 | Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats. ( Han, J; Jia, W; Liu, X; Wei, L; Xiao, Y; Zhang, J; Zhu, C, 2015) |
| " Pioglitazone treatment normalized mitoflash frequency and morphology while restored mitochondrial respiratory function and insulin sensitivity in 12 weeks mt-cpYFP db/db mice." | 3.81 | Mitoflash altered by metabolic stress in insulin-resistant skeletal muscle. ( Cheng, H; Ding, Y; Fang, H; Hou, N; Ma, Q; Pan, L; Shang, W; Sun, T; Sun, X; Wang, X; Xiao, Y; Zhang, X; Zhou, J, 2015) |
| "The combination of dimethylbiguanide and pioglitazone was more effective for the treatment of PCOS complicated with IR than simple pioglitazone; chronic inflammation occurrence was possibly one of reasons for insulin sensitivity reduction of patients with PCOS." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| "In this study, the cellular model of insulin resistance was used to investigate the mechanisms involved in the endothelial protective effects of pioglitazone in a vascular endothelial cell damage model." | 3.80 | The endothelial protective effects of pioglitazone on insulin resistance in endothelial cells. ( Jin, J; Kong, J; Yang, O; Zeng, H, 2014) |
| "It is insinuated that VAT is associated with late phase obesity CIDEC decrease and insulin resistance, while pioglitazone enhances CIDEC through activation of PPAR-γ, increases its expression, and decreases lipolysis, hence preventing an increase of blood sugar in mice exposed to HFD." | 3.80 | Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice. ( Ma, C; Naqvi, S; Shamsi, BH; Xiao, Y, 2014) |
| " Administration of DAGA (200 mg/kg) reduced SBP and significantly improved the FPG and HOMA-IR (homeostatis model assessment-insulin resistance) with modest improvement in lipid profile without decrease in body weight similar to pioglitazone." | 3.79 | Effect of a deacyl gymnemic acid on glucose homeostasis & metabolic parameters in a rat model of metabolic syndrome. ( Bhansali, S; Malhotra, S; Pandhi, P; Shafiq, N; Sharma, S; Singh, AP; Singh, I; Singh, PK, 2013) |
| "Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD." | 3.79 | Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. ( Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL, 2013) |
| "Hydrogen saturated saline showed great efficiency in improving the insulin sensitivity and lowering blood glucose and lipids." | 3.78 | Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress. ( Huang, Q; Kang, ZM; Wang, QJ; Xu, MJ; Zha, XJ; Zou, DJ, 2012) |
| " We investigated the effect of cafeteria diet and pioglitazone on body weight, insulin resistance, and adiponectin/ghrelin levels in an experimental study on male Wistar rats." | 3.78 | A study on the short-term effect of cafeteria diet and pioglitazone on insulin resistance and serum levels of adiponectin and ghrelin. ( Bazzo, ML; Colombo, G; Colombo, MD; d'Acampora, AJ; Nogueira, CL; Schiavon, LL, 2012) |
| " In addition to measuring BW, circulating glucose level, and BP, the following procedures were also carried out: insulin challenge (insulin sensitivity), losartan challenge (renin-angiotensin system activity), Nw-nitro-L arginine-methyl ester hydrochloride (LNAME) challenge (nitric oxide [NO] system activity), and evaluation of serum angiotensin converting enzyme (ACE) activity." | 3.78 | Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats. ( Bagchi, D; Echard, B; Fu, J; Kaylor, M; Perricone, NV; Preuss, HG; Zhuang, C, 2012) |
| "To explore the adipose tissue endocrine mechanism of pioglitazone and its possible prophylactic role in insulin resistance." | 3.78 | The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance. ( Gong, Y; Li, C; Li, J; Liu, Y; Mu, Y; Pan, C; Tian, H; Xiao, Y, 2012) |
| " Here, we tested the effect of a potent and selective peroxisome proliferator-activated receptor-γ agonist, rivoglitazone (Rivo), a newly synthesized thiazolidinedione derivative, on adiponectin, insulin resistance, and atherosclerosis." | 3.77 | Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. ( Funahashi, T; Hirata, A; Hiuge-Shimizu, A; Kihara, S; Maeda, N; Nakamura, K; Nakatsuji, H; Okuno, A; Shimomura, I, 2011) |
| "Pioglitazone, a full peroxisome proliferator-activated receptor (PPAR)-γ agonist, improves insulin sensitivity by increasing circulating adiponectin levels." | 3.77 | Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes. ( Hirai, H; Kudoh, A; Satoh, H; Watanabe, T, 2011) |
| " Pioglitazone improved glucose, insulin sensitivity, and triglycerides without influencing the contour of the waveforms." | 3.77 | Ocular blood flow analysis detects microvascular abnormalities in impaired glucose tolerance. ( Agnew, CE; Hamilton, PK; Harbinson, MT; Lockhart, CJ; McCann, AJ; McVeigh, GE; Millar, AM; Quinn, CE, 2011) |
| " Pioglitazone treatment (3 mg/kg body weight/d for 6 weeks), a peroxisome proliferator-activated receptor γ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent benefits." | 3.77 | Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. ( Cheng, H; Ding, Y; Han, C; Hou, N; Huang, PL; Li, C; Li, K; Liu, N; Liu, Y; Mao, J; Raab, S; Sebokova, E; Shang, S; Song, Z; Wang, H; Wang, J; Xue, L; Zhang, H; Zhang, R; Zhang, X; Zhang, Y; Zheng, W; Zhu, T, 2011) |
| " In this study, thirteen-week-old spontaneously hypertensive (SHR)/NDmcr-cp rats, representing a genetic model of metabolic syndrome, were treated daily with placebo, irbesartan (30 mg/kg), valsartan (10 mg/kg), or pioglitazone (10 mg/kg) for 4 weeks." | 3.77 | Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. ( Jin, D; Miyazaki, M; Takai, S, 2011) |
| "Here we investigated cinnamaldehyde (CA) effect on diabetes-induced hypertension." | 3.77 | Cinnamaldehyde protects from the hypertension associated with diabetes. ( Badawy, D; El-Bassossy, HM; Fahmy, A, 2011) |
| " The purpose of this study was to determine whether pioglitazone stimulates adipogenesis in vivo and whether this process relates to improved insulin sensitivity." | 3.76 | Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. ( Abbasi, F; Cushman, SW; Lamendola, C; Liu, T; McLaughlin, TM; Reaven, GM; Sherman, A; Tsao, P; Yee, G, 2010) |
| " To test this hypothesis, we analyzed long-term metabolic effects of pioglitazone and the activation of nPKC-epsilon and -theta isoforms in an animal model of the metabolic syndrome, the spontaneously hypertensive rat (a congenic SHR strain with wild type Cd36 gene) fed a diet with 60 % sucrose from the age of 4 to 8 months." | 3.76 | Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats. ( Kazdová, L; Marková, I; Mlejnek, P; Musilová, A; Pravenec, M; Šimáková, M; Zídek, V, 2010) |
| "Pioglitazone improves insulin resistance in T2DM in association with mobilization of fat and toxic lipid metabolites out of muscle." | 3.76 | Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. ( Baig, R; Bajaj, M; Cline, GW; Coletta, DK; DeFronzo, RA; Hardies, LJ; Koul, S; Monroy, A; Musi, N; Shulman, GI; Sriwijitkamol, A; Suraamornkul, S, 2010) |
| " Ten-week-old male OLETF and LETO rats were divided into three groups of nine each and treated with vehicle or oral administration of 3 or 10 mg/kg/day pioglitazone, an agent that improves insulin resistance." | 3.76 | Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome. ( Fujii, R; Hara, I; Iba, A; Inagaki, T; Kohjimoto, Y; Kuramoto, T; Matsumura, N; Mori, T; Nanpo, Y; Nishizawa, S; Shintani, Y, 2010) |
| " We investigated the effects of curcumin on fructose-induced hypertriglyceridemia and liver steatosis and explored its preventive mechanisms in rats." | 3.76 | Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. ( Hu, QH; Kong, LD; Li, JM; Li, YC, 2010) |
| "SOD-mediated vasorelaxation may contribute to the chronic antihypertensive effect and/or the improvement in insulin sensitivity following pioglitazone treatment." | 3.76 | Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. ( Bryer-Ash, M; Dorafshar, AH; Khoe, M; Lyon, C; Moodley, K, 2010) |
| " Pioglitazone, an anti-diabetic drug, improves insulin resistance, but its influence on sympathetic nerve activity is not clear." | 3.76 | Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with α-glucosidase inhibitor. ( Furusho, H; Ikeda, T; Inomata, J; Kaneko, S; Kato, T; Kobayashi, D; Murai, H; Ota, T; Takamura, M; Takamura, T; Takashima, S; Takeshita, Y; Usui, S, 2010) |
| " All rats were examined for body weight, serum and hepatic biochemical indices, content of malondialdehyde (MDA), activities of superoxide dismutase (SOD) and pathological changes in liver and pancreas, as well as protein tyrosine phosphatase 1B (PTP1B) expression in liver." | 3.76 | Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats. ( Cheng, WM; Hu, XY; Li, J; Lu, YX; Sun, YX; Wang, LY; Zhang, Q, 2010) |
| " In this issue of the British Journal of Pharmacology, Collino and colleagues report that pioglitazone can reduce hepatic inflammation and insulin resistance in rats administered a high cholesterol and fructose diet." | 3.76 | Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. ( Chatterjee, PK, 2010) |
| " We examined how improvements in muscular insulin sensitivity following rosiglitazone (ROSI) or pioglitazone (PIO) treatment would affect muscle mitochondrial function in patients with type 2 diabetes mellitus (T2DM)." | 3.76 | Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. ( Almdal, T; Boushel, R; Dela, F; Hansen, CN; Haugaard, SB; Madsbad, S; Ploug, T; Prats, C; Rabøl, R, 2010) |
| "The aim of this study was to evaluate the efficacy of pioglitazone on metabolic parameters in drug-naïve Japanese type 2 diabetic patients with (Diabetes Mellitus Metabolic Syndrome [DMMS] group, n = 36) and without (Diabetes Mellitus non-Metabolic Sundrome [DMNMS] group, n = 36) metabolic syndrome." | 3.76 | Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome. ( Kutoh, E, 2010) |
| " Pioglitazone treatment altered fat distribution, improved insulin sensitivity and normalized lipid and insulin level in rats on the high-fat diet." | 3.76 | Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. ( Jena, G; Ramarao, P; Vikram, A, 2010) |
| " Here, in an animal model of obesity and insulin resistance, the metabolic response to cevoglitazar, a dual PPARalpha/gamma, was characterized using a combination of in vivo and ex vivo magnetic resonance methodologies and compared to treatment effects of fenofibrate, a PPARalpha agonist, and pioglitazone, a PPARgamma agonist." | 3.75 | Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. ( Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D, 2009) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 3.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "We studied the effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and serum concentrations and tissue expression of visfatin in normal Sprague-Dawley rats and rats with insulin resistance induced by high-fat diet (HF)." | 3.75 | Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats. ( Lv, Q; Wang, L; Wang, W; Wang, Y; Zhou, X, 2009) |
| "05) were higher on the IL/H study day than on the glycerol study day, indicating persistence of NEFA-induced insulin resistance." | 3.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| "The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease." | 3.74 | The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus. ( Itoh, S; Katagiri, T; Kobayashi, Y; Kodama, Y; Konno, N; Nishio, K; Satoh, R; Shigemitsu, M, 2008) |
| "The change in peripheral insulin sensitivity after treatment with pioglitazone and during the infusion of the lipid emulsion was the main outcome measure." | 3.74 | Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. ( Ackermans, MT; Aerts, JM; Allick, G; Groener, JE; Heijligenberg, R; Meijer, AJ; Sauerwein, HP; Serlie, MJ; Voermans, BC, 2007) |
| " Using a murine model of steatohepatitis (mice fed a diet deficient in methionine and choline-MCD diet), we tested the effects of the insulin-sensitising, PPARgamma agonist drug pioglitazone (PGZ) on systemic and intrahepatic insulin sensitivity and on liver pathology." | 3.74 | Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. ( Horsmans, YJ; Lebrun, VA; Leclercq, IA; Stärkel, P, 2007) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| " PPAR-gamma agonists like pioglitazone decrease insulin resistance and have been shown to reduce neointimal hyperplasia in the short-term." | 3.74 | Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. ( Desouza, CV; Gerety, M; Hamel, FG, 2007) |
| "To clarify the causal relationship between insulin resistance and the development of NASH, steatohepatitis was induced in obese diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) and nondiabetic control Long-Evans Tokushima Otsuka (LETO) rats by feeding them a methionine and choline-deficient (MCD) diet." | 3.74 | Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. ( Akahori, H; Kaneko, S; Kita, Y; Kurita, S; Matsuzawa, N; Misu, H; Nakanuma, Y; Ota, T; Sakurai, M; Takamura, T; Uno, M; Zen, Y, 2007) |
| "Pioglitazone is widely used for the treatment of diabetic patients with insulin resistance." | 3.74 | Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. ( Bukhari, A; Fujisaka, S; Haruta, T; Ishizuka, K; Kanatani, Y; Kishimoto, T; Kobayashi, M; Naka, T; Urakaze, M; Usui, I, 2007) |
| " It also significantly decreased the level of gene expression of tumour necrosis factor-alpha, an insulin resistance-inducing factor in retroperitoneal WAT, as did pioglitazone and rosiglitazone." | 3.74 | Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. ( Hirosumi, J; Kawamura, I; Kimura, C; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S, 2007) |
| " The administration of pioglitazone, a PPARgamma agonist, to Zucker obese rats greatly improved their insulin sensitivity." | 3.74 | Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats. ( Hibino, Y; Kawashima, Y; Kudo, N; Mitsumoto, A; Nishikawa, M; Toyama, T, 2007) |
| "These findings suggest that long-term therapy with pioglitazone may be necessary to maintain improvements in disease activity in patients with NASH, although weight gain during treatment may ultimately limit its beneficial effects." | 3.74 | The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. ( Borg, B; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Loomba, R; Lutchman, G; Modi, A; Premkumar, A; Promrat, K, 2007) |
| "The present study demonstrated that pioglitazone can restore the nocturnal BP declines in parallel to reductions in the HOMA index, suggesting that insulin resistance may play an important role in the genesis of circadian BP rhythms." | 3.74 | Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. ( Anan, F; Eshima, N; Fukunaga, N; Iwao, T; Kaneda, K; Masaki, T; Okada, K; Saikawa, T; Teshima, Y; Umeno, Y; Wakasugi, K; Yonemochi, H; Yoshimatsu, H, 2007) |
| "To evaluate the effects of pioglitazone on menstruation and the metabolic parameters of non-obese women of reproductive age with polycystic ovary syndrome (PCOS) and compare the effects among different subgroups of PCOS patients with different clinical presentations." | 3.74 | Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. ( Choi, D; Koo, YA; Shin, SY; Yoon, BK, 2007) |
| "The present results suggest that pioglitazone improves not only insulin resistance, but also the dysfunctions in vascular control regulated by adrenergic and CGRPergic nerves in the hyperinsulinaemic state." | 3.74 | Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia. ( Egawa, T; Hanafusa, N; Kawasaki, H; Mio, M; Takatori, S; Yabumae, N; Zamami, Y, 2008) |
| "Pioglitazone improved insulin sensitivity after 4 weeks combined with lower glucose and insulin levels without any change in BMI." | 3.74 | High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects. ( Graham, TE; Hammarstedt, A; Kahn, BB; Kainulainen, S; Laakso, M; Pihlajamäki, J; Smith, U, 2008) |
| "Treatment of OLETF rats with pioglitazone improved insulin sensitivity and kidney/body weight, but had a little effect on blood pressure." | 3.74 | Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. ( Cha, DR; Han, JY; Han, KH; Han, SY; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK, 2008) |
| "Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels." | 3.74 | Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. ( DeFronzo, RA; Miyazaki, Y, 2008) |
| "Sixteen patients with acromegaly undergoing pituitary surgery (and 16 patients with type 2 diabetes treated with pioglitazone) were included." | 3.73 | Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. ( A Spinas, G; Bernays, R; Brändle, M; Schmid, C; Seiler, H; Wiesli, P; Zapf, J; Zwimpfer, C, 2005) |
| "In 6- and 10-week-old obesity-prone (fa/fa) Zucker diabetic fatty (ZDF) rats, effects of prevention and intervention therapies, respectively, were compared between PPARalpha/gamma agonist, ragaglitazar (RAGA) and separate PPARgamma and alpha agonists, pioglitazone (PIO) and bezafibrate (BF)." | 3.73 | The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. ( Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP, 2005) |
| " We hypothesized that lipopolysaccharide (LPS) from periodontal pathogens stimulated adipocytes to produce IL-6, and that the production was suppressed by the drugs targeted against insulin resistance, thiazolidinedione (pioglitazone), since this agent potentially showed an anti-inflammatory effect." | 3.73 | Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. ( Kokeguchi, S; Naruishi, H; Nishimura, F; Soga, Y; Takashiba, S; Yamaguchi, M, 2005) |
| "The data suggest that treatment with pioglitazone improves insulin sensitivity in low-dose STZ and high sucrose-fat diet induced obese rats." | 3.73 | Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. ( Chen, YT; Ding, SY; Liu, Q; Shen, ZF; Sun, SJ; Xie, MZ, 2005) |
| " We evaluated the effect of 24- to 48-h 8 microM l-805645 or 10 microM pioglitazone on 25 mM D-glucose-induced markers of fibrosis in HK-2 cells." | 3.73 | PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. ( Chen, X; Panchapakesan, U; Pollock, CA; Sumual, S, 2005) |
| "We report beneficial effects of pioglitazone on insulin resistance in diabetes mellitus accompanied with myotonic dystrophy (DM1)." | 3.73 | [Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone]. ( Isobe, T; Kawai, M; Ogata, K; Ogawa, M; Oya, Y; Shirafuji, T; Yamamoto, T, 2005) |
| "Insulin-resistant, obesity-prone mice (KK strain) were treated with pioglitazone, placebo, or the sulfonylurea compound, glipizide, for 2." | 3.73 | Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. ( Bodary, PF; Eitzman, DT; Jongeward, KL; King, SA; Vargas, FB; Wickenheiser, KJ, 2005) |
| "We have evaluated the effects of a 2 week treatment with pioglitazone (Pio, 4mg/kg x d) on hepatic and peripheral insulin sensitivity, plasma adiponectin, and resistin concentrations in lipid-infused rats." | 3.73 | Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. ( Boden, G; Li, L; Tang, Y; Yang, G, 2006) |
| "To determine the effects of pioglitazone (30 mg once daily for 16 weeks) on insulin sensitivity, insulin-mediated vasodilation, vascular inflammatory markers, fat distribution and lipids in Asian Indians and Caucasians of European ancestry." | 3.73 | Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. ( Gerhard-Herman, MD; O'connor, ME; Raji, A; Simonson, DC; Williams, JS, 2006) |
| "Adipogenesis is an important process for the improvement of insulin resistance by peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as rosiglitazone and pioglitazone." | 3.73 | A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. ( Aramori, I; Fujimura, T; Kimura, C; Mutoh, S; Oe, T; Sakuma, H; Takata, Y, 2006) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| " Pioglitazone can attenuate insulin resistance and biochemical and histological injury in high fat-induced fatty liver in rats." | 3.73 | Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. ( Li, YM; Xu, GY; Xu, L; Xu, P; Yu, CH; Zhang, XG, 2006) |
| " The development of insulin resistance was determined by tyrosine phosphorylation of insulin receptor and insulin receptor substrate-1, phosphatidylinositol 3-kinase activity associated with insulin receptor substrate-1 and glucose uptake." | 3.72 | Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. ( Dey, CS; Kumar, N, 2003) |
| " Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 3.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
| "These findings suggest that pioglitazone and EPA may improve glucose tolerance by directly increasing hepatic insulin sensitivity, while fenofibrate may improve glucose tolerance by improving hepatic glycogen metabolism in the GK rats." | 3.72 | Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver. ( Horiike, N; Iwai, M; Kanno, S; Matsui, H; Matsuura, B; Minami, H; Onji, M; Tsubouchi, E, 2004) |
| "To investigate the ameliorations of pioglitazone, a member of the thiazolidinedione group of antidiabetic agents, on insulin resistance in spontaneous OLETF rats with impaired glucose tolerance (IGT-OLETF)." | 3.72 | [Ameliorations of pioglitazone on insulin resistance in spontaneous IGT-OLETF rats]. ( Chen, YT; Ding, SY; Shen, ZF; Xie, MZ, 2004) |
| "We examined the effect of pioglitazone on abdominal fat distribution to elucidate the mechanisms via which pioglitazone improves insulin resistance in patients with type 2 diabetes mellitus." | 3.71 | Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. ( Cusi, K; DeFronzo, RA; Hardies, J; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y, 2002) |
| " Therefore, the effect of BRX-220 on insulin sensitivity was compared with the action of pioglitazone (PGZ) in high fat (HF) diet-induced insulin resistance (IR) of rats." | 3.71 | Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance. ( Demcáková, E; Klimes, I; Koranyi, L; Kürthy, M; Mogyorosi, T; Nagy, K; Seböková, E; Ukropec, J, 2002) |
| "In order to evaluate the relationship between tumour necrosis factor-alpha (TNF-alpha) level in muscle and metabolic abnormalities in obesity and diabetes mellitus, pioglitazone, a novel insulin-sensitizing agent, was administered to Wistar fatty rats and time-dependent changes in muscle TNF-alpha content and plasma indicators of diabetes and obesity were measured." | 3.70 | Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. ( Ikeda, H; Murase, K; Odaka, H; Suzuki, M; Tayuki, N, 1998) |
| "The role of insulin resistance in the impaired glucose-stimulated insulin release of Zucker fatty rats was investigated using the insulin-sensitizing thiazolidinedione drug pioglitazone." | 3.69 | Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. ( de Souza, CJ; Meglasson, MD; Robinson, DD; Ulrich, RG; Yu, JH, 1995) |
| " In addition, the effects of treatment with pioglitazone, an antidiabetic agent that acts by increasing insulin sensitivity in muscle, liver, and other tissues, were assessed." | 3.69 | Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. ( Colca, JR; Kurowski, TG; Ruderman, NB; Saha, AK, 1994) |
| "These studies were designed to assess the effects of pioglitazone, a new oral antidiabetic agent that acts by improving insulin sensitivity, on blood pressure, plasma and tissue lipids, and insulin resistance in the Dahl salt-sensitive (Dahl-S) rat." | 3.69 | Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone. ( Colca, JR; Corkey, BE; Cunningham, BA; Holbert, RI; Kurowski, TG; Ruderman, NB; Saha, AK, 1996) |
| "We examined the effect of pioglitazone, a thiazolidinedione derivative that increases insulin sensitivity without increasing insulin secretion, on the development and maintenance of hypertension in sucrose-fed SHR." | 3.69 | Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. ( Fujita, H; Hatta, T; Itoh, H; Kawa, T; Kiyama, M; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Nakamura, K; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| " Oral administration of pioglitazone (20 mg/kg twice daily or 40 mg/kg/day for 4 weeks), an agent known to ameliorate insulin sensitivity, significantly decreased plasma glucose levels during the treatment period." | 3.69 | KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. ( Morimoto, Y; Nishikawa, K; Ohashi, M, 1997) |
| " To address this problem, we have studied the in vivo effect of pioglitazone on glucose metabolism and gene expression in the adipose tissue of an animal model of obesity with insulin resistance, the obese Zucker (fa/fa) rat." | 3.69 | Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. ( Auwerx, J; Berthault, MF; Doaré, L; Dugail, I; Ferré, P; Foufelle, F; Guerre-Millo, M; Hallakou, S; Kergoat, M; Morin, J, 1997) |
| " To determine if increasing insulin sensitivity corrects this defect of endothelial function, we evaluated the effects of an insulin-sensitizing agent, pioglitazone, on arterial pressure and in vitro vascular reactivity in three groups of Sprague Dawley rats: 1) control; 2) 60% fructose diet for 4 weeks; 3) 60% fructose diet plus pioglitazone (20 mg/kg daily, by oral gavage)." | 3.69 | Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. ( Kotchen, TA; Reddy, S; Zhang, HY, 1997) |
| " The objective of this investigation was to determine if a novel antidiabetic agent, pioglitazone, ameliorated hepatic insulin resistance in KKA(y) mice and to identify any alterations in PIP2-phospholipase C activity of liver plasma membranes that may accompany changes in insulin sensitivity." | 3.68 | Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity. ( Bleasdale, JE; Swanson, ML, 1993) |
| "Effects of pioglitazone (5-[4-[2-(5-etyl-2-pyridyl)ethoxy] benzyl]-2,4-thiazolidinedione, AD-4833, also known as U-72, 107E) on peripheral and hepatic insulin resistance were examined using genetically obese-hyperglycemic rats, Wistar fatty." | 3.68 | Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. ( Ikeda, H; Shimura, Y; Sugiyama, Y, 1990) |
| " Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS." | 2.94 | Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. ( Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA, 2020) |
| "Pioglitazone intake is effective in nonalcoholic steatohepatitis management." | 2.82 | Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs. ( Bu, H; Takahashi, H; Wang, H; Zhao, W; Zhao, Y, 2022) |
| "Insulin resistance is associated with blunted sympathetic nervous system (SNS) response to carbohydrate ingestion which may contribute to postprandial hypotension and impaired body weight homeostasis." | 2.80 | Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome. ( Dixon, JB; Eikelis, N; Grima, MT; Lambert, EA; Lambert, GW; Nestel, PJ; Richards, K; Sari, CI; Schlaich, MP; Straznicky, NE, 2015) |
| ": Insulin resistance is associated with nonresponse to hepatitis C virus (HCV) treatment." | 2.79 | Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. ( Alston-Smith, B; Andersen, J; Chung, RT; Glesby, MJ; Hadigan, C; Kitch, D; Luetkemeyer, A; Marks, KM; Tien, P, 2014) |
| "Pioglitazone treatment resulted in a change in augmentation index of -4." | 2.79 | Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy. ( Bian, A; Cunningham, A; Oeser, AM; Ormseth, MJ; Shintani, A; Solus, J; Stein, CM; Tanner, SB, 2014) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 2.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n = 10; difference of means = 205,618 IU/ml; 95% CI 26,600 to 384,600; P<0." | 2.77 | Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. ( Buck, M; Chojkier, M; Donohue, M; Elkhayat, H; Sabry, D, 2012) |
| "Pioglitazone treatment significantly increased body mass index (P<0." | 2.76 | Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. ( Ahn, CW; Cha, BS; Cho, MH; Kim, KR; Lee, HC; Nam, JS; Park, JS; Yoo, JS, 2011) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Pioglitazone was better than glibenclamide in decreasing HbA (1c), FPG, FPI, lipid profile, and in improving inflammatory parameters such as Hs-CRP, and ADN." | 2.76 | Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. ( Bianchi, L; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P, 2011) |
| "Sixty type 2 diabetes mellitus subjects were randomly assigned to receive pioglitazone (30 mg/d, n = 19), rosiglitazone (4 mg/d, n = 20), or placebo (medical nutrition therapy, n = 21) for 12 weeks." | 2.75 | Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. ( Ersoy, C; Guclu, M; Gul, CB; Imamoglu, S; Kiyici, S; Oral, AY; Oz Gul, O; Tuncel, E; Ulukaya, E; Yilmaz, Y, 2010) |
| "Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels." | 2.75 | Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Ishihara, K; Kitagawa, Y; Nakamura, N; Nakano, K; Obayashi, H; Ogata, M; Ohta, M; Takashima, T; Yamasaki, M, 2010) |
| "Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis." | 2.75 | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. ( Bass, NM; Brunt, EM; Chalasani, N; Clark, J; Diehl, AM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Lavine, JE; McCullough, A; Neuschwander-Tetri, BA; Robuck, PR; Sanyal, AJ; Tonascia, J; Unalp, A; Van Natta, M, 2010) |
| "Twenty-eight patients with type 2 diabetes already on metformin, without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n=14) and pioglitazone (30 mg od) in group B (n=14) for 6 months." | 2.74 | Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2009) |
| "Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)." | 2.74 | Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009) |
| "Treatment naive patients with type 2 diabetes received 15-30 mg/day pioglitazone monotherapy." | 2.74 | Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes. ( Fukushima, T; Kutoh, E, 2009) |
| "Two hundred seventy-one type 2 diabetes mellitus patients with poor glycemic control and who were overweight were enrolled in this study." | 2.74 | Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2009) |
| "placebo in patients with type 2 diabetes uncontrolled by metformin and a sulphonylurea or a glinide." | 2.74 | Earlier triple therapy with pioglitazone in patients with type 2 diabetes. ( Charpentier, G; Halimi, S, 2009) |
| "Twenty-seven patients with type 2 diabetes mellitus were divided into pioglitazone-treated (Pio), metformin-treated (Met), and exercise-treated (Ex) groups." | 2.73 | Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. ( Araki, T; Emoto, M; Inaba, M; Koyama, H; Lee, E; Mori, K; Nishizawa, Y; Shoji, T; Teramura, M; Yokoyama, H, 2008) |
| "Pioglitazone treatment resulted in a significant reduction in fasting levels of PI and SPI compared to those of the controls." | 2.73 | Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. ( Al Majali, K; Bailey, CJ; Betteridge, DJ; Cooper, MB, 2008) |
| "The pioglitazone was effective in reducing plasma glucose and HbA1c from the baseline levels from Week 4 onward." | 2.73 | Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. ( Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007) |
| "Pioglitazone has shown promise in secondary stroke prevention for insulin-resistant patients; however, its use is not yet widespread." | 2.72 | Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. ( Krinock, MJ; Singhal, NS, 2021) |
| "We studied 12 subjects with type 2 diabetes (average age 58." | 2.72 | Pioglitazone treatment improves nitrosative stress in type 2 diabetes. ( Barlow, PM; Casellini, CM; Parson, HK; Ullal, J; Vinik, AI, 2006) |
| "Insulin resistance is a common problem in obese patients with type 2 diabetes." | 2.72 | Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. ( Biesenbach, G; Grafinger, P; Raml, A, 2006) |
| "With pioglitazone treatment, E(2) responses to r-hFSH remained unchanged during low-dose insulin infusion, whereas a highly significant (P < 0." | 2.71 | Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. ( Chang, RJ; Coffler, MS; Dahan, MH; Malcom, PJ; Patel, K; Yoo, RY, 2003) |
| "Pioglitazone was well tolerated; the main side effects were weight gain (averaging 4%) and an increase in total body adiposity." | 2.71 | A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. ( Doo, E; Freedman, RJ; Ghany, M; Heller, T; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Lutchman, G; Park, Y; Premkumar, A; Promrat, K; Soza, A; Uwaifo, GI; Yanovski, JA, 2004) |
| "Isohumulone treatment did not result in significant body weight gain, although pioglitazone treatment did increase body weight (10." | 2.71 | Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. ( Ezaki, O; Fujiwara, D; Ikeshima, E; Kanaya, T; Kondo, K; Odai, H; Oikawa, S; Shiraki, M; Tsuboyama-Kasaoka, N; Yajima, H, 2004) |
| "Treatment with pioglitazone was also associated with higher ovulation rates (P < 0." | 2.71 | Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. ( Brettenthaler, N; De Geyter, C; Huber, PR; Keller, U, 2004) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 2.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease." | 2.71 | Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. ( Forst, T; Füllert, SD; Hohberg, C; Kann, P; Konrad, T; Langenfeld, MR; Lübben, G; Pfützner, A; Sachara, C, 2005) |
| "Pioglitazone treatment also provided significant benefit with respect to plasma HDL-C and triglyceride levels." | 2.70 | Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. ( Einhorn, D; Glazer, NB; Hershon, K; Rosenstock, J; Yu, S, 2002) |
| "Twenty NIDDM subjects (mean age 58." | 2.68 | Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. ( Baba, S; Eguchi, H; Hozumi, T; Ikeda, M; Ishida, Y; Kaneko, T; Kawamori, R; Kubota, M; Omori, Y; Sasaki, H; Sato, A; Shichiri, M; Tominaga, M; Uehara, M; Wasada, T; Yamasaki, Y, 1997) |
| "Nonalcoholic fatty liver disease (NAFLD) is an often unrecognized complication of type 2 diabetes (T2DM) associated with significant economic burden and poor long-term hepatic and extrahepatic outcomes." | 2.66 | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. ( Budd, J; Cusi, K, 2020) |
| "Pioglitazone is a potent insulin sensitizer, preserves beta-cell function, causes durable reduction in HbA1c, corrects multiple components of metabolic syndrome and improves nonalcoholic fatty liver disease/nonalcoholic steatohepatitis." | 2.61 | Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. ( Abdul-Ghani, M; DeFronzo, RA; Inzucchi, S; Nissen, SE, 2019) |
| "Nonalcoholic fatty liver disease (NAFLD), the most prevalent cause of chronic liver disease worldwide, is strongly associated with obesity and insulin resistance." | 2.61 | Nonalcoholic Fatty Liver Disease and Obesity Treatment. ( Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM, 2019) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| "Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach." | 2.58 | Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. ( De Ponti, F; Marchesini, G; Mazzotti, A; Poluzzi, E; Raschi, E, 2018) |
| "Type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in the community, and share common pathogenic mechanisms." | 2.55 | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? ( Caletti, MT; Forlani, G; Marchesini, G; Marchignoli, F; Mazzotti, A, 2017) |
| "Nonalcoholic fatty liver disease is the most common cause of liver dysfunction in the western world because of its close association with obesity, insulin resistance and dyslipidaemia." | 2.52 | Nonalcoholic fatty liver disease: new treatments. ( Anstee, QM; Day, CP; Hardy, T, 2015) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide." | 2.49 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder in the Western world." | 2.49 | Nonalcoholic fatty liver disease: current issues and novel treatment approaches. ( Bril, F; Cusi, K; Lomonaco, R; Sunny, NE, 2013) |
| "Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients." | 2.47 | Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. ( Forst, T; Pfützner, A, 2011) |
| "Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world." | 2.47 | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011) |
| "Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS." | 2.46 | The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010) |
| "To date, clinical trials conducted in type 2 diabetes patients have used combinations of sitagliptin (100 mg/day) and pioglitazone (30 - 45 mg/day) as separate tablets." | 2.46 | Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. ( Bailey, CJ; Flatt, PR; Green, BD, 2010) |
| "Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atherosclerotic and cardiovascular events." | 2.46 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. ( Cersosimo, E; DeFronzo, RA; Triplitt, C, 2010) |
| "Pioglitazone has favorable effects on important components of metabolic syndrome including blood pressure." | 2.44 | [Pioglitazone effects on blood pressure in patients with metabolic syndrome]. ( Kushiro, T; Takahashi, A, 2008) |
| "Type 2 diabetes is characterised by a gradual decline in glycaemic control and progression from oral glucose-lowering monotherapy to combination therapy and exogenous insulin therapy." | 2.44 | Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. ( Hanefeld, M, 2007) |
| "Treatment with Rosiglitazone should be reconsidered because of a potential cardiovascular risk." | 2.44 | [Therapy with glitazones--a risk for cardiovascular disease?]. ( Erdmann, E; Hoppe, UC; Michels, G; Rottlaender, D, 2007) |
| "The prevalence of type 2 diabetes mellitus (T2DM) is growing at an alarming rate and reaching epidemic proportions, and cardiovascular disease continues to be one of the leading causes of death in the United States." | 2.44 | PPARgamma agonists and coronary atherosclerosis. ( Chilton, R; Sulistio, MS; Thukral, N; Zion, A, 2008) |
| "Insulin resistance is a major intermediate link between disordered glucose metabolism and macrovascular complications." | 2.43 | [Glucose-independent impact of the glitazones on the cardiovascular outcome]. ( Hanefeld, M, 2005) |
| "Insulin resistance is a principal underlying defect in type 2 DM along with beta-cell dysfunction, and this insulin resistance underpins many of the abnormalities associated with the metabolic syndrome." | 2.43 | The Clinical Significance of PPAR Gamma Agonism. ( Campbell, IW, 2005) |
| "The primary aim must be the treatment of the insulin resistance." | 2.43 | [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005) |
| " Long term administration of PPARgamma activator pioglitazone ameliorated the activity of NASH." | 2.43 | [PPAR and NASH]. ( Aoyama, T; Tanaka, N, 2006) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 2.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Inflammation is known to have a pathogenic role in atherosclerosis and the genesis of acute coronary syndromes." | 2.43 | Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006) |
| "Insulin resistance has a complex etiology, with multiple manifestations across the organ systems involved in glucose homeostasis." | 2.43 | Metformin and pioglitazone: Effectively treating insulin resistance. ( Staels, B, 2006) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "Patients with type 2 diabetes mellitus frequently have coexistent dyslipidemia, hypertension, and obesity, and are at risk for microvascular and macrovascular disease complications such as myocardial infarction, stroke, retinopathy, and microalbuminuria." | 2.42 | Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. ( Chilton, RJ; Stolar, MW, 2003) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| "Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world." | 2.41 | New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. ( Henry, RR; Mudaliar, S, 2001) |
| "Insulin resistance is a change in physiologic regulation such that a fixed dose of insulin causes less of an effect on glucose metabolism than occurs in normal individuals." | 2.41 | Insulin resistance and its treatment by thiazolidinediones. ( Banerji, MA; Lebovitz, HE, 2001) |
| "Type 2 diabetes is a disorder that has numerous components, including insulin resistance, an insulin secretory defect, and an increase in hepatic glucose production." | 2.41 | Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. ( Peters, AL, 2001) |
| "Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported." | 2.41 | [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. ( Ikeda, H; Sugiyama, Y, 2001) |
| "Type 2 diabetes is increasingly common and can be difficult to control." | 2.41 | Actos (pioglitazone): a new treatment for type 2 diabetes. ( Lawrence, JM; Reckless, JP, 2001) |
| "Pioglitazone is a potent agonist for the peroxisome proliferator activated receptor(PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported." | 2.41 | [Pharmacological effects of a thiazolidinedione derivative, pioglitazone]. ( Ikeda, H; Sugiyama, Y, 2001) |
| "Pioglitazone is a TZD that reduces plasma glucose levels by increasing peripheral glucose utilisation and decreasing hepatic glucose production." | 2.41 | New solutions for type 2 diabetes mellitus: the role of pioglitazone. ( Grossman, LD, 2002) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| "Metformin was used as a positive control." | 1.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "The combined treatment with INS 18 U/kg + PIO 5 mg/kg was more effective in preventing advanced cachexia in TB rats than each treatment alone, emerging as the best approach, considering the lower dosage and higher efficacy." | 1.91 | Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity. ( Bazotte, RB; Bertolini, GL; Biazi, GR; Cassolla, P; de Souza Galia, WB; de Souza, HM; Diaz, BF; Ferraz, LS; Frasson, IG; Kurauti, MA; Mareze-Costa, CE; Marmentini, C; Miksza, DR; Peres, SB, 2023) |
| "After NAFLD induction, the serum level of IL-10 significantly increased and serum IL-1β, TNF-α levels significantly decreased by injection of both doses of Shilajit and pioglitazone (P<0." | 1.72 | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. ( Asadikaram, G; Ghezelbash, B; Khaksari, M; Shahrokhi, M; Shahrokhi, N; Shirazpour, S, 2022) |
| "Screening for NAFLD remains challenging especially in those with diabetes because liver enzymes are often in the normal range and the performance of NAFLD scores is limited." | 1.62 | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? ( Kahl, S; Roden, M; Schröder, B, 2021) |
| "However, insulin resistance was ameliorated by pioglitazone with or without fish oil treatment and the discontinuation of fish oil." | 1.56 | Impact of discontinuation of fish oil after pioglitazone-fish oil combination therapy in diabetic KK mice. ( Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M, 2020) |
| "It is the compensatory hyperinsulinemia rather than insulin resistance per se that causes blood pressure elevation." | 1.56 | Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats. ( Chen, Y; Li, G; Pan, L; Shen, X; Tian, Y; Wang, H, 2020) |
| "Pioglitazone has been used for the treatment of nonalcoholic fatty liver disease (NAFLD) related to diabetes." | 1.51 | Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. ( de Mendonça, M; de Sousa, É; Dos Santos, BAC; Rodrigues, AC, 2019) |
| "Type 2 diabetes was induced in male Sprague-Dawley rats by combination of high fat diet and low dose streptozotocin (35mg/kg)." | 1.48 | Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. ( Abdel-Rahman, N; Eissa, LA; Eraky, SM, 2018) |
| "Pioglitazone treatment did not influence body weight or ovarian weight in either group." | 1.48 | Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. ( Baba, T; Endo, T; Honnma, H; Ikeda, K; Kiya, T; Kuno, Y; Morishita, M; Saito, T, 2018) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 1.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| "Treatment with pioglitazone ameliorated Aβ42 deposition in the hippocampus by increasing IDE and PPARγ expression." | 1.46 | Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation. ( Cao, M; Chen, Z; Li, R; Wang, Z; Yang, S; Zhang, M, 2017) |
| "Insulin resistance was induced in C57BL/6J mice using 4 wk of a high-fat compared with a low-fat diet." | 1.46 | Long-term rates of mitochondrial protein synthesis are increased in mouse skeletal muscle with high-fat feeding regardless of insulin-sensitizing treatment. ( Ehrlicher, SE; Hamilton, KL; Miller, BF; Newsom, SA; Robinson, MM; Stierwalt, HD, 2017) |
| "Treatment with pioglitazone caused an increase in body weight gain in Pemt(-/-) mice that was mainly due to increased adiposity." | 1.43 | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. ( Armstrong, EA; Gao, X; Jacobs, RL; Kassiri, Z; Lehner, R; Lingrell, S; Quiroga, AD; Takawale, A; van der Veen, JN; Vance, DE; Yager, JY, 2016) |
| "Atorvastatin treatment (Group D) abolished PPHTg which became comparable to controls, pioglitazone treatment partially blunted PPHTg resulting in intermediate PPHTg." | 1.43 | Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes. ( Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK, 2016) |
| "Insulin sensitivity was obtained with hyperinsulinemic euglycemic clamp." | 1.43 | PPARγ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats. ( Feng, Z; Kusunoki, M; Nakamura, T; Nishina, A; Oda, K; Sato, D; Takahashi, K; Tsutsumi, K, 2016) |
| "Insulin resistance is known to be a risk factor for cognitive impairment, most likely linked to insulin signaling, microglia overactivation, and beta amyloid (Aβ) deposition in the brain." | 1.43 | Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. ( Gad, ES; Moustafa, YM; Zaitone, SA, 2016) |
| "Treatment with pioglitazone or nicorandil either alone or in combination successfully ameliorated the deleterious effects of HFD on the all previous parameters." | 1.42 | Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. ( Elshazly, SM, 2015) |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | 1.42 | Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. ( Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) |
| "The laminopathy variant familial partial lipodystrophy type 2 or Dunnigan syndrome (FPLD2) is the most common cause of partial LD." | 1.42 | [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia]. ( Kalashnikova, MF; Melnichenko, GA; Sorkina, EL; Tyulpakov, AN, 2015) |
| "Pioglitazone treatment suppressed mRNA and protein expression of fetuin-A in Fao hepatoma cells." | 1.40 | Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. ( Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A, 2014) |
| "T0901317 treatment induced significant insulin resistance in C57BL/6 mice." | 1.40 | Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ. ( Li, H; Lu, W; Pan, Q; Wu, F; Yin, X; Yu, D; Zhang, S; Zheng, F, 2014) |
| "Pioglitazone treatment increased the cross-sectional area of adipocytes by 18% (p = 0." | 1.40 | Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity. ( Adu, A; Finlin, BS; Kern, PA; Peterson, CA; Rasouli, N; Shipp, LR; Spencer, M; Yang, L; Zhu, B, 2014) |
| "A rat model of type 2 diabetes (T2D) was established with streptozotocin (STZ)." | 1.39 | Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes. ( Hu, SH; Jiang, T; Yang, SS; Yang, Y, 2013) |
| "Pioglitazone (PIO) is a member of the thiazolidinediones - a group of insulin-sensitizing drugs that are selective agonists of peroxisome proliferator-activated receptor gamma (PPARγ)." | 1.39 | Pioglitazone does not improve insulin signaling in mice with GH over-expression. ( Bartke, A; Gesing, A; Masternak, MM, 2013) |
| "Muscular insulin resistance is a characteristic of obesity and type 2 diabetes, but little is known about fatty acid (FA) metabolism in insulin-resistant skeletal muscle." | 1.39 | Pioglitazone-induced increase in the stearoyl-CoA desaturation index and fat accumulation in rat muscles are not related to lipoprotein lipase activity. ( Matsuo, T; Ochiai, M, 2013) |
| "The objective of the current study was to assess the possible pharmacokinetic interactions of spirulina with glitazones in an insulin resistance rat model." | 1.39 | Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model. ( Al-Dhubiab, BE; Chattopadhyaya, I; Gupta, A; Gupta, S; Kumria, R; Nair, A, 2013) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| "Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence." | 1.38 | An unusual cause of delayed puberty: Berardinelli- Seip syndrome. ( Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V, 2012) |
| " Insulin resistance induced by chronic administration of PGRN was suppressed by neutralizing IL-6 in vivo." | 1.38 | PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. ( Hosooka, T; Kitazawa, S; Matsubara, T; Matsuo, E; Minami, K; Mita, A; Nishimura, O; Seino, S; Takahashi, K; Tamori, Y; Watanabe, M; Yokoi, N, 2012) |
| "Insulin resistance was induced in rats by feeding a high-fructose diet for six weeks." | 1.38 | Beneficial impact of Zingiber zerumbet on insulin sensitivity in fructose-fed rats. ( Chang, CJ; Chang, YS; Liu, IM; Tzeng, TF, 2012) |
| "5h and bioavailability of 85%." | 1.38 | NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ( Chaudhary, S; Dube, A; Kothari, V; Sachan, N; Upasani, CD, 2012) |
| "6 nM) with partial PPARγ agonism (EC(50) = 212 nM, 31% max) and oral bioavailability in rat." | 1.37 | Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. ( Bigge, CF; Casimiro-Garcia, A; Chen, J; Davis, JA; Dudley, DA; Edmunds, JJ; Ellis, T; Esmaeil, N; Filzen, GF; Flynn, D; Geyer, A; Heemstra, RJ; Jalaie, M; Ohren, JF; Ostroski, R; Schaum, RP; Stoner, C, 2011) |
| "Insulin resistance was induced in rats by feeding a high fructose diet for 6 weeks." | 1.37 | Angelica acutiloba root attenuates insulin resistance induced by high-fructose diet in rats. ( Chang, CJ; Liou, SS; Liu, IM; Tzeng, TF, 2011) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12 weeks of the 16-week period." | 1.37 | Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. ( Dong, C; Hou, L; Hou, X; Liu, X; Luo, D; Wang, M; Xu, S, 2011) |
| "A total of 101 patients with type 2 diabetes were treated for 12 weeks with pioglitazone (15 mg/day)." | 1.37 | Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. ( Azarpira, N; Dabbaghmanesh, MH; Namvaran, F; Rahimi-Moghaddam, P, 2011) |
| "Pioglitazone has an important role in the treatment of patients with Type 2 diabetes." | 1.37 | Which is the eligible patient to be treated with pioglitazone? The expert view. ( Avogaro, A; Betteridge, J; Bonadonna, R; Campbell, IW; Crepaldi, G; Farinaro, E; Federici, M; Schernthaner, GH; Staels, B, 2011) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12weeks of the 16-week period." | 1.36 | Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. ( Hao, Y; Hou, L; Liu, X; Luo, D; Zhang, S; Zheng, M, 2010) |
| "Combined PIO and BEZA therapy in Type 2 diabetes does not decrease intrahepatic triglyceride content or postprandial endogenous glucose production." | 1.36 | Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content. ( Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R, 2010) |
| "Insulin resistance is a characteristic of type 2 diabetes and is a major independent risk factor for progression to the disease." | 1.36 | Generation, validation and humanisation of a novel insulin resistant cell model. ( Brady, JD; Crowther, D; Feuerstein, GZ; Grierson, CE; Hansen, MK; Hundal, HS; Logie, L; Morris, AD; Pearson, E; Ruiz-Alcaraz, AJ; Schofield, CJ; Shepherd, B; Sutherland, C; Tommasi, AM, 2010) |
| "Pioglitazone treatment in type 2 diabetes mellitus produced significant improvements in glycaemic control, plasma lipids, blood pressure and inflammation." | 1.36 | Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. ( Alemdar, R; Aydin, M; Basar, C; Caglar, O; Ordu, S; Ozhan, H; Yalcin, S; Yazici, M, 2010) |
| "Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0." | 1.35 | Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. ( Beck-Nielsen, H; Glintborg, D; Højlund, K; Jensen, T; Knudsen, S; Kruse, TA; Skov, V; Tan, Q, 2008) |
| "Hyperinsulinemia is associated with enhanced MMP-9 serum levels, potentially facilitating monocyte migration to and infiltration of adipose tissue and the arterial wall, thereby contributing to the increased cardiovascular risk in obese, hyperinsulinemic patients." | 1.35 | Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. ( Clemenz, M; Fleck, E; Graf, K; Kappert, K; Kintscher, U; Meyborg, H; Stawowy, P, 2008) |
| "Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin." | 1.35 | The ratio of leptin to adiponectin can be used as an index of insulin resistance. ( Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y, 2008) |
| "Pioglitazone and insulin treatments, but not metformin, reduced hyperglycemia, polydipsia, and polyphagia." | 1.35 | Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes. ( Andreotti, S; Borges-Silva, Cd; Campana, AB; de Campos, TB; Fonseca-Alaniz, MH; Lima, FB; Machado, UF; Okamoto, M; Takada, J, 2008) |
| "Insulin resistance is related to the atherosclerotic process." | 1.34 | Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. ( Harano, Y; Suzuki, M; Takamisawa, I; Yoshimasa, Y, 2007) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 1.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Pioglitazone abolished the CCK-8-evoked hyperinsulinemia (P < 0." | 1.34 | Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders? ( DiMagno, MJ; Gangireddy, SR; Hao, Y; Lee, SH; Owyang, C; Reddy, RC, 2007) |
| "Pioglitazone treatment reduced both hepatic lipid content (12." | 1.34 | Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. ( Fujii, M; Hirota, Y; Kasuga, M; Kawamitsu, H; Kouyama, K; Maeda, K; Ohara, T; Sugimura, K; Teranishi, T; Zenibayashi, M, 2007) |
| "Pioglitazone (10 mg/kg) was then administered by gavage daily for 11 weeks to the pioglitazone group." | 1.33 | [The impact of pioglitazone on plasma homocysteine high-fat diet-induced insulin resistance in rats]. ( Liu, HF; Lu, JM; Ma, FL; Pan, CY; Yang, GQ; Zou, XM, 2005) |
| "A total of 32 patients with type 2 diabetes were studied." | 1.33 | Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. ( Babaya, N; Fujisawa, T; Ikegami, H; Inoue, K; Itoi-Babaya, M; Kawabata, Y; Nishino, M; Nojima, K; Ogihara, T; Ono, M; Taniguchi, H, 2005) |
| "Treatment with pioglitazone decreased the neointimal content of lipid in 20-week-old mice from 50 +/- 6% to 30 +/- 7%, p=0." | 1.33 | Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. ( Clough, MH; Schneider, DJ; Sobel, BE; Taatjes, DJ; Wadsworth, MP; White, MF, 2005) |
| "A patient with type 2 diabetes and hypothalamic damage due to a suprasellar tumor developed impaired glycemic control and central obesity." | 1.33 | Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. ( Goto, T; Igaki, N; Tanaka, M, 2005) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | 1.33 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| "Thirty-six patients with type 2 diabetes and HbA1c >or= 6." | 1.33 | Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. ( Dorkhan, M; Frid, A; Groop, L; Hallengren, B; Lantz, M, 2006) |
| "Pioglitazone, or vehicle, was administered for 4 wk to 8-wk-old obese Zucker rats." | 1.33 | The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. ( Burnier, M; Cefai, D; Maillard, M; Nussberger, J; Perregaux, C; Zanchi, A, 2006) |
| "Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance." | 1.33 | Pioglitazone increases gallbladder volume in insulin-resistant obese mice. ( Al-Azzawi, HH; Lu, D; Mathur, A; Nakeeb, A; Pitt, HA; Swartz-Basile, DA, 2006) |
| "Pioglitazone pretreatment of diabetic islets restored their glucose sensitivity." | 1.33 | Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets. ( Sjöholm, A; Zhang, F; Zhang, Q, 2006) |
| "Pioglitazone treatment reduced the concentration of plasma free fatty acids in rats fed on either diet." | 1.33 | Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles. ( Baranowski, M; Górski, J; Zabielski, P; Zendzian-Piotrowska, M, 2006) |
| "For the treatment of type 2 diabetes we now have available a wide spectrum of oral antidiabetic agents and insulins that make it possible to offer the patient an individualized, pathophysiologically oriented therapy." | 1.32 | [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. ( Fischer, S; Hanefeld, M, 2003) |
| "In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration." | 1.32 | Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. ( Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Piper, P; Pratipanawatr, T; Suraamornkul, S, 2004) |
| "Treatment with pioglitazone thus protects against beta-cell damage and would be useful for restoration of insulin secretory capacity in obese diabetes individuals." | 1.32 | Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. ( Ishida, H; Itagaki, E; Katahira, H; Katsuta, H; Maruyama, M; Nagamatsu, S; Nakamichi, Y; Ozawa, S; Takizawa, M; Tanaka, T; Yamaguchi, S; Yoshimoto, K, 2004) |
| "Treatment with pioglitazone for 8 weeks lowered glycated albumin level (27." | 1.32 | Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients. ( Hiramatsu, S; Karashima, T; Tajiri, Y, 2004) |
| "Pioglitazone treatment significantly decreased AIP from baseline in each of the study groups." | 1.32 | Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. ( Glazer, NB; Johns, D; Tan, MH, 2004) |
| " Data have been lacking on their use in combination with both sulfonylurea and metformin among patients of type 2 diabetes who are on insulin therapy secondary to failure of routine oral hypoglycemic drugs in controlling their diabetes." | 1.32 | Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. ( Chandalia, HB; Fafadia, A; Joshi, SR; Panikar, V; Santvana, C, 2003) |
| "pioglitazone was well tolerated." | 1.32 | [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes]. ( Fan, J; Gao, H; Li, Y; Liao, Z; Wang, C; Wang, Y; Yu, H; Yu, Y; Zhao, W, 2003) |
| "In untreated rats insulin sensitivity decreased by 46% over 3-6 h of elevated FFA, whereas it remained normal but with a 50% increase in FFA clearance in Pio-treated rats." | 1.31 | Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. ( Cooney, GJ; Dzamko, N; Ellis, B; Frangioudakis, G; Furler, SM; Iglesias, MA; Kraegen, EW; Ye, JM, 2002) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| "When pioglitazone was administered to the rats at a dose of 10 mg/kg/day for 4 weeks from 12 weeks of age, plasma triglyceride and insulin levels and systolic blood pressure decreased, and blood glucose reduction in response to insulin was normalized." | 1.30 | Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. ( Ikeda, H; Nomura, C; Odaka, H; Suzuki, M, 1997) |
| " Metabolites 6-9 have been identified after dosing of rats and dogs." | 1.29 | Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. ( Colca, JR; Fisher, RM; Kletzein, RF; Parker, TT; Tanis, SP, 1996) |
| "Pioglitazone treatment prevented the development of hypertension and reduced plasma insulin concentration by 70% and 37% in rats fed a high-fat or glucose diet, respectively (P < ." | 1.29 | Pioglitazone attenuates diet-induced hypertension in rats. ( DeGrange, LM; Kaufman, LN; Peterson, MM, 1995) |
| "Pioglitazone treatment of diabetic animals significantly enhanced the effects of insulin to reverse elevated blood glucose." | 1.29 | Insulin sensitization in diabetic rat liver by an antihyperglycemic agent. ( Colca, JR; Hofmann, C; Lorenz, K; Palazuk, BJ; Williams, D, 1995) |
| "As obesity is a major risk factor for noninsulin-dependent diabetes mellitus, adipose tissue may generate a mediator that influences the activity of insulin on various target tissues." | 1.29 | Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. ( Braithwaite, SS; Colca, JR; Hofmann, C; Hotamisligil, GS; Lorenz, K; Palazuk, BJ; Spiegelman, BM, 1994) |
| "Insulin sensitivity was increased by pioglitazone hydrochloride (P = 0." | 1.29 | Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. ( Baum, ST; Bergman, RN; Elson, DF; Kemnitz, JW; Meglasson, MD; Roecker, EB, 1994) |
| "Pioglitazone treatment did not change insulin binding in high-fat-fed rats, but increased insulin-stimulated autophosphorylation of insulin receptors to the level of control animals." | 1.29 | Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. ( Iwanishi, M; Kobayashi, M, 1993) |
| "Pioglitazone treatment did not change insulin binding in Wistar fatty rats but increased insulin-stimulated autophosphorylation of insulin receptors to 78% over the level in the control but not the basal state." | 1.28 | Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. ( Egawa, K; Iwanishi, M; Kobayashi, M; Shigeta, Y, 1992) |
| "Insulin resistance is one of pathogenic factors for non-insulin-dependent diabetes mellitus (NIDDM)." | 1.28 | Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. ( Fujita, T; Ikeda, H; Shimura, Y; Sugiyama, Y; Taketomi, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 43 (6.47) | 18.2507 |
| 2000's | 295 (44.36) | 29.6817 |
| 2010's | 274 (41.20) | 24.3611 |
| 2020's | 53 (7.97) | 2.80 |
| Authors | Studies |
|---|---|
| Tanis, SP | 2 |
| Parker, TT | 2 |
| Colca, JR | 13 |
| Fisher, RM | 1 |
| Kletzein, RF | 1 |
| Chittiboyina, AG | 1 |
| Venkatraman, MS | 1 |
| Mizuno, CS | 1 |
| Desai, PV | 1 |
| Patny, A | 1 |
| Benson, SC | 1 |
| Ho, CI | 1 |
| Kurtz, TW | 1 |
| Pershadsingh, HA | 1 |
| Avery, MA | 1 |
| Casimiro-Garcia, A | 1 |
| Filzen, GF | 1 |
| Flynn, D | 1 |
| Bigge, CF | 1 |
| Chen, J | 4 |
| Davis, JA | 1 |
| Dudley, DA | 1 |
| Edmunds, JJ | 1 |
| Esmaeil, N | 1 |
| Geyer, A | 1 |
| Heemstra, RJ | 1 |
| Jalaie, M | 1 |
| Ohren, JF | 1 |
| Ostroski, R | 1 |
| Ellis, T | 1 |
| Schaum, RP | 1 |
| Stoner, C | 1 |
| Patel, OP | 1 |
| Mishra, A | 1 |
| Maurya, R | 1 |
| Saini, D | 1 |
| Pandey, J | 1 |
| Taneja, I | 1 |
| Raju, KS | 1 |
| Kanojiya, S | 1 |
| Shukla, SK | 1 |
| Srivastava, MN | 1 |
| Wahajuddin, M | 1 |
| Tamrakar, AK | 1 |
| Srivastava, AK | 1 |
| Yadav, PP | 1 |
| Artman, GD | 1 |
| Larsen, SD | 1 |
| McDonald, WG | 4 |
| Gadwood, RC | 1 |
| Kletzien, RF | 3 |
| Zeller, JB | 1 |
| Lee, PH | 1 |
| Adams, WJ | 2 |
| Abdalla, MA | 1 |
| Shah, N | 1 |
| Deshmukh, H | 1 |
| Sahebkar, A | 1 |
| Östlundh, L | 1 |
| Al-Rifai, RH | 1 |
| Atkin, SL | 3 |
| Sathyapalan, T | 2 |
| Lee, SK | 1 |
| Park, CY | 2 |
| Kim, J | 2 |
| Kim, D | 1 |
| Choe, H | 1 |
| Kim, JH | 1 |
| Hong, JP | 1 |
| Lee, YJ | 1 |
| Heo, Y | 1 |
| Park, HS | 1 |
| Jang, YJ | 1 |
| Scherer, PE | 3 |
| Aggarwal, H | 1 |
| Pathak, P | 1 |
| Kumar, Y | 1 |
| Jagavelu, K | 1 |
| Dikshit, M | 1 |
| Lule, KO | 1 |
| Akarsu, E | 1 |
| Sayiner, ZA | 1 |
| Lule, NO | 1 |
| Balci, SO | 1 |
| Demirel, C | 1 |
| Bozdag, Z | 1 |
| Korkmaz, M | 1 |
| Yilmaz, I | 1 |
| Chinta, PK | 1 |
| Tambe, S | 1 |
| Umrani, D | 1 |
| Pal, AK | 1 |
| Nandave, M | 1 |
| Spence, JD | 5 |
| Viscoli, C | 1 |
| Kernan, WN | 16 |
| Young, LH | 13 |
| Furie, K | 1 |
| DeFronzo, R | 4 |
| Abdul-Ghani, M | 4 |
| Dandona, P | 1 |
| Inzucchi, SE | 16 |
| Ghezelbash, B | 1 |
| Shahrokhi, N | 1 |
| Khaksari, M | 1 |
| Asadikaram, G | 1 |
| Shahrokhi, M | 1 |
| Shirazpour, S | 1 |
| Samms, RJ | 1 |
| Cheng, CC | 1 |
| Fourcaudot, M | 1 |
| Heikkinen, S | 1 |
| Khattab, A | 1 |
| Adams, J | 2 |
| Cersosimo, E | 6 |
| Triplitt, C | 4 |
| Puckett, C | 2 |
| Tsintzas, K | 1 |
| Adams, AC | 2 |
| Abdul-Ghani, MA | 3 |
| DeFronzo, RA | 20 |
| Norton, L | 1 |
| Xiang, H | 1 |
| Chen, H | 1 |
| Liu, Y | 4 |
| Dodd, D | 1 |
| Pao, AC | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 1 |
| Wahid, A | 1 |
| Nunez Lopez, YO | 1 |
| Casu, A | 1 |
| Kovacova, Z | 2 |
| Petrilli, AM | 1 |
| Sideleva, O | 1 |
| Tharp, WG | 2 |
| Pratley, RE | 4 |
| Iizaka, T | 1 |
| Kodama, E | 1 |
| Mikura, K | 1 |
| Iida, T | 1 |
| Imai, H | 1 |
| Hashizume, M | 1 |
| Kigawa, Y | 1 |
| Sugisawa, C | 1 |
| Tadokoro, R | 1 |
| Endo, K | 1 |
| Otsuka, F | 1 |
| Isoda, M | 1 |
| Ebihara, K | 2 |
| Ishibashi, S | 2 |
| Nagasaka, S | 1 |
| Moody, AJ | 1 |
| Molina-Wilkins, M | 1 |
| Clarke, GD | 1 |
| Merovci, A | 1 |
| Solis-Herrera, C | 1 |
| Chilton, RJ | 2 |
| Iozzo, P | 1 |
| Gastaldelli, A | 8 |
| Al-Jaber, H | 1 |
| Mohamed, NA | 1 |
| Govindharajan, VK | 1 |
| Taha, S | 1 |
| John, J | 1 |
| Halim, S | 1 |
| Alser, M | 1 |
| Al-Muraikhy, S | 1 |
| Anwardeen, NR | 1 |
| Agouni, A | 1 |
| Elhissi, A | 1 |
| Al-Naemi, HA | 1 |
| Al-Mansoori, L | 1 |
| Elrayess, MA | 1 |
| Zhao, Y | 6 |
| Zhao, W | 4 |
| Wang, H | 8 |
| Bu, H | 3 |
| Takahashi, H | 3 |
| Triwatana, W | 3 |
| Satirapoj, B | 3 |
| Supasyndh, O | 3 |
| Nata, N | 3 |
| Mirzaie, S | 2 |
| Yousefi, AR | 2 |
| Masoumi, R | 2 |
| Rostami, B | 2 |
| Amanlou, H | 2 |
| Zakaraya, ZZ | 1 |
| AlTamimi, L | 1 |
| Hailat, M | 2 |
| Ahmad, MN | 1 |
| Qinna, NA | 1 |
| Ghanim, BY | 1 |
| Saadh, MJ | 2 |
| Al-Dmour, N | 1 |
| Dayyih, WA | 1 |
| Tamimi, LN | 1 |
| Zakaraya, Z | 1 |
| Abu Dayyih, W | 1 |
| Daoud, E | 1 |
| Abed, A | 1 |
| Majeed, B | 1 |
| Abumansour, H | 1 |
| Aburumman, A | 1 |
| Majeed, JM | 1 |
| Hamad, M | 1 |
| McClelland, TJ | 1 |
| Fowler, AJ | 1 |
| Davies, TW | 1 |
| Pearse, R | 1 |
| Prowle, J | 1 |
| Puthucheary, Z | 1 |
| Zhao, H | 1 |
| Wang, D | 2 |
| Xing, C | 1 |
| Lv, B | 1 |
| Wang, X | 2 |
| He, B | 1 |
| Yoo, J | 1 |
| Jeon, J | 1 |
| Baik, M | 1 |
| Zeng, H | 2 |
| Huang, Y | 2 |
| Liu, D | 2 |
| Xie, T | 1 |
| Chen, Z | 3 |
| Huang, Q | 2 |
| Zhou, X | 3 |
| Lai, X | 1 |
| Liu, J | 3 |
| Bell, DSH | 1 |
| Jerkins, T | 1 |
| Miksza, DR | 1 |
| Biazi, GR | 1 |
| Frasson, IG | 1 |
| de Souza Galia, WB | 2 |
| Ferraz, LS | 1 |
| Diaz, BF | 1 |
| Kurauti, MA | 1 |
| Marmentini, C | 1 |
| Mareze-Costa, CE | 1 |
| Peres, SB | 1 |
| Cassolla, P | 2 |
| Bertolini, GL | 1 |
| Bazotte, RB | 1 |
| de Souza, HM | 2 |
| Deng, M | 1 |
| Wen, Y | 1 |
| Yan, J | 1 |
| Fan, Y | 1 |
| Wang, Z | 2 |
| Zhang, R | 2 |
| Ren, L | 2 |
| Ba, Y | 1 |
| Lu, Q | 1 |
| Fan, H | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Iizuka, Y | 2 |
| Chiba, K | 1 |
| Kim, H | 2 |
| Hirako, S | 2 |
| Wada, M | 3 |
| Matsumoto, A | 2 |
| de Mendonça, M | 2 |
| de Sousa, É | 2 |
| da Paixão, AO | 1 |
| Araújo Dos Santos, B | 1 |
| Roveratti Spagnol, A | 1 |
| Murata, GM | 1 |
| Araújo, HN | 1 |
| Imamura de Lima, T | 1 |
| Passos Simões Fróes Guimarães, DS | 1 |
| Silveira, LR | 1 |
| Rodrigues, AC | 2 |
| Lebovitz, HE | 2 |
| Rashid, A | 1 |
| Ganie, MA | 1 |
| Wani, IA | 2 |
| Bhat, GA | 1 |
| Shaheen, F | 1 |
| Shrivastava, M | 1 |
| Shah, ZA | 1 |
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Villarroya, F | 1 |
| Seo, JA | 1 |
| Kang, MC | 1 |
| Yang, WM | 1 |
| Hwang, WM | 1 |
| Kim, SS | 1 |
| Hong, SH | 1 |
| Heo, JI | 1 |
| Vijyakumar, A | 1 |
| Pereira de Moura, L | 1 |
| Uner, A | 1 |
| Huang, H | 1 |
| Lee, SH | 2 |
| Lima, IS | 1 |
| Park, KS | 1 |
| Kim, MS | 3 |
| Dagon, Y | 1 |
| Willnow, TE | 1 |
| Aroda, V | 2 |
| Ciaraldi, TP | 3 |
| Henry, RR | 11 |
| Kim, YB | 1 |
| Carboni, E | 2 |
| Carta, AR | 1 |
| Tian, Y | 1 |
| Chen, Y | 2 |
| Shen, X | 1 |
| Pan, L | 3 |
| Li, G | 1 |
| Hegazy, M | 1 |
| El-Shafey, M | 1 |
| Abulsoud, AI | 1 |
| Elsadek, BEM | 1 |
| Abd Elaziz, AI | 1 |
| Salama, SA | 1 |
| Kiran, A | 1 |
| Viscoli, CM | 15 |
| Furie, KL | 14 |
| Gorman, M | 10 |
| Budd, J | 1 |
| Cusi, K | 9 |
| Sun, Y | 1 |
| Yu, Q | 1 |
| Xie, J | 1 |
| Mohammed, ED | 1 |
| Zhang, Z | 1 |
| Tian, W | 1 |
| Gangarapu, V | 1 |
| Al-Gendy, AA | 1 |
| Wei, J | 1 |
| Sun, B | 1 |
| Hurren, KM | 1 |
| Dunham, MW | 1 |
| Finlin, BS | 2 |
| Memetimin, H | 1 |
| Zhu, B | 2 |
| Confides, AL | 1 |
| Vekaria, HJ | 1 |
| El Khouli, RH | 1 |
| Johnson, ZR | 1 |
| Westgate, PM | 1 |
| Morris, AJ | 1 |
| Sullivan, PG | 1 |
| Dupont-Versteegden, EE | 1 |
| Kern, PA | 12 |
| Krinock, MJ | 1 |
| Singhal, NS | 1 |
| Luo, Q | 1 |
| Su, Z | 1 |
| Xing, J | 1 |
| Wu, J | 1 |
| Xiang, L | 1 |
| Pan, H | 1 |
| Wu, X | 1 |
| Zhang, X | 4 |
| Li, J | 3 |
| Yan, F | 1 |
| Zhang, H | 4 |
| Ponirakis, G | 1 |
| Jayyousi, A | 1 |
| Zirie, MA | 1 |
| Al-Mohannadi, S | 1 |
| Almuhannadi, H | 1 |
| Petropoulos, IN | 1 |
| Khan, A | 1 |
| Gad, H | 1 |
| Migahid, O | 1 |
| Megahed, A | 1 |
| Qazi, M | 1 |
| AlMarri, F | 1 |
| Al-Khayat, F | 1 |
| Mahfoud, Z | 1 |
| Malik, RA | 1 |
| Lam, YY | 1 |
| Tsai, SF | 1 |
| Chen, PC | 1 |
| Kuo, YM | 1 |
| Chen, YW | 1 |
| Al-Muzafar, HM | 1 |
| Alshehri, FS | 1 |
| Amin, KA | 1 |
| El-Fayoumi, S | 1 |
| Mansour, R | 1 |
| Mahmoud, A | 1 |
| Fahmy, A | 2 |
| Ibrahim, I | 1 |
| Schröder, B | 1 |
| Kahl, S | 1 |
| Roden, M | 3 |
| Lee, M | 3 |
| Ovbiagele, B | 3 |
| Saver, JL | 3 |
| Della Pepa, G | 1 |
| Russo, M | 1 |
| Vitale, M | 1 |
| Carli, F | 1 |
| Vetrani, C | 1 |
| Masulli, M | 1 |
| Riccardi, G | 1 |
| Vaccaro, O | 1 |
| Rivellese, AA | 1 |
| Bozzetto, L | 1 |
| Pires Mendes, C | 1 |
| Postal, BG | 1 |
| Silva Frederico, MJ | 1 |
| Gonçalves Marques Elias, R | 1 |
| Aiceles de Medeiros Pinto, V | 1 |
| da Fonte Ramos, C | 1 |
| Devantier Neuenfeldt, P | 1 |
| Nunes, RJ | 1 |
| Mena Barreto Silva, FR | 1 |
| Jensterle, M | 1 |
| Goricar, K | 1 |
| Janez, A | 1 |
| Katsiki, N | 3 |
| Mikhailidis, DP | 2 |
| Lovejoy, AM | 9 |
| Dagogo-Jack, S | 2 |
| Ismail-Beigi, F | 3 |
| Korytkowski, MT | 2 |
| Schwartz, GG | 6 |
| Mao, H | 1 |
| Lockyer, P | 1 |
| Li, L | 2 |
| Ballantyne, CM | 1 |
| Patterson, C | 1 |
| Xie, L | 1 |
| Pi, X | 1 |
| Shen, JD | 1 |
| Wei, Y | 1 |
| Li, YJ | 1 |
| Qiao, JY | 1 |
| Li, YC | 2 |
| Yang, S | 3 |
| Cao, M | 1 |
| Li, R | 1 |
| Zhang, M | 1 |
| Li, X | 1 |
| Wang, E | 1 |
| Yin, B | 1 |
| Fang, D | 1 |
| Chen, P | 2 |
| Wang, G | 1 |
| Zhao, J | 1 |
| Chen, W | 3 |
| Rydén, L | 1 |
| Mellbin, L | 1 |
| Vigueira, PA | 2 |
| McCommis, KS | 1 |
| Hodges, WT | 1 |
| Schweitzer, GG | 1 |
| Cole, SL | 1 |
| Oonthonpan, L | 1 |
| Taylor, EB | 1 |
| Finck, BN | 2 |
| Newsom, SA | 1 |
| Miller, BF | 1 |
| Hamilton, KL | 1 |
| Ehrlicher, SE | 1 |
| Stierwalt, HD | 1 |
| Robinson, MM | 1 |
| Dawson, AJ | 1 |
| Kilpatrick, ES | 2 |
| Coady, AM | 2 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 1 |
| Ahmed, L | 1 |
| Eraky, SM | 1 |
| Abdel-Rahman, N | 1 |
| Eissa, LA | 1 |
| Ford, GA | 5 |
| Guarino, PD | 4 |
| Conwit, R | 8 |
| Tanne, D | 4 |
| Zamami, Y | 2 |
| Imanishi, M | 1 |
| Takechi, K | 1 |
| Ishizawa, K | 1 |
| Stuart, AC | 1 |
| Sico, JJ | 1 |
| Tayal, AH | 1 |
| Cote, R | 1 |
| Hankey, GJ | 1 |
| Dearborn, JL | 1 |
| Kent, DM | 1 |
| Fayad, P | 1 |
| Stuart, A | 1 |
| Campbell, JM | 1 |
| Adanichkin, N | 1 |
| Kurmis, R | 1 |
| Munn, Z | 1 |
| Musso, G | 1 |
| Cassader, M | 1 |
| Gambino, R | 1 |
| Jin-Shan, H | 1 |
| Xue-Bin, L | 1 |
| Liu, WC | 1 |
| Wu, CW | 1 |
| Tain, YL | 1 |
| Fu, MH | 1 |
| Hung, CY | 1 |
| Chen, IC | 1 |
| Chen, LW | 1 |
| Wu, KLH | 1 |
| Yaghi, S | 2 |
| Kamel, H | 1 |
| Dearborn, J | 1 |
| Kasner, SE | 1 |
| Morley, LC | 1 |
| Tang, T | 1 |
| Yasmin, E | 1 |
| Norman, RJ | 1 |
| Balen, AH | 1 |
| Wang, LN | 1 |
| Xia, JY | 1 |
| Sun, K | 1 |
| Hepler, C | 1 |
| Ghaben, AL | 1 |
| Gupta, RK | 1 |
| An, YA | 1 |
| Holland, WL | 2 |
| Morley, TS | 1 |
| Gordillo, R | 2 |
| Kusminski, CM | 1 |
| Khan, IM | 1 |
| Malik, BR | 1 |
| Randhawa, FA | 1 |
| Butt, NF | 1 |
| Malik, U | 2 |
| Hamid, S | 1 |
| Mac Grory, B | 1 |
| Morishita, M | 1 |
| Endo, T | 2 |
| Baba, T | 1 |
| Kuno, Y | 1 |
| Ikeda, K | 1 |
| Kiya, T | 1 |
| Honnma, H | 1 |
| Saito, T | 1 |
| Kalavalapalli, S | 1 |
| Bril, F | 3 |
| Koelmel, JP | 1 |
| Abdo, K | 1 |
| Guingab, J | 1 |
| Andrews, P | 1 |
| Li, WY | 1 |
| Jose, D | 1 |
| Yost, RA | 1 |
| Frye, RF | 1 |
| Garrett, TJ | 1 |
| Sunny, NE | 2 |
| Mohamed, HE | 1 |
| Asker, ME | 1 |
| Younis, NN | 1 |
| Shaheen, MA | 1 |
| Eissa, RG | 1 |
| Moulton, CD | 1 |
| Hopkins, CWP | 1 |
| Ismail, K | 1 |
| Stahl, D | 1 |
| Curtis, JP | 2 |
| Gorman, MJ | 2 |
| Spatz, ES | 1 |
| Lovejoy, A | 1 |
| Abbott, JD | 2 |
| Jacoby, DL | 2 |
| Kolansky, DM | 2 |
| Ling, FS | 2 |
| Pfau, SE | 2 |
| Hirano, T | 1 |
| Kumar, R | 1 |
| Pilania, RK | 1 |
| Bhatia, A | 1 |
| Dayal, D | 1 |
| Patel, R | 1 |
| Shah, G | 1 |
| Raschi, E | 1 |
| Mazzotti, A | 2 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Marchesini, G | 2 |
| Robakis, TK | 1 |
| Watson-Lin, K | 1 |
| Wroolie, TE | 2 |
| Myoraku, A | 1 |
| Nasca, C | 1 |
| Bigio, B | 1 |
| McEwen, B | 1 |
| Rasgon, NL | 2 |
| Shawky, NM | 1 |
| Shehatou, GSG | 1 |
| Suddek, GM | 1 |
| Gameil, NM | 1 |
| Inzucchi, S | 1 |
| Nissen, SE | 1 |
| Dearborn-Tomazos, J | 1 |
| Zhu, K | 1 |
| Qian, L | 1 |
| Lin, Y | 1 |
| An, L | 1 |
| Mu, G | 1 |
| Ma, G | 1 |
| Brunner, KT | 1 |
| Henneberg, CJ | 1 |
| Wilechansky, RM | 1 |
| Long, MT | 1 |
| Dos Santos, BAC | 1 |
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Derosa, G | 11 |
| Cicero, AF | 8 |
| Franzetti, IG | 4 |
| Querci, F | 4 |
| Carbone, A | 2 |
| Piccinni, MN | 5 |
| D'Angelo, A | 9 |
| Fogari, E | 5 |
| Maffioli, P | 10 |
| Upreti, V | 1 |
| Dhull, P | 1 |
| Patnaik, SK | 1 |
| Kumar, KV | 1 |
| VanderLugt, JT | 1 |
| Shashlo, A | 1 |
| Liang, J | 1 |
| Zhou, R | 1 |
| Orloff, DG | 1 |
| Genovese, S | 1 |
| Passaro, A | 1 |
| Brunetti, P | 2 |
| Comaschi, M | 1 |
| Cucinotta, D | 1 |
| Egan, CG | 1 |
| Chinea, B | 1 |
| Bravi, F | 1 |
| Di Pietro, C | 2 |
| Hu, SH | 1 |
| Jiang, T | 1 |
| Yang, SS | 1 |
| Yang, Y | 1 |
| Consoli, A | 1 |
| Formoso, G | 1 |
| Yin, QQ | 1 |
| Pei, JJ | 1 |
| Xu, S | 4 |
| Luo, DZ | 1 |
| Dong, SQ | 1 |
| Sun, MH | 1 |
| You, L | 1 |
| Sun, ZJ | 1 |
| Liu, XP | 1 |
| Hill, NR | 1 |
| Levy, JC | 1 |
| Matthews, DR | 1 |
| Phielix, E | 1 |
| Brehm, A | 1 |
| Bernroider, E | 1 |
| Krssak, M | 1 |
| Anderwald, CH | 1 |
| Krebs, M | 1 |
| Schmid, AI | 1 |
| Nowotny, P | 1 |
| Arikawe, AP | 1 |
| Oyerinde, A | 1 |
| Olatunji-Bello, II | 1 |
| Obika, LF | 1 |
| Mehta, RJ | 1 |
| Schnure, JJ | 1 |
| Yang, SC | 1 |
| Tseng, HL | 1 |
| Shieh, KR | 1 |
| Bhansali, S | 1 |
| Shafiq, N | 1 |
| Pandhi, P | 2 |
| Singh, AP | 1 |
| Singh, I | 1 |
| Singh, PK | 1 |
| Sharma, S | 1 |
| Malhotra, S | 2 |
| Tripathy, D | 7 |
| Schwenke, DC | 6 |
| Banerji, M | 5 |
| Bray, GA | 6 |
| Buchanan, TA | 8 |
| Clement, SC | 6 |
| Kitabchi, AE | 6 |
| Mudaliar, S | 7 |
| Ratner, RE | 5 |
| Stentz, FB | 6 |
| Musi, N | 11 |
| Reaven, PD | 7 |
| Chen, M | 1 |
| Deng, D | 1 |
| Fang, Z | 1 |
| Xu, M | 1 |
| Hu, H | 1 |
| Luo, L | 1 |
| Wang, Y | 4 |
| Gesing, A | 1 |
| Bartke, A | 1 |
| Masternak, MM | 1 |
| Mudaliar, SR | 2 |
| Ochiai, M | 1 |
| Matsuo, T | 1 |
| Ormseth, MJ | 2 |
| Oeser, AM | 2 |
| Cunningham, A | 2 |
| Bian, A | 2 |
| Shintani, A | 2 |
| Solus, J | 2 |
| Tanner, S | 1 |
| Stein, CM | 2 |
| Bone, HG | 1 |
| Lindsay, R | 1 |
| McClung, MR | 1 |
| Perez, AT | 2 |
| Raanan, MG | 1 |
| Spanheimer, RG | 1 |
| Zhao, ZQ | 1 |
| Luo, R | 1 |
| Li, LY | 1 |
| Tian, FS | 1 |
| Zheng, XL | 1 |
| Xiong, HL | 1 |
| Sun, LT | 1 |
| Esterson, YB | 1 |
| Zhang, K | 1 |
| Koppaka, S | 1 |
| Kehlenbrink, S | 1 |
| Kishore, P | 1 |
| Raghavan, P | 1 |
| Maginley, SR | 1 |
| Carey, M | 1 |
| Hawkins, M | 1 |
| Takei, Y | 1 |
| Fruci, B | 1 |
| Giuliano, S | 1 |
| Mazza, A | 1 |
| Malaguarnera, R | 1 |
| Belfiore, A | 1 |
| Xiang, AH | 2 |
| Watanabe, RM | 1 |
| Gupta, A | 1 |
| Nair, A | 1 |
| Kumria, R | 1 |
| Al-Dhubiab, BE | 1 |
| Chattopadhyaya, I | 1 |
| Gupta, S | 1 |
| Yamamoto, Y | 2 |
| Kim, K | 1 |
| Kamei, N | 2 |
| Shimada, T | 1 |
| Liu, L | 1 |
| Moore, K | 1 |
| Woo, JR | 1 |
| Shoelson, SE | 2 |
| Lee, J | 2 |
| Valerón, PF | 1 |
| de Pablos-Velasco, PL | 1 |
| Tahara, N | 1 |
| Matsui, T | 1 |
| Yamagishi, S | 1 |
| Konda, VR | 1 |
| Desai, A | 1 |
| Darland, G | 1 |
| Grayson, N | 1 |
| Bland, JS | 1 |
| Marks, KM | 1 |
| Kitch, D | 1 |
| Chung, RT | 1 |
| Hadigan, C | 1 |
| Andersen, J | 1 |
| Tien, P | 1 |
| Luetkemeyer, A | 1 |
| Alston-Smith, B | 1 |
| Glesby, MJ | 1 |
| Ochi, A | 1 |
| Mori, K | 3 |
| Emoto, M | 4 |
| Nakatani, S | 1 |
| Morioka, T | 3 |
| Motoyama, K | 2 |
| Fukumoto, S | 2 |
| Imanishi, Y | 1 |
| Koyama, H | 4 |
| Ishimura, E | 1 |
| Inaba, M | 4 |
| Zhang, W | 1 |
| Xu, YZ | 1 |
| Liu, B | 1 |
| Wu, R | 1 |
| Yang, YY | 1 |
| Xiao, XQ | 1 |
| Tseng, CH | 1 |
| Kemp, DE | 1 |
| Schinagle, M | 1 |
| Gao, K | 1 |
| Conroy, C | 1 |
| Ganocy, SJ | 1 |
| Calabrese, JR | 1 |
| Kurtz, CL | 1 |
| Peck, BC | 1 |
| Fannin, EE | 1 |
| Beysen, C | 1 |
| Miao, J | 1 |
| Landstreet, SR | 1 |
| Ding, S | 1 |
| Turaga, V | 1 |
| Lund, PK | 1 |
| Turner, S | 1 |
| Biddinger, SB | 1 |
| Vickers, KC | 1 |
| Sethupathy, P | 1 |
| Tanaka, S | 2 |
| Monden, M | 1 |
| Shoji, T | 4 |
| Fukui, M | 2 |
| Fujii, H | 1 |
| Nishizawa, Y | 3 |
| Campia, U | 1 |
| Matuskey, LA | 1 |
| Tesauro, M | 1 |
| Cardillo, C | 1 |
| Panza, JA | 1 |
| Sakata, S | 1 |
| Mera, Y | 1 |
| Kuroki, Y | 1 |
| Nashida, R | 1 |
| Kakutani, M | 1 |
| Ohta, T | 1 |
| Tanner, SB | 1 |
| Stabile, G | 1 |
| Borrielli, I | 1 |
| Artenisio, AC | 1 |
| Bruno, LM | 1 |
| Benvenga, S | 1 |
| Giunta, L | 1 |
| La Marca, A | 1 |
| Volpe, A | 1 |
| Pizzo, A | 1 |
| Li, LJ | 1 |
| Li, GD | 1 |
| Wei, HL | 1 |
| Liu, YM | 1 |
| Li, F | 1 |
| Xie, B | 1 |
| Wang, B | 3 |
| Li, CL | 1 |
| Zheng, F | 1 |
| Zhang, S | 2 |
| Lu, W | 1 |
| Wu, F | 1 |
| Yin, X | 1 |
| Yu, D | 1 |
| Pan, Q | 1 |
| Li, H | 2 |
| Hsu, CS | 1 |
| Hsu, SJ | 1 |
| Lin, HH | 1 |
| Tseng, TC | 1 |
| Wang, CC | 1 |
| Chen, DS | 1 |
| Kao, JH | 1 |
| Hu, L | 1 |
| Shen, H | 1 |
| Wu, QF | 1 |
| Tian, L | 1 |
| Hu, MH | 1 |
| Spencer, M | 1 |
| Yang, L | 1 |
| Adu, A | 1 |
| Shipp, LR | 1 |
| Rasouli, N | 11 |
| Peterson, CA | 3 |
| Okazaki, S | 1 |
| Takahashi, T | 1 |
| Iwamura, T | 1 |
| Nakaki, J | 1 |
| Sekiya, Y | 1 |
| Yagi, M | 1 |
| Kumagai, H | 2 |
| Sato, M | 1 |
| Sakami, S | 1 |
| Nitta, A | 1 |
| Kawai, K | 1 |
| Kainoh, M | 1 |
| Jin, J | 1 |
| Yang, O | 1 |
| Kong, J | 1 |
| Shamsi, BH | 1 |
| Ma, C | 1 |
| Naqvi, S | 1 |
| Xiao, Y | 4 |
| Sripetchwandee, J | 1 |
| Pipatpiboon, N | 1 |
| Pratchayasakul, W | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Xie, X | 1 |
| Long, L | 1 |
| Li, W | 1 |
| Yang, X | 1 |
| Li, S | 2 |
| Wang, L | 3 |
| Zanchi, A | 4 |
| Tappy, L | 1 |
| Lê, KA | 1 |
| Bortolotti, M | 1 |
| Theumann, N | 1 |
| Halabi, G | 1 |
| Gauthier, T | 1 |
| Mathieu, C | 1 |
| Tremblay, S | 1 |
| Bertrand, PC | 1 |
| Burnier, M | 3 |
| Teta, D | 1 |
| Maggs, D | 1 |
| Brass, LM | 3 |
| Carolei, A | 2 |
| Parsons, MW | 2 |
| Peduzzi, PN | 2 |
| Ringleb, PA | 1 |
| Elshazly, SM | 1 |
| Jin, SM | 1 |
| Cho, YM | 1 |
| Ku, BJ | 1 |
| Ahn, CW | 2 |
| Cha, BS | 3 |
| Min, KW | 1 |
| Sung, YA | 1 |
| Baik, SH | 1 |
| Lee, KW | 1 |
| Yoon, KH | 1 |
| Lee, MK | 1 |
| Park, SW | 1 |
| Cobb, JE | 1 |
| Gall, W | 1 |
| Adam, KP | 1 |
| George, T | 1 |
| Ferrannini, E | 2 |
| Zhu, C | 1 |
| Liu, X | 3 |
| Han, J | 2 |
| Zhang, J | 1 |
| Wei, L | 1 |
| Jia, W | 1 |
| Zaitone, SA | 3 |
| Barakat, BM | 1 |
| Bilasy, SE | 1 |
| Fawzy, MS | 1 |
| Abdelaziz, EZ | 1 |
| Farag, NE | 2 |
| Irving, BA | 2 |
| Carter, RE | 2 |
| Soop, M | 2 |
| Weymiller, A | 1 |
| Syed, H | 1 |
| Karakelides, H | 1 |
| Bhagra, S | 1 |
| Short, KR | 1 |
| Tatpati, L | 2 |
| Barazzoni, R | 1 |
| Nair, KS | 2 |
| Hardy, T | 1 |
| Anstee, QM | 1 |
| Day, CP | 1 |
| He, J | 1 |
| Xu, C | 1 |
| Kuang, J | 1 |
| Liu, Q | 3 |
| Jiang, H | 1 |
| Mo, L | 1 |
| Geng, B | 1 |
| Xu, G | 1 |
| Straznicky, NE | 1 |
| Grima, MT | 1 |
| Sari, CI | 1 |
| Eikelis, N | 1 |
| Lambert, GW | 1 |
| Nestel, PJ | 1 |
| Richards, K | 1 |
| Dixon, JB | 1 |
| Schlaich, MP | 1 |
| Lambert, EA | 1 |
| Liu, HJ | 1 |
| Zhang, CY | 1 |
| Song, F | 1 |
| Xiao, T | 1 |
| Meng, J | 1 |
| Zhang, Q | 3 |
| Liang, CL | 1 |
| Wang, J | 3 |
| Zhang, B | 1 |
| Liu, YR | 1 |
| Sun, T | 2 |
| Zhou, HG | 1 |
| Ding, Y | 2 |
| Fang, H | 1 |
| Shang, W | 1 |
| Hou, N | 2 |
| Sun, X | 1 |
| Ma, Q | 1 |
| Zhou, J | 1 |
| Cheng, H | 2 |
| Tozzo, E | 1 |
| Bhat, G | 1 |
| Cheon, K | 1 |
| Camacho, RC | 1 |
| Warshauer, JT | 1 |
| Lopez, X | 1 |
| Hicks, J | 1 |
| Anuwe, E | 1 |
| Blankfard, MB | 1 |
| Lingvay, I | 1 |
| Matsumoto, Y | 1 |
| Ishii, M | 1 |
| Hayashi, Y | 2 |
| Miyazaki, S | 1 |
| Sugita, T | 1 |
| Sumiya, E | 1 |
| Sekimizu, K | 1 |
| Sorkina, EL | 1 |
| Kalashnikova, MF | 1 |
| Melnichenko, GA | 1 |
| Tyulpakov, AN | 1 |
| Li, JE | 1 |
| Futawaka, K | 1 |
| Yamamoto, H | 2 |
| Kasahara, M | 1 |
| Tagami, T | 1 |
| Liu, TH | 1 |
| Moriyama, K | 1 |
| Rajagopalan, S | 1 |
| Dutta, P | 1 |
| Hota, D | 1 |
| Bhansali, A | 2 |
| Srinivasan, A | 1 |
| Chakrabarti, A | 1 |
| Tanaka, R | 1 |
| Yamashiro, K | 1 |
| Okuma, Y | 1 |
| Shimura, H | 1 |
| Nakamura, S | 1 |
| Ueno, Y | 1 |
| Tanaka, Y | 1 |
| Miyamoto, N | 1 |
| Tomizawa, Y | 1 |
| Nakahara, T | 1 |
| Furukawa, Y | 1 |
| Watada, H | 1 |
| Kawamori, R | 6 |
| Hattori, N | 1 |
| Urabe, T | 1 |
| Ying, W | 1 |
| Tseng, A | 1 |
| Chang, RC | 1 |
| Morin, A | 1 |
| Brehm, T | 1 |
| Triff, K | 1 |
| Nair, V | 1 |
| Zhuang, G | 1 |
| Song, H | 1 |
| Kanameni, S | 1 |
| Golding, MC | 1 |
| Bazer, FW | 1 |
| Chapkin, RS | 1 |
| Safe, S | 1 |
| Zhou, B | 1 |
| Gao, F | 1 |
| Du, W | 1 |
| Zafar, MI | 1 |
| Shafqat, RA | 1 |
| Jian, L | 1 |
| Cai, Q | 1 |
| Lu, F | 1 |
| Lin, KW | 2 |
| Robakis, T | 1 |
| Rasgon, N | 1 |
| Lin, J | 1 |
| Epel, E | 1 |
| Blackburn, E | 1 |
| Zhu, YX | 1 |
| Zhang, ML | 1 |
| Zhong, Y | 2 |
| Wang, C | 3 |
| Jia, WP | 1 |
| van der Veen, JN | 1 |
| Lingrell, S | 1 |
| Gao, X | 1 |
| Quiroga, AD | 1 |
| Takawale, A | 2 |
| Armstrong, EA | 1 |
| Yager, JY | 1 |
| Kassiri, Z | 1 |
| Lehner, R | 1 |
| Vance, DE | 1 |
| Jacobs, RL | 1 |
| Aslam, M | 1 |
| Aggarwal, S | 1 |
| Sharma, KK | 1 |
| Galav, V | 1 |
| Madhu, SV | 1 |
| Sato, D | 1 |
| Oda, K | 1 |
| Kusunoki, M | 1 |
| Nishina, A | 1 |
| Takahashi, K | 3 |
| Feng, Z | 1 |
| Tsutsumi, K | 1 |
| Nakamura, T | 1 |
| Adams, HP | 1 |
| Berger, L | 1 |
| Clark, W | 1 |
| Coull, B | 1 |
| Kleindorfer, D | 1 |
| O'Leary, JR | 1 |
| Ringleb, P | 1 |
| Sen, S | 1 |
| Winder, TR | 1 |
| Wei, W | 1 |
| Xie, H | 1 |
| Collins, S | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Khodeer, DM | 1 |
| Moustafa, YM | 2 |
| Ninomiya, H | 1 |
| Hirata, A | 3 |
| Kozawa, J | 1 |
| Nakata, S | 1 |
| Kimura, T | 1 |
| Kitamura, T | 2 |
| Yasuda, T | 2 |
| Otsuki, M | 1 |
| Imagawa, A | 1 |
| Kaneto, H | 4 |
| Funahashi, T | 3 |
| Shimomura, I | 5 |
| Ntaios, G | 1 |
| Kent, TA | 1 |
| Shahataa, MG | 1 |
| Mostafa-Hedeab, G | 1 |
| Ali, EF | 1 |
| Mahdi, EA | 1 |
| Mahmoud, FA | 1 |
| Orsak, B | 1 |
| Lomonaco, R | 2 |
| Hecht, J | 1 |
| Ortiz-Lopez, C | 1 |
| Tio, F | 2 |
| Hardies, J | 3 |
| Darland, C | 2 |
| Webb, A | 1 |
| Portillo-Sanchez, P | 1 |
| Gumbilai, V | 1 |
| Aizawa-Abe, M | 1 |
| Ebihara, C | 1 |
| Zhao, M | 1 |
| Mashimo, T | 1 |
| Hosoda, K | 1 |
| Serikawa, T | 1 |
| Nakao, K | 1 |
| Gad, ES | 1 |
| Sharma, M | 1 |
| Mohapatra, J | 1 |
| Nagar, J | 1 |
| Chatterjee, A | 1 |
| Ramachandran, B | 1 |
| Jain, MR | 1 |
| Liu, A | 2 |
| Kim, SH | 2 |
| Ariel, D | 2 |
| Abbasi, F | 7 |
| Lamendola, C | 6 |
| Cardell, J | 2 |
| Patel, S | 2 |
| Tomasso, V | 2 |
| Mojaddidi, H | 2 |
| Grove, K | 2 |
| Tsao, PS | 2 |
| Kushida, CA | 2 |
| Reaven, GM | 7 |
| Barthel, A | 1 |
| Espinoza, SE | 1 |
| Wang, CP | 1 |
| Banerji, MA | 2 |
| Perazzo, H | 1 |
| Dufour, JF | 1 |
| Izawa, T | 2 |
| Sakurai, K | 1 |
| Insogna, KL | 1 |
| Kelly, MA | 1 |
| Colle, R | 1 |
| de Larminat, D | 1 |
| Rotenberg, S | 1 |
| Hozer, F | 1 |
| Hardy, P | 1 |
| Verstuyft, C | 1 |
| Fève, B | 1 |
| Corruble, E | 1 |
| Liao, HW | 2 |
| Lin, CH | 1 |
| de Fatima Silva, F | 1 |
| Ortiz-Silva, M | 1 |
| Graciano, MF | 1 |
| Zaia, CT | 1 |
| Zaia, D | 1 |
| Carpinelli, ÂR | 1 |
| da Silva, FG | 1 |
| Wu, YL | 1 |
| Chen, TH | 1 |
| Caletti, MT | 1 |
| Marchignoli, F | 1 |
| Forlani, G | 1 |
| Okoduwa, SI | 1 |
| Umar, IA | 1 |
| James, DB | 1 |
| Inuwa, HM | 1 |
| Shang, J | 1 |
| Previs, SF | 1 |
| Conarello, S | 1 |
| Chng, K | 1 |
| Zhu, Y | 1 |
| Souza, SC | 1 |
| Staup, M | 1 |
| Xie, D | 1 |
| Zycband, E | 1 |
| Schlessinger, K | 1 |
| Johnson, VP | 1 |
| Arreaza, G | 1 |
| Liu, F | 1 |
| Levitan, D | 1 |
| van Heek, M | 1 |
| Erion, M | 1 |
| Kelley, DE | 1 |
| Bajpeyi, S | 1 |
| Pasarica, M | 1 |
| Conley, KE | 1 |
| Newcomer, BR | 1 |
| Jubrias, SA | 1 |
| Gamboa, C | 1 |
| Murray, K | 1 |
| Sereda, O | 1 |
| Sparks, LM | 1 |
| Smith, SR | 1 |
| Glintborg, D | 7 |
| Højlund, K | 3 |
| Andersen, NR | 1 |
| Hansen, BF | 1 |
| Beck-Nielsen, H | 5 |
| Wojtaszewski, JF | 1 |
| Cho, LW | 1 |
| Keevil, BG | 1 |
| Overbeck, K | 1 |
| Genné, D | 1 |
| Golay, A | 1 |
| Negro, F | 1 |
| Skov, V | 2 |
| Knudsen, S | 1 |
| Tan, Q | 1 |
| Jensen, T | 1 |
| Kruse, TA | 1 |
| Sugamura, K | 1 |
| Sugiyama, S | 1 |
| Matsuzawa, Y | 1 |
| Nozaki, T | 1 |
| Horibata, Y | 1 |
| Ogawa, H | 1 |
| Farin, HM | 2 |
| McGraw, L | 1 |
| McLaughlin, T | 2 |
| Salvadeo, SA | 7 |
| Takahashi, A | 1 |
| Kushiro, T | 2 |
| Araki, T | 2 |
| Yokoyama, H | 2 |
| Lee, E | 1 |
| Teramura, M | 1 |
| Tan, GD | 1 |
| Savage, DB | 1 |
| Fielding, BA | 1 |
| Collins, J | 1 |
| Hodson, L | 1 |
| Humphreys, SM | 1 |
| O'Rahilly, S | 1 |
| Chatterjee, K | 1 |
| Frayn, KN | 1 |
| Karpe, F | 1 |
| Basu, R | 1 |
| Basu, A | 1 |
| Chandramouli, V | 1 |
| Norby, B | 1 |
| Dicke, B | 1 |
| Shah, P | 1 |
| Cohen, O | 1 |
| Landau, BR | 1 |
| Rizza, RA | 1 |
| Erdem, G | 1 |
| Dogru, T | 1 |
| Tasci, I | 1 |
| Bozoglu, E | 1 |
| Muhsiroglu, O | 1 |
| Tapan, S | 1 |
| Ercin, CN | 1 |
| Sonmez, A | 1 |
| Zinn, A | 1 |
| Felson, S | 1 |
| Fisher, E | 1 |
| Schwartzbard, A | 1 |
| Abe, M | 3 |
| Okada, K | 3 |
| Kikuchi, F | 2 |
| Matsumoto, K | 3 |
| Dorkhan, M | 3 |
| Frid, A | 2 |
| Groop, L | 2 |
| Ferrari, I | 6 |
| Gravina, A | 4 |
| Ohara, K | 1 |
| Uchida, A | 2 |
| Nagasaka, R | 1 |
| Ushio, H | 1 |
| Ohshima, T | 1 |
| Nishio, K | 1 |
| Shigemitsu, M | 1 |
| Kodama, Y | 1 |
| Itoh, S | 2 |
| Konno, N | 1 |
| Satoh, R | 1 |
| Katagiri, T | 1 |
| Kobayashi, Y | 2 |
| Krag, MB | 2 |
| Rasmussen, LM | 1 |
| Hansen, TK | 1 |
| Frystyk, J | 3 |
| Flyvbjerg, A | 3 |
| Møller, N | 1 |
| Jørgensen, JO | 2 |
| Kawamura, S | 1 |
| Sakai, A | 1 |
| Maruta, M | 1 |
| Xie, Y | 1 |
| Zhu, T | 3 |
| Yu, J | 1 |
| Zha, JM | 1 |
| DI, WJ | 1 |
| Ding, GX | 1 |
| Rodríguez, A | 2 |
| Reviriego, J | 1 |
| Polavieja, P | 1 |
| Mesa, J | 1 |
| Papathanassiou, K | 2 |
| Naka, KK | 3 |
| Kazakos, N | 3 |
| Kanioglou, C | 2 |
| Makriyiannis, D | 2 |
| Pappas, K | 2 |
| Katsouras, CS | 3 |
| Liveris, K | 2 |
| Kolettis, T | 1 |
| Tsatsoulis, A | 3 |
| Michalis, LK | 3 |
| Ghaisas, M | 1 |
| Navghare, V | 1 |
| Zope, V | 1 |
| Tanwar, M | 1 |
| Deshpande, A | 1 |
| Laurent, D | 2 |
| Gounarides, JS | 1 |
| Gao, J | 1 |
| Boettcher, BR | 1 |
| Valizadeh, N | 1 |
| Tehrani, MR | 1 |
| Amoli, MM | 1 |
| Bandarian, F | 1 |
| Aoyama, T | 2 |
| Ikejima, K | 1 |
| Kon, K | 1 |
| Okumura, K | 1 |
| Arai, K | 1 |
| Watanabe, S | 1 |
| Lima, NK | 1 |
| Pfützner, A | 10 |
| Schöndorf, T | 2 |
| Hanefeld, M | 8 |
| Lübben, G | 5 |
| Kann, PH | 1 |
| Karagiannis, E | 2 |
| Wilhelm, B | 1 |
| Forst, T | 12 |
| Collet-Gaudillat, C | 1 |
| Billon-Bancel, A | 1 |
| Beressi, JP | 1 |
| Mereu, R | 4 |
| Ciccarelli, L | 3 |
| Narsing Rao, L | 1 |
| Jacob, JJ | 1 |
| Paul, TV | 1 |
| Rajarathinam, S | 1 |
| Thomas, N | 1 |
| Seshadri, MS | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Kutoh, E | 2 |
| Fukushima, T | 1 |
| Gropler, RJ | 1 |
| Palumbo, I | 2 |
| Serfaty, L | 1 |
| Fartoux, L | 1 |
| Poupon, R | 1 |
| Czaja, MJ | 1 |
| Kaku, K | 1 |
| Schneider, F | 1 |
| Vossler, S | 1 |
| Franke, S | 1 |
| Bär, F | 1 |
| Konrad, T | 3 |
| Leary, ET | 1 |
| Charpentier, G | 1 |
| Halimi, S | 1 |
| Yao-Borengasser, A | 8 |
| Varma, V | 7 |
| Spencer, HJ | 4 |
| McGehee, RE | 5 |
| Mehta, JL | 1 |
| Oz Gul, O | 1 |
| Tuncel, E | 1 |
| Yilmaz, Y | 1 |
| Ulukaya, E | 1 |
| Gul, CB | 1 |
| Kiyici, S | 1 |
| Oral, AY | 1 |
| Guclu, M | 1 |
| Ersoy, C | 1 |
| Imamoglu, S | 1 |
| Hamada, Y | 1 |
| Makino, H | 3 |
| Shimizu, I | 1 |
| Murao, S | 1 |
| Kondo, S | 1 |
| Tabara, Y | 1 |
| Fujiyama, M | 1 |
| Fujii, Y | 1 |
| Takada, Y | 1 |
| Nakai, K | 1 |
| Izumi, K | 1 |
| Ohashi, J | 1 |
| Kawamura, R | 1 |
| Yamauchi, J | 1 |
| Takata, Y | 3 |
| Nishida, W | 1 |
| Hashiramoto, M | 1 |
| Onuma, H | 2 |
| Osawa, H | 2 |
| Kroese, JM | 2 |
| Mooij, CF | 1 |
| van der Graaf, M | 1 |
| Hermus, AR | 2 |
| Tack, CJ | 3 |
| Lorenzi, O | 1 |
| Veyrat-Durebex, C | 1 |
| Wollheim, CB | 1 |
| Villemin, P | 1 |
| Rohner-Jeanrenaud, F | 1 |
| Vischer, UM | 1 |
| Vischer, U | 1 |
| Yoshiuchi, K | 2 |
| Matsuoka, TA | 2 |
| Kasami, R | 1 |
| Kohno, K | 1 |
| Iwawaki, T | 1 |
| Nakatani, Y | 1 |
| Yamasaki, Y | 5 |
| Matsuhisa, M | 6 |
| Koenen, TB | 1 |
| Sweep, FC | 1 |
| van der Laak, J | 1 |
| Stalenhoef, AF | 3 |
| de Graaf, J | 3 |
| van Tits, LJ | 1 |
| Stienstra, R | 1 |
| Munkhtulga, L | 1 |
| Nagashima, S | 1 |
| Nakayama, K | 1 |
| Utsumi, N | 1 |
| Yanagisawa, Y | 1 |
| Gotoh, T | 1 |
| Omi, T | 1 |
| Kumada, M | 1 |
| Zolzaya, K | 1 |
| Lkhagvasuren, T | 1 |
| Kagawa, Y | 2 |
| Fujiwara, H | 1 |
| Hosoya, Y | 1 |
| Hyodo, M | 1 |
| Horie, H | 1 |
| Kojima, M | 1 |
| Iwamoto, S | 1 |
| Makino, N | 1 |
| Maeda, T | 2 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Mimori, K | 1 |
| Han, SJ | 1 |
| Hur, KY | 1 |
| Kim, YS | 1 |
| Kang, ES | 2 |
| Kim, SI | 1 |
| Kwak, JY | 1 |
| Kim, DJ | 1 |
| Choi, SH | 1 |
| Lee, HC | 2 |
| Lv, Q | 1 |
| Wang, W | 1 |
| Randazzo, S | 1 |
| Higgins, LS | 1 |
| Depaoli, AM | 1 |
| McLaughlin, TM | 1 |
| Liu, T | 1 |
| Yee, G | 1 |
| Tsao, P | 1 |
| Cushman, SW | 1 |
| Sherman, A | 1 |
| Khattab, M | 1 |
| Emad, M | 1 |
| Abdelaleem, A | 1 |
| Eslam, M | 1 |
| Atef, R | 1 |
| Shaker, Y | 1 |
| Hamdy, L | 1 |
| Marková, I | 1 |
| Zídek, V | 1 |
| Musilová, A | 1 |
| Šimáková, M | 1 |
| Mlejnek, P | 1 |
| Kazdová, L | 1 |
| Pravenec, M | 1 |
| Erdmann, E | 3 |
| Wilcox, R | 1 |
| Luo, D | 2 |
| Zheng, M | 1 |
| Hao, Y | 2 |
| Hou, L | 2 |
| Ragonesi, PD | 2 |
| Gadaleta, G | 2 |
| Schönauer, M | 1 |
| Bajaj, M | 4 |
| Baig, R | 1 |
| Suraamornkul, S | 4 |
| Hardies, LJ | 4 |
| Coletta, DK | 1 |
| Cline, GW | 1 |
| Monroy, A | 1 |
| Koul, S | 1 |
| Sriwijitkamol, A | 1 |
| Shulman, GI | 2 |
| Nakano, K | 1 |
| Hasegawa, G | 2 |
| Yamasaki, M | 1 |
| Ishihara, K | 1 |
| Takashima, T | 1 |
| Kitagawa, Y | 1 |
| Fujinami, A | 1 |
| Ohta, M | 1 |
| Hara, H | 2 |
| Adachi, T | 2 |
| Ogata, M | 1 |
| Obayashi, H | 1 |
| Nakamura, N | 1 |
| Iba, A | 1 |
| Kohjimoto, Y | 1 |
| Mori, T | 1 |
| Kuramoto, T | 1 |
| Nishizawa, S | 1 |
| Fujii, R | 1 |
| Nanpo, Y | 1 |
| Matsumura, N | 1 |
| Shintani, Y | 1 |
| Inagaki, T | 1 |
| Hara, I | 1 |
| Simó, R | 1 |
| Caveda, E | 1 |
| Li, JM | 1 |
| Kong, LD | 2 |
| Hu, QH | 1 |
| Araki, A | 1 |
| Collino, M | 1 |
| Aragno, M | 1 |
| Castiglia, S | 1 |
| Miglio, G | 1 |
| Tomasinelli, C | 1 |
| Boccuzzi, G | 1 |
| Thiemermann, C | 1 |
| Fantozzi, R | 1 |
| Dorafshar, AH | 1 |
| Moodley, K | 1 |
| Khoe, M | 1 |
| Lyon, C | 1 |
| Bryer-Ash, M | 1 |
| Unal, R | 2 |
| Labbate, C | 1 |
| Ranganathan, G | 4 |
| Maillard, M | 2 |
| Jornayvaz, FR | 1 |
| Vinciguerra, M | 1 |
| Deleaval, P | 1 |
| Nussberger, J | 2 |
| Pechere-Bertschi, A | 1 |
| Sanyal, AJ | 3 |
| Chalasani, N | 3 |
| Kowdley, KV | 2 |
| McCullough, A | 1 |
| Diehl, AM | 2 |
| Bass, NM | 2 |
| Neuschwander-Tetri, BA | 2 |
| Lavine, JE | 1 |
| Tonascia, J | 1 |
| Unalp, A | 1 |
| Van Natta, M | 1 |
| Clark, J | 1 |
| Brunt, EM | 2 |
| Kleiner, DE | 3 |
| Hoofnagle, JH | 3 |
| Robuck, PR | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Soma, M | 1 |
| Balasubramanian, R | 1 |
| Gerrard, J | 1 |
| Dalla Man, C | 1 |
| Firbank, MJ | 1 |
| Lane, A | 1 |
| English, PT | 1 |
| Cobelli, C | 1 |
| Taylor, R | 1 |
| Kobayashi, D | 1 |
| Takamura, M | 1 |
| Murai, H | 1 |
| Usui, S | 1 |
| Ikeda, T | 1 |
| Inomata, J | 1 |
| Takashima, S | 1 |
| Kato, T | 3 |
| Furusho, H | 1 |
| Takeshita, Y | 1 |
| Ota, T | 4 |
| Takamura, T | 3 |
| Kaneko, S | 3 |
| Sheth, SH | 1 |
| Larson, RJ | 1 |
| Vikram, A | 2 |
| Jena, G | 2 |
| Logie, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Schofield, CJ | 1 |
| Hundal, HS | 1 |
| Feuerstein, GZ | 1 |
| Brady, JD | 1 |
| Crowther, D | 1 |
| Tommasi, AM | 1 |
| Grierson, CE | 1 |
| Shepherd, B | 1 |
| Morris, AD | 1 |
| Hansen, MK | 1 |
| Pearson, E | 1 |
| Sutherland, C | 1 |
| Derwahl, M | 1 |
| Jacob, S | 1 |
| Hohberg, C | 4 |
| Blümner, E | 1 |
| Lehmann, U | 2 |
| Fuchs, W | 2 |
| Lu, YX | 1 |
| Sun, YX | 1 |
| Wang, LY | 1 |
| Cheng, WM | 1 |
| Hu, XY | 1 |
| Bailey, CJ | 3 |
| Green, BD | 1 |
| Flatt, PR | 1 |
| Chatterjee, PK | 1 |
| Rabøl, R | 1 |
| Boushel, R | 1 |
| Almdal, T | 1 |
| Hansen, CN | 1 |
| Ploug, T | 1 |
| Haugaard, SB | 1 |
| Prats, C | 1 |
| Madsbad, S | 2 |
| Dela, F | 1 |
| de Pablos-Velasco, P | 1 |
| Kalantaridou, SN | 1 |
| Kravariti, M | 1 |
| Bechlioulis, A | 1 |
| Calis, KA | 1 |
| Makrigiannakis, A | 1 |
| Chrousos, GP | 1 |
| Ramarao, P | 2 |
| Brouwers, MC | 1 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 2 |
| Takahara, M | 1 |
| Shiraiwa, T | 1 |
| Kuroda, A | 1 |
| Sakamoto, F | 1 |
| Naka, T | 2 |
| Miyashita, K | 1 |
| Sakamoto, K | 1 |
| Matsuoka, T | 1 |
| Ordu, S | 1 |
| Ozhan, H | 1 |
| Alemdar, R | 1 |
| Aydin, M | 1 |
| Basar, C | 1 |
| Caglar, O | 1 |
| Yazici, M | 1 |
| Yalcin, S | 1 |
| Iwase, M | 1 |
| Asano, T | 1 |
| Sasaki, N | 1 |
| Yoshizumi, H | 1 |
| Hiramatsu, S | 2 |
| Sakai, Y | 1 |
| Ogo, A | 1 |
| Iida, M | 1 |
| Papamichael, ND | 1 |
| Yarasheski, KE | 1 |
| Cade, WT | 1 |
| Overton, ET | 1 |
| Mondy, KE | 1 |
| Hubert, S | 1 |
| Laciny, E | 1 |
| Bopp, C | 1 |
| Lassa-Claxton, S | 1 |
| Reeds, DN | 1 |
| Park, JS | 1 |
| Cho, MH | 1 |
| Nam, JS | 1 |
| Yoo, JS | 1 |
| Kim, KR | 1 |
| Magkos, F | 1 |
| Brennan, A | 1 |
| Sweeney, L | 1 |
| Doweiko, J | 1 |
| Karchmer, AW | 1 |
| Mantzoros, CS | 1 |
| Wu, S | 1 |
| Aguilar, AL | 1 |
| Ostrow, V | 1 |
| De Luca, F | 1 |
| Coker, RH | 1 |
| Phanavanh, B | 5 |
| Kawashima, S | 1 |
| Tochino, Y | 1 |
| Kato, K | 1 |
| Yamamoto, K | 1 |
| Yamamoto, T | 3 |
| Eriksen, M | 1 |
| Pørneki, AD | 1 |
| Burns, JS | 1 |
| Gaster, M | 1 |
| Hiuge-Shimizu, A | 1 |
| Maeda, N | 1 |
| Nakatsuji, H | 1 |
| Nakamura, K | 2 |
| Okuno, A | 2 |
| Kihara, S | 2 |
| Liu, IM | 2 |
| Tzeng, TF | 2 |
| Liou, SS | 1 |
| Chang, CJ | 2 |
| Joya-Galeana, J | 1 |
| Fernandez, M | 1 |
| Cervera, A | 1 |
| Reyna, S | 1 |
| Ghosh, S | 2 |
| To, AW | 1 |
| Ribe, EM | 1 |
| Chuang, TT | 1 |
| Schroeder, JE | 1 |
| Lovestone, S | 1 |
| Oki, N | 1 |
| Nonaka, S | 1 |
| Ozaki, S | 1 |
| Hodis, HN | 1 |
| Mack, WJ | 1 |
| Williams, K | 1 |
| Tschöpe, D | 2 |
| Lobmann, R | 1 |
| Merke, J | 1 |
| Müller, J | 1 |
| Harrison, SA | 3 |
| Schenker, S | 2 |
| Fujitaka, K | 1 |
| Otani, H | 1 |
| Jo, F | 1 |
| Jo, H | 1 |
| Nomura, E | 1 |
| Iwasaki, M | 1 |
| Nishikawa, M | 2 |
| Iwasaka, T | 2 |
| Kudoh, A | 1 |
| Satoh, H | 4 |
| Hirai, H | 1 |
| Watanabe, T | 1 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Hou, X | 1 |
| Wang, M | 1 |
| Dong, C | 1 |
| Quinn, CE | 1 |
| Hamilton, PK | 1 |
| McCann, AJ | 1 |
| Agnew, CE | 1 |
| Millar, AM | 1 |
| Lockhart, CJ | 1 |
| Harbinson, MT | 1 |
| McVeigh, GE | 1 |
| Smith, BW | 1 |
| Adams, LA | 2 |
| Bianchi, L | 1 |
| Papanas, N | 1 |
| Hatzitolios, AI | 1 |
| Maltezos, E | 1 |
| Raab, S | 1 |
| Zheng, W | 1 |
| Liu, N | 1 |
| Xue, L | 1 |
| Song, Z | 1 |
| Mao, J | 1 |
| Li, K | 1 |
| Zhang, Y | 1 |
| Han, C | 1 |
| Shang, S | 1 |
| Li, C | 2 |
| Sebokova, E | 2 |
| Huang, PL | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Miyazaki, M | 1 |
| Bell, DS | 1 |
| O'Keefe, JH | 1 |
| El-Bassossy, HM | 1 |
| Badawy, D | 1 |
| Namvaran, F | 2 |
| Azarpira, N | 2 |
| Rahimi-Moghaddam, P | 2 |
| Dabbaghmanesh, MH | 2 |
| Shyangdan, D | 1 |
| Clar, C | 1 |
| Ghouri, N | 1 |
| Henderson, R | 1 |
| Gurung, T | 1 |
| Preiss, D | 1 |
| Sattar, N | 1 |
| Fraser, A | 1 |
| Waugh, N | 1 |
| Pita, J | 1 |
| Panadero, A | 1 |
| Soriano-Guillén, L | 1 |
| Rodríguez, E | 1 |
| Rovira, A | 1 |
| Matsubara, T | 1 |
| Mita, A | 1 |
| Minami, K | 1 |
| Hosooka, T | 1 |
| Kitazawa, S | 1 |
| Tamori, Y | 1 |
| Yokoi, N | 1 |
| Watanabe, M | 1 |
| Matsuo, E | 1 |
| Nishimura, O | 1 |
| Seino, S | 1 |
| Avogaro, A | 1 |
| Federici, M | 1 |
| Betteridge, J | 1 |
| Bonadonna, R | 1 |
| Campbell, IW | 2 |
| Schernthaner, GH | 1 |
| Staels, B | 2 |
| Farinaro, E | 1 |
| Crepaldi, G | 1 |
| Chang, YS | 1 |
| Hamzeh, FM | 1 |
| Pandya, PK | 1 |
| Sheikh, MY | 1 |
| Vierling, JM | 1 |
| Yokoe, H | 1 |
| Yuasa, F | 1 |
| Yuyama, R | 1 |
| Murakawa, K | 1 |
| Miyasaka, Y | 1 |
| Yoshida, S | 1 |
| Tsujimoto, S | 1 |
| Sugiura, T | 2 |
| Chojkier, M | 1 |
| Elkhayat, H | 1 |
| Sabry, D | 1 |
| Donohue, M | 1 |
| Buck, M | 1 |
| Elbein, SC | 2 |
| Sharma, NK | 1 |
| Das, SK | 1 |
| Ziaee, A | 1 |
| Oveisi, S | 1 |
| Abedini, A | 1 |
| Hashemipour, S | 1 |
| Karimzadeh, T | 1 |
| Ghorbani, A | 1 |
| Du, Q | 2 |
| Wang, YJ | 2 |
| Wu, B | 2 |
| Han, P | 1 |
| Zhao, YY | 2 |
| Chaudhary, S | 1 |
| Dube, A | 1 |
| Kothari, V | 1 |
| Sachan, N | 1 |
| Upasani, CD | 1 |
| Bell, LN | 1 |
| Muralidharan, S | 1 |
| Chalasani, S | 1 |
| Fullenkamp, AM | 1 |
| Wilson, LA | 1 |
| McCullough, AJ | 2 |
| Unalp-Arida, A | 1 |
| Chambers, KT | 1 |
| Hall, AM | 1 |
| Mitra, MS | 1 |
| Qi, N | 1 |
| Pan, Y | 1 |
| Hong, Y | 1 |
| Zhang, QY | 1 |
| McCoy, RG | 1 |
| Srinivasan, M | 1 |
| Chow, L | 1 |
| Weymiller, AJ | 1 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Banerjee, S | 1 |
| Mohan, V | 1 |
| Bedi, S | 1 |
| Unnikrishnan, R | 1 |
| Sahay, BK | 1 |
| Joshpi, S | 1 |
| Misra, A | 1 |
| Cipolletta, D | 1 |
| Feuerer, M | 1 |
| Li, A | 1 |
| Benoist, C | 1 |
| Mathis, D | 1 |
| Wang, QJ | 1 |
| Zha, XJ | 1 |
| Kang, ZM | 1 |
| Xu, MJ | 1 |
| Zou, DJ | 1 |
| Colombo, G | 1 |
| Bazzo, ML | 1 |
| Nogueira, CL | 1 |
| Colombo, MD | 1 |
| Schiavon, LL | 1 |
| d'Acampora, AJ | 1 |
| Preuss, HG | 1 |
| Echard, B | 1 |
| Fu, J | 1 |
| Perricone, NV | 1 |
| Bagchi, D | 1 |
| Kaylor, M | 1 |
| Zhuang, C | 1 |
| Chen, SG | 1 |
| He, JW | 1 |
| Sheng, CJ | 1 |
| Cheng, XY | 1 |
| Qu, S | 1 |
| Wang, KS | 1 |
| Lu, ML | 1 |
| Yu, YC | 1 |
| Fan, B | 1 |
| Yu, X | 1 |
| Gong, Y | 1 |
| Mu, Y | 1 |
| Tian, H | 1 |
| Pan, C | 1 |
| Kashani, L | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Modabbernia, A | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Ashrafi, M | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Mayama, R | 1 |
| Sakai, K | 1 |
| Suciu, N | 1 |
| Iwashita, M | 1 |
| Beydoun, H | 1 |
| Kancherla, V | 1 |
| Stadtmauer, L | 1 |
| Beydoun, M | 1 |
| Dutta, D | 1 |
| Maisnam, I | 1 |
| Mukhopadhyay, S | 1 |
| Chowdhury, S | 1 |
| Ide, N | 1 |
| Arnetz, L | 1 |
| Alvarsson, M | 1 |
| Brismar, K | 1 |
| Ekberg, NR | 1 |
| Stumvoll, M | 1 |
| Häring, HU | 1 |
| Mori, Y | 2 |
| Sekihara, H | 2 |
| Yamanouchi, T | 1 |
| Toyota, T | 2 |
| Sugiyama, Y | 8 |
| Kobayashi, M | 6 |
| Iwata, M | 2 |
| Hiratani, K | 1 |
| Ohmura, E | 1 |
| Hosaka, D | 1 |
| Imai, Y | 1 |
| Kawazu, S | 1 |
| Kitaoka, H | 2 |
| Kadowaki, T | 5 |
| Kotake, H | 1 |
| Sohda, T | 4 |
| Kawamatsu, Y | 1 |
| Fujita, T | 6 |
| Meguro, K | 3 |
| Ikeda, H | 11 |
| Ye, JM | 1 |
| Frangioudakis, G | 1 |
| Iglesias, MA | 1 |
| Furler, SM | 1 |
| Ellis, B | 1 |
| Dzamko, N | 1 |
| Cooney, GJ | 1 |
| Kraegen, EW | 1 |
| Kumar, N | 1 |
| Dey, CS | 1 |
| Miyachi, N | 1 |
| Takeuchi, T | 1 |
| Takeuchi, Y | 1 |
| Kamiya, F | 1 |
| Imaeda, K | 1 |
| Okayama, N | 1 |
| Shimizu, M | 1 |
| Itoh, M | 2 |
| Takeda, K | 2 |
| Toda, K | 1 |
| Saibara, T | 1 |
| Nakagawa, M | 3 |
| Saika, K | 1 |
| Onishi, T | 1 |
| Shizuta, Y | 1 |
| Fischer, S | 1 |
| Pavo, I | 1 |
| Jermendy, G | 1 |
| Varkonyi, TT | 1 |
| Kerenyi, Z | 1 |
| Gyimesi, A | 1 |
| Shoustov, S | 1 |
| Shestakova, M | 1 |
| Herz, M | 3 |
| Johns, D | 7 |
| Schluchter, BJ | 1 |
| Festa, A | 1 |
| Tan, MH | 8 |
| Wilmsen, HM | 1 |
| Carter, L | 1 |
| Reehman, N | 1 |
| Bravata, DM | 1 |
| McVeety, JC | 1 |
| Horwitz, RI | 1 |
| Osawa, K | 1 |
| Romualdi, D | 2 |
| Guido, M | 2 |
| Ciampelli, M | 1 |
| Giuliani, M | 2 |
| Leoni, F | 1 |
| Perri, C | 1 |
| Lanzone, A | 2 |
| Suzuki, M | 6 |
| Odaka, H | 4 |
| Winkler, K | 1 |
| Füllert, S | 1 |
| Friedrich, I | 1 |
| Destani, R | 1 |
| Baumstark, MW | 1 |
| Krebs, K | 1 |
| Wieland, H | 1 |
| März, W | 1 |
| Shibasaki, M | 1 |
| Itou, T | 1 |
| Bujo, H | 1 |
| Saito, Y | 4 |
| Stolar, MW | 1 |
| Shadid, S | 3 |
| Jensen, MD | 3 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Coffler, MS | 1 |
| Patel, K | 1 |
| Dahan, MH | 1 |
| Yoo, RY | 1 |
| Malcom, PJ | 1 |
| Chang, RJ | 1 |
| Piper, P | 1 |
| Glass, L | 2 |
| Pratipanawatr, T | 2 |
| Miyazaki, Y | 3 |
| Gilling, L | 1 |
| Suwattee, P | 1 |
| DeSouza, C | 1 |
| Asnani, S | 2 |
| Fonseca, V | 2 |
| Promrat, K | 2 |
| Lutchman, G | 2 |
| Uwaifo, GI | 1 |
| Freedman, RJ | 1 |
| Soza, A | 1 |
| Heller, T | 2 |
| Doo, E | 1 |
| Ghany, M | 2 |
| Premkumar, A | 2 |
| Park, Y | 1 |
| Liang, TJ | 2 |
| Yanovski, JA | 1 |
| Suriano, R | 1 |
| Costantini, B | 1 |
| Apa, R | 1 |
| Zirlik, A | 1 |
| Leugers, A | 1 |
| Lohrmann, J | 1 |
| Ernst, S | 1 |
| Sobel, BE | 2 |
| Bode, C | 1 |
| Nordt, TK | 1 |
| Ishida, H | 1 |
| Takizawa, M | 1 |
| Ozawa, S | 1 |
| Nakamichi, Y | 1 |
| Yamaguchi, S | 1 |
| Katsuta, H | 1 |
| Tanaka, T | 1 |
| Maruyama, M | 1 |
| Katahira, H | 1 |
| Yoshimoto, K | 1 |
| Itagaki, E | 1 |
| Nagamatsu, S | 1 |
| Tajiri, Y | 1 |
| Karashima, T | 1 |
| Prasithsirikul, W | 1 |
| Bunnag, P | 1 |
| Glazer, NB | 4 |
| Widel, M | 3 |
| Gilmore, KJ | 2 |
| Matsuura, B | 1 |
| Kanno, S | 1 |
| Minami, H | 1 |
| Tsubouchi, E | 1 |
| Iwai, M | 1 |
| Matsui, H | 1 |
| Horiike, N | 1 |
| Onji, M | 1 |
| Inoue, M | 1 |
| Maehata, E | 1 |
| Suzuki, S | 2 |
| Durbin, RJ | 1 |
| Yajima, H | 1 |
| Ikeshima, E | 1 |
| Shiraki, M | 1 |
| Kanaya, T | 1 |
| Fujiwara, D | 1 |
| Odai, H | 1 |
| Tsuboyama-Kasaoka, N | 1 |
| Ezaki, O | 2 |
| Oikawa, S | 1 |
| Kondo, K | 1 |
| Minoura, H | 3 |
| Takeshita, S | 3 |
| Ita, M | 2 |
| Hirosumi, J | 3 |
| Mabuchi, M | 2 |
| Kawamura, I | 3 |
| Nakajima, S | 1 |
| Nakayama, O | 1 |
| Kayakiri, H | 1 |
| Oku, T | 1 |
| Ohkubo-Suzuki, A | 1 |
| Fukagawa, M | 1 |
| Kojo, H | 1 |
| Hanioka, K | 1 |
| Yamasaki, N | 1 |
| Imoto, T | 1 |
| Mutoh, S | 4 |
| Tan, M | 1 |
| González Gálvez, G | 1 |
| Antúnez, O | 1 |
| Fabián, G | 1 |
| Flores-Lozano, F | 1 |
| Zúñiga Guajardo, S | 1 |
| Garza, E | 1 |
| Morales, H | 1 |
| Konkoy, C | 1 |
| Dobiásová, M | 1 |
| Negro, R | 1 |
| Dazzi, D | 1 |
| Hassan, H | 1 |
| Pezzarossa, A | 1 |
| Panikar, V | 1 |
| Chandalia, HB | 1 |
| Joshi, SR | 1 |
| Fafadia, A | 1 |
| Santvana, C | 1 |
| Strand, J | 1 |
| Halse, J | 1 |
| Eriksson, JW | 1 |
| Clausen, J | 1 |
| Konkoy, CS | 1 |
| Brettenthaler, N | 1 |
| De Geyter, C | 1 |
| Huber, PR | 1 |
| Keller, U | 1 |
| Yokote, K | 2 |
| Honjo, S | 2 |
| Kobayashi, K | 1 |
| Fujimoto, M | 1 |
| Kawamura, H | 1 |
| Mori, S | 1 |
| Yang, B | 1 |
| Brown, KK | 1 |
| Chen, L | 1 |
| Carrick, KM | 1 |
| Clifton, LG | 1 |
| McNulty, JA | 1 |
| Winegar, DA | 1 |
| Strum, JC | 1 |
| Stimpson, SA | 1 |
| Pahel, GL | 1 |
| Ding, SY | 2 |
| Shen, ZF | 3 |
| Chen, YT | 3 |
| Xie, MZ | 3 |
| Hattori, S | 2 |
| Kasai, M | 1 |
| Namatame, T | 2 |
| Hattori, Y | 3 |
| Kasai, K | 3 |
| Khan, M | 1 |
| Xu, Y | 1 |
| Edwards, G | 1 |
| Urquhart, R | 3 |
| Mariz, S | 2 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Yu, Y | 1 |
| Li, Y | 1 |
| Fan, J | 1 |
| Yu, H | 1 |
| Liao, Z | 1 |
| Gao, H | 1 |
| Hammarstedt, A | 2 |
| Sopasakis, VR | 1 |
| Gogg, S | 1 |
| Jansson, PA | 1 |
| Smith, U | 3 |
| Angulo, P | 1 |
| Mofrad, PS | 1 |
| Contos, MJ | 1 |
| Sargeant, C | 1 |
| Luketic, VA | 1 |
| Sterling, RK | 1 |
| Stravitz, RT | 1 |
| Shiffman, ML | 1 |
| Clore, J | 1 |
| Mills, AS | 1 |
| Raue, U | 1 |
| Miles, LM | 3 |
| Lu, T | 2 |
| Di Gregorio, GB | 2 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Ramachandran, A | 1 |
| Snehalatha, C | 1 |
| Salini, J | 1 |
| Vijay, V | 1 |
| Wiesli, P | 1 |
| Bernays, R | 1 |
| Brändle, M | 1 |
| Zwimpfer, C | 1 |
| Seiler, H | 1 |
| Zapf, J | 1 |
| A Spinas, G | 1 |
| Schmid, C | 1 |
| Pickavance, LC | 1 |
| Brand, CL | 1 |
| Wassermann, K | 1 |
| Wilding, JP | 1 |
| Ceriello, A | 1 |
| Eckland, DJ | 1 |
| Yamaguchi, M | 1 |
| Nishimura, F | 1 |
| Naruishi, H | 1 |
| Soga, Y | 1 |
| Kokeguchi, S | 1 |
| Takashiba, S | 1 |
| Yang, GQ | 1 |
| Lu, JM | 1 |
| Liu, HF | 1 |
| Ma, FL | 1 |
| Zou, XM | 1 |
| Pan, CY | 1 |
| Tomono, S | 1 |
| Uchiyama, T | 1 |
| Ohyama, Y | 1 |
| Ono, M | 1 |
| Ikegami, H | 1 |
| Fujisawa, T | 1 |
| Nojima, K | 1 |
| Kawabata, Y | 1 |
| Nishino, M | 1 |
| Taniguchi, H | 1 |
| Itoi-Babaya, M | 1 |
| Babaya, N | 1 |
| Inoue, K | 1 |
| Ogihara, T | 1 |
| Göke, B | 2 |
| Sun, SJ | 2 |
| Watanabe, I | 1 |
| Tani, S | 1 |
| Anazawa, T | 1 |
| Kanmatsuse, K | 1 |
| Clough, MH | 1 |
| Schneider, DJ | 1 |
| White, MF | 1 |
| Wadsworth, MP | 1 |
| Taatjes, DJ | 1 |
| Langenfeld, MR | 1 |
| Kann, P | 2 |
| Füllert, SD | 1 |
| Sachara, C | 1 |
| Panchapakesan, U | 1 |
| Sumual, S | 1 |
| Pollock, CA | 1 |
| Chen, X | 1 |
| Schumm-Draeger, PM | 2 |
| Oya, Y | 1 |
| Isobe, T | 1 |
| Shirafuji, T | 1 |
| Ogata, K | 1 |
| Ogawa, M | 1 |
| Kawai, M | 1 |
| Laakso, M | 2 |
| Richardson, C | 1 |
| Hida, K | 1 |
| Wada, J | 2 |
| Eguchi, J | 1 |
| Baba, M | 1 |
| Seida, A | 1 |
| Hashimoto, I | 1 |
| Okada, T | 1 |
| Yasuhara, A | 1 |
| Nakatsuka, A | 1 |
| Shikata, K | 1 |
| Hourai, S | 1 |
| Futami, J | 1 |
| Watanabe, E | 1 |
| Matsuki, Y | 1 |
| Hiramatsu, R | 1 |
| Akagi, S | 1 |
| Kanwar, YS | 1 |
| Takakura, S | 2 |
| Seki, J | 2 |
| Manda, T | 2 |
| Horio, T | 2 |
| Suzuki, K | 3 |
| Takamisawa, I | 3 |
| Hiuge, A | 2 |
| Kamide, K | 1 |
| Takiuchi, S | 1 |
| Iwashima, Y | 1 |
| Yoshimasa, Y | 3 |
| Kawano, Y | 2 |
| Støving, RK | 1 |
| Hagen, C | 3 |
| Hermann, AP | 3 |
| Veldhuis, JD | 2 |
| Andersen, M | 4 |
| Tong, NW | 1 |
| Wan, Q | 1 |
| Liu, XJ | 1 |
| Wu, H | 1 |
| Pahler, S | 1 |
| Pfützner, AH | 1 |
| Igaki, N | 1 |
| Tanaka, M | 1 |
| Goto, T | 1 |
| Bodary, PF | 1 |
| Vargas, FB | 1 |
| King, SA | 1 |
| Jongeward, KL | 1 |
| Wickenheiser, KJ | 1 |
| Eitzman, DT | 1 |
| Os, I | 1 |
| Szapary, PO | 1 |
| Bloedon, LT | 1 |
| Samaha, FF | 1 |
| Duffy, D | 1 |
| Wolfe, ML | 1 |
| Soffer, D | 1 |
| Reilly, MP | 1 |
| Chittams, J | 1 |
| Rader, DJ | 1 |
| Jawa, A | 1 |
| LaForge, R | 1 |
| Otvos, JD | 1 |
| Tahara, H | 1 |
| Okuno, Y | 1 |
| Abbink, EJ | 1 |
| De Haan, JH | 1 |
| Heerschap, A | 1 |
| Yang, G | 1 |
| Tang, Y | 2 |
| Boden, G | 1 |
| Waugh, J | 1 |
| Keating, GM | 1 |
| Plosker, GL | 1 |
| Easthope, S | 1 |
| Robinson, DM | 1 |
| Qayyum, R | 1 |
| Adomaityte, J | 1 |
| Kubota, N | 2 |
| Terauchi, Y | 2 |
| Kubota, T | 1 |
| Yano, W | 1 |
| Ogata, H | 1 |
| Tokuyama, K | 1 |
| Takamoto, I | 1 |
| Mineyama, T | 1 |
| Ishikawa, M | 1 |
| Moroi, M | 1 |
| Sugi, K | 1 |
| Yamauchi, T | 2 |
| Ueki, K | 1 |
| Tobe, K | 1 |
| Noda, T | 1 |
| Nagai, R | 1 |
| Peters, RK | 1 |
| Kjos, SL | 1 |
| Marroquin, A | 1 |
| Goico, J | 1 |
| Ochoa, C | 1 |
| Kawakubo, M | 1 |
| Vinik, AI | 2 |
| Perriello, G | 1 |
| Pampanelli, S | 1 |
| Lewis, G | 1 |
| de Winter, W | 1 |
| DeJongh, J | 1 |
| Post, T | 1 |
| Ploeger, B | 1 |
| Moules, I | 1 |
| Eckland, D | 1 |
| Danhof, M | 1 |
| Ullal, J | 2 |
| Parson, HK | 1 |
| Barlow, PM | 1 |
| Casellini, CM | 1 |
| El Midaoui, A | 1 |
| Wu, L | 1 |
| Wang, R | 1 |
| de Champlain, J | 1 |
| Hiralal, R | 1 |
| Koo, KK | 1 |
| Gerstein, HC | 1 |
| Itoh, Y | 1 |
| Obata, T | 1 |
| Tajima, N | 1 |
| Sourij, H | 1 |
| Zweiker, R | 1 |
| Wascher, TC | 1 |
| Raji, A | 1 |
| Gerhard-Herman, MD | 1 |
| Williams, JS | 1 |
| O'connor, ME | 1 |
| Simonson, DC | 1 |
| Fujimura, T | 1 |
| Kimura, C | 2 |
| Oe, T | 1 |
| Sakuma, H | 1 |
| Aramori, I | 1 |
| Otto, C | 1 |
| Otto, B | 1 |
| Pfeiffer, AF | 1 |
| Lehrke, M | 1 |
| Vogeser, M | 1 |
| Spranger, J | 1 |
| Parhofer, KG | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Ning, ZQ | 1 |
| Lu, XP | 1 |
| Tanaka, N | 1 |
| Korenaga, M | 1 |
| Kawaguchi, K | 1 |
| Korenaga, K | 1 |
| Uchida, K | 1 |
| Sakaida, I | 1 |
| Henriksen, JE | 2 |
| Vinik, A | 1 |
| Parson, H | 1 |
| Lantz, M | 1 |
| Hallengren, B | 1 |
| Perregaux, C | 1 |
| Cefai, D | 1 |
| Xu, P | 1 |
| Zhang, XG | 1 |
| Li, YM | 1 |
| Yu, CH | 1 |
| Xu, L | 1 |
| Xu, GY | 1 |
| Taniguchi, Y | 1 |
| Ooie, T | 1 |
| Takahashi, N | 1 |
| Shinohara, T | 1 |
| Yonemochi, H | 2 |
| Hara, M | 1 |
| Yoshimatsu, H | 2 |
| Saikawa, T | 2 |
| Berria, R | 2 |
| Lucidi, S | 1 |
| Belfort, R | 2 |
| De Filippis, E | 1 |
| Easton, C | 1 |
| Brytzki, R | 1 |
| Jovanovic, L | 1 |
| Pokrovskaya, I | 1 |
| Lecka-Czernik, B | 1 |
| Ríos-Vázquez, R | 1 |
| Marzoa-Rivas, R | 1 |
| Gil-Ortega, I | 1 |
| Kaski, JC | 1 |
| Schneider, CA | 1 |
| Schwartz, EA | 1 |
| Starks, TN | 1 |
| Phan, J | 1 |
| Reue, K | 1 |
| Harano, Y | 1 |
| Biesenbach, G | 1 |
| Grafinger, P | 1 |
| Raml, A | 1 |
| Al-Azzawi, HH | 1 |
| Mathur, A | 1 |
| Lu, D | 1 |
| Swartz-Basile, DA | 1 |
| Nakeeb, A | 1 |
| Pitt, HA | 1 |
| Serlie, MJ | 1 |
| Allick, G | 1 |
| Groener, JE | 1 |
| Ackermans, MT | 1 |
| Heijligenberg, R | 1 |
| Voermans, BC | 1 |
| Aerts, JM | 1 |
| Meijer, AJ | 1 |
| Sauerwein, HP | 1 |
| Leclercq, IA | 1 |
| Lebrun, VA | 1 |
| Stärkel, P | 1 |
| Horsmans, YJ | 1 |
| Zhang, F | 1 |
| Sjöholm, A | 1 |
| Tamura, H | 1 |
| Mokuno, H | 1 |
| Daita, H | 1 |
| Bodles, AM | 2 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Fried, SK | 2 |
| Sharma, PK | 1 |
| Sialy, R | 1 |
| Brown, K | 1 |
| Finch, J | 1 |
| Balas, B | 1 |
| Pulcini, J | 1 |
| Ma, JZ | 1 |
| Dwivedi, S | 1 |
| Havranek, R | 1 |
| Fincke, C | 1 |
| Bannayan, GA | 1 |
| Zdravkovic, V | 1 |
| Hamilton, JK | 1 |
| Daneman, D | 1 |
| Cummings, EA | 1 |
| Desouza, CV | 1 |
| Gerety, M | 1 |
| Hamel, FG | 1 |
| Demidova, TIu | 1 |
| Ametov, AS | 1 |
| Titova, OI | 1 |
| Kurita, S | 1 |
| Matsuzawa, N | 1 |
| Kita, Y | 1 |
| Uno, M | 1 |
| Akahori, H | 1 |
| Misu, H | 1 |
| Sakurai, M | 1 |
| Zen, Y | 1 |
| Nakanuma, Y | 1 |
| Zendzian-Piotrowska, M | 1 |
| Baranowski, M | 1 |
| Zabielski, P | 1 |
| Górski, J | 1 |
| Casolaro, A | 1 |
| Pettiti, M | 1 |
| Nannipieri, M | 1 |
| Ciociaro, D | 1 |
| Frascerra, S | 1 |
| Buzzigoli, E | 1 |
| Baldi, S | 1 |
| Mari, A | 1 |
| Igarashi, M | 2 |
| Jimbu, Y | 1 |
| Kimura, M | 2 |
| Yamaguchi, H | 1 |
| Tominaga, M | 4 |
| Kurebayashi, S | 1 |
| Kouhara, H | 1 |
| Kasayama, S | 1 |
| Kanatani, Y | 1 |
| Usui, I | 2 |
| Ishizuka, K | 1 |
| Bukhari, A | 1 |
| Fujisaka, S | 1 |
| Urakaze, M | 1 |
| Haruta, T | 2 |
| Kishimoto, T | 1 |
| Gaikwad, AB | 1 |
| Viswanad, B | 1 |
| Weber, M | 2 |
| Marx, N | 1 |
| Koehler, C | 1 |
| Baurecht, W | 1 |
| Takebayashi, K | 2 |
| Suetsugu, M | 2 |
| Wakabayashi, S | 2 |
| Aso, Y | 2 |
| Inukai, T | 2 |
| Eguchi, K | 1 |
| Tomizawa, H | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Numao, T | 1 |
| Fukuda, T | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| Teramoto, T | 1 |
| Yamada, N | 1 |
| Shirai, K | 1 |
| Yamamoto, R | 1 |
| Matsumoto, S | 1 |
| Matsutomo, R | 1 |
| Reddy, RC | 1 |
| Gangireddy, SR | 1 |
| Owyang, C | 1 |
| DiMagno, MJ | 1 |
| Toyama, T | 1 |
| Kudo, N | 1 |
| Hibino, Y | 1 |
| Mitsumoto, A | 1 |
| Kawashima, Y | 1 |
| Modi, A | 1 |
| Borg, B | 1 |
| Loomba, R | 1 |
| Rashidi, AA | 1 |
| Deeg, MA | 1 |
| Buse, JB | 1 |
| Goldberg, RB | 1 |
| Kendall, DM | 1 |
| Zagar, AJ | 1 |
| Jacober, SJ | 1 |
| Khan, MA | 1 |
| de Rivas, B | 1 |
| Luque, M | 1 |
| Martell, N | 1 |
| Fernández, C | 1 |
| Fernández-Cruz, A | 1 |
| Anan, F | 1 |
| Masaki, T | 1 |
| Fukunaga, N | 1 |
| Teshima, Y | 1 |
| Iwao, T | 1 |
| Kaneda, K | 1 |
| Umeno, Y | 1 |
| Wakasugi, K | 1 |
| Eshima, N | 1 |
| Koo, YA | 1 |
| Shin, SY | 1 |
| Yoon, BK | 1 |
| Choi, D | 1 |
| Teranishi, T | 1 |
| Ohara, T | 1 |
| Maeda, K | 1 |
| Zenibayashi, M | 1 |
| Kouyama, K | 1 |
| Hirota, Y | 1 |
| Kawamitsu, H | 1 |
| Fujii, M | 1 |
| Sugimura, K | 1 |
| Kasuga, M | 1 |
| Sheffield, CA | 1 |
| Kane, MP | 1 |
| Busch, RS | 1 |
| DU, RQ | 2 |
| Li, HL | 2 |
| Yang, WY | 2 |
| Xiao, JZ | 2 |
| Lou, DJ | 2 |
| Bai, XP | 2 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Cooper, MB | 1 |
| Al Majali, K | 1 |
| Betteridge, DJ | 1 |
| Khashab, M | 1 |
| Kappert, K | 1 |
| Meyborg, H | 1 |
| Clemenz, M | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Kintscher, U | 1 |
| Stawowy, P | 1 |
| Handberg, A | 1 |
| Kaizu, K | 1 |
| Rottlaender, D | 1 |
| Michels, G | 1 |
| Hoppe, UC | 1 |
| Eckert, S | 1 |
| Lundershausen, R | 1 |
| Scherbaum, WA | 1 |
| Schnell, O | 1 |
| Standl, E | 1 |
| Walter, H | 1 |
| Fujishiro, T | 1 |
| Maezawa, Y | 1 |
| Sato, S | 1 |
| Koshizaka, M | 1 |
| Pérez, YY | 1 |
| Jiménez-Ferrer, E | 1 |
| Zamilpa, A | 1 |
| Hernández-Valencia, M | 1 |
| Alarcón-Aguilar, FJ | 1 |
| Tortoriello, J | 1 |
| Román-Ramos, R | 1 |
| Oda, N | 1 |
| Imamura, S | 1 |
| Uchida, Y | 1 |
| Inagaki, K | 1 |
| Kakizawa, H | 1 |
| Hayakawa, N | 1 |
| Suzuki, A | 1 |
| Takeda, J | 1 |
| Horikawa, Y | 1 |
| Doggrell, SA | 1 |
| Takatori, S | 1 |
| Yabumae, N | 1 |
| Hanafusa, N | 1 |
| Mio, M | 1 |
| Egawa, T | 1 |
| Kawasaki, H | 1 |
| Pihlajamäki, J | 1 |
| Graham, TE | 1 |
| Kainulainen, S | 1 |
| Kahn, BB | 1 |
| Nielsen, S | 1 |
| Guo, Z | 1 |
| Pedersen, SB | 1 |
| Schmitz, O | 1 |
| Christiansen, JS | 1 |
| Ko, GJ | 1 |
| Kang, YS | 1 |
| Han, SY | 1 |
| Lee, MH | 1 |
| Song, HK | 1 |
| Han, KH | 1 |
| Kim, HK | 1 |
| Han, JY | 1 |
| Cha, DR | 1 |
| Jensen, LT | 1 |
| Bennett, P | 1 |
| Bourassa, MG | 1 |
| Berry, C | 1 |
| Sulistio, MS | 1 |
| Zion, A | 1 |
| Thukral, N | 1 |
| Chilton, R | 1 |
| Takada, J | 1 |
| Fonseca-Alaniz, MH | 1 |
| de Campos, TB | 1 |
| Andreotti, S | 1 |
| Campana, AB | 1 |
| Okamoto, M | 1 |
| Borges-Silva, Cd | 1 |
| Machado, UF | 1 |
| Lima, FB | 1 |
| Maegawa, H | 1 |
| Ide, R | 1 |
| Hasegawa, M | 1 |
| Ugi, S | 1 |
| Egawa, K | 2 |
| Iwanishi, M | 3 |
| Kikkawa, R | 1 |
| Shigeta, Y | 2 |
| Kashiwagi, A | 1 |
| Iritani, N | 1 |
| Fukuda, H | 1 |
| de Souza, CJ | 2 |
| Yu, JH | 1 |
| Robinson, DD | 1 |
| Ulrich, RG | 1 |
| Meglasson, MD | 2 |
| Kaufman, LN | 1 |
| Peterson, MM | 1 |
| DeGrange, LM | 1 |
| Hofmann, C | 2 |
| Lorenz, K | 2 |
| Williams, D | 1 |
| Palazuk, BJ | 2 |
| Daimon, M | 2 |
| Eguchi, H | 2 |
| Matsumoto, M | 1 |
| Sekikawa, A | 1 |
| Yamatani, K | 1 |
| Sasaki, H | 3 |
| Saha, AK | 2 |
| Kurowski, TG | 2 |
| Ruderman, NB | 2 |
| Braithwaite, SS | 1 |
| Hotamisligil, GS | 1 |
| Spiegelman, BM | 1 |
| Kemnitz, JW | 1 |
| Elson, DF | 1 |
| Roecker, EB | 1 |
| Baum, ST | 1 |
| Bergman, RN | 1 |
| Towns, R | 1 |
| Kostyo, JL | 1 |
| Bleasdale, JE | 1 |
| Swanson, ML | 1 |
| Weinstein, SP | 1 |
| Holand, A | 1 |
| O'Boyle, E | 1 |
| Haber, RS | 1 |
| Umeda, F | 1 |
| Cunningham, BA | 1 |
| Holbert, RI | 1 |
| Corkey, BE | 1 |
| Yoshii, H | 1 |
| Petrie, J | 1 |
| Small, M | 1 |
| Connell, J | 1 |
| Shi, ZQ | 1 |
| Wan, C | 1 |
| Lekas, M | 1 |
| Rodgers, CD | 1 |
| Giacca, A | 1 |
| Vranic, M | 1 |
| Nakata, T | 1 |
| Hatta, T | 1 |
| Kiyama, M | 1 |
| Kawa, T | 1 |
| Morimoto, S | 1 |
| Miki, S | 1 |
| Moriguchi, J | 1 |
| Fujita, H | 1 |
| Itoh, H | 1 |
| Sasaki, S | 1 |
| Morimoto, Y | 1 |
| Nishikawa, K | 1 |
| Ohashi, M | 1 |
| Hallakou, S | 1 |
| Doaré, L | 1 |
| Foufelle, F | 1 |
| Kergoat, M | 1 |
| Guerre-Millo, M | 1 |
| Berthault, MF | 1 |
| Dugail, I | 1 |
| Morin, J | 1 |
| Auwerx, J | 1 |
| Ferré, P | 1 |
| Solomon, SS | 1 |
| Mishra, SK | 1 |
| Cwik, C | 1 |
| Rajanna, B | 1 |
| Postlethwaite, AE | 1 |
| Nomura, C | 1 |
| Kotchen, TA | 1 |
| Reddy, S | 1 |
| Zhang, HY | 1 |
| Imano, E | 1 |
| Kanda, T | 2 |
| Kajimoto, Y | 1 |
| Kaneko, T | 2 |
| Baba, S | 2 |
| Murase, K | 2 |
| Tayuki, N | 1 |
| Wasada, T | 1 |
| Sato, A | 1 |
| Omori, Y | 1 |
| Ikeda, M | 2 |
| Kubota, M | 2 |
| Ishida, Y | 1 |
| Hozumi, T | 1 |
| Uehara, M | 1 |
| Shichiri, M | 1 |
| Kinoshita, J | 1 |
| Mochizuki, K | 1 |
| Niwa, M | 1 |
| Arisaka, T | 1 |
| Ikebuchi, M | 1 |
| Tohdo, R | 1 |
| Shibata, T | 1 |
| Matsui, K | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Nishimiya, T | 1 |
| Ochi, M | 1 |
| Miki, H | 1 |
| Tamemoto, H | 1 |
| Komeda, K | 1 |
| Satoh, S | 1 |
| Nakano, R | 1 |
| Ishii, C | 1 |
| Sugiyama, T | 1 |
| Eto, K | 2 |
| Tsubamoto, Y | 1 |
| Murakami, K | 1 |
| Naito, M | 1 |
| Toyoshima, Y | 1 |
| Shiota, K | 1 |
| Aizawa, S | 1 |
| Shimizu, N | 1 |
| Oguma, Y | 1 |
| Kataoka, K | 1 |
| Manaka, H | 1 |
| Krentz, AJ | 1 |
| Melander, A | 1 |
| Ludvik, B | 1 |
| Naruse, M | 1 |
| Yoshimoto, T | 1 |
| Tanabe, A | 1 |
| Takagi, S | 1 |
| Tago, K | 1 |
| Takano, K | 1 |
| Filz, HP | 1 |
| Peters, AL | 1 |
| Morita, H | 1 |
| Oki, Y | 1 |
| Ito, T | 1 |
| Ohishi, H | 1 |
| Nakamura, H | 1 |
| Takano, A | 1 |
| Uno, T | 1 |
| Kawahara, J | 1 |
| Ueno, E | 1 |
| Sasaoka, T | 1 |
| Ishibashi, O | 1 |
| Ohya, Y | 1 |
| Nakamura, Y | 1 |
| Abe, I | 1 |
| Fujishima, M | 1 |
| Eckhardt, M | 1 |
| Gagen, K | 1 |
| Dong, M | 1 |
| Burkey, BF | 1 |
| Lawrence, JM | 1 |
| Reckless, JP | 1 |
| Rosenblatt, S | 1 |
| Miskin, B | 1 |
| Prince, MJ | 1 |
| Robertson, KE | 1 |
| Jazet, IM | 1 |
| Meinders, AE | 1 |
| Birkeland, KI | 1 |
| Lotz, N | 1 |
| Grossman, LD | 1 |
| Mahankali, A | 1 |
| Matsuda, M | 1 |
| Mahankali, S | 1 |
| Mandarino, LJ | 1 |
| Verspohl, EJ | 1 |
| Weiland, F | 1 |
| Rosenstock, J | 1 |
| Einhorn, D | 1 |
| Hershon, K | 1 |
| Yu, S | 1 |
| Kane, JP | 1 |
| Kürthy, M | 2 |
| Mogyorosi, T | 2 |
| Nagy, K | 2 |
| Demcáková, E | 1 |
| Ukropec, J | 1 |
| Koranyi, L | 1 |
| Klimes, I | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Hofmann, CA | 2 |
| Mizuno, K | 1 |
| Momose, Y | 1 |
| Edwards, CW | 1 |
| Hillman, RM | 1 |
| Taketomi, S | 2 |
| Shimura, Y | 3 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Pioglitazone on the Regulation of Insulin Secretion in Patients With Type 2 Diabetes[NCT00656864] | Phase 4 | 24 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| The Activation of Brown and Beige Fat and Role in Insulin Sensitivity[NCT02919176] | Early Phase 1 | 39 participants (Actual) | Interventional | 2016-09-01 | Completed | ||
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes[NCT03936829] | 10 participants (Anticipated) | Interventional | 2019-04-28 | Recruiting | |||
| Calisthenics Versus High-intensity Interval Exercises on Health-related Outcomes in Patients With Non-alcoholic Fatty Liver[NCT06032650] | 60 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | |||
| Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients[NCT01570660] | 24 participants (Actual) | Interventional | 2002-02-28 | Completed | |||
| Physicians Committee for Responsible Medicine, A Randomized, Crossover Trial of the Effect of a Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes[NCT04088981] | 60 participants (Anticipated) | Interventional | 2024-07-31 | Suspended (stopped due to The study was not initiated due to COVID-19 restrictions.) | |||
| Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion[NCT02370121] | Phase 2 | 24 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Inflammation and Insulin Resistance in Rheumatoid Arthritis[NCT00763139] | 34 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment[NCT00708175] | Phase 4 | 156 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961] | Phase 3 | 602 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance[NCT00835120] | Phase 4 | 34 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipolar I Depression: An Open-Label Study[NCT04569448] | Phase 3 | 58 participants (Anticipated) | Interventional | 2021-05-10 | Recruiting | ||
| Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals[NCT01253928] | Phase 4 | 16 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction[NCT03658031] | Phase 3 | 576 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance[NCT00443755] | Phase 2 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome: Effects of Reversing Insulin Resistance by Drug Treatment[NCT00408850] | Phase 3 | 44 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406] | Phase 2 | 166 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders[NCT01559857] | Phase 4 | 37 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial[NCT02796664] | 58 participants (Actual) | Interventional | 2016-06-23 | Completed | |||
| Identifying Targets of Maladaptive Metabolic Responses in Heart Failure[NCT03032627] | 55 participants (Actual) | Interventional | 2017-03-20 | Active, not recruiting | |||
| Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).[NCT00994682] | Phase 4 | 176 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[NCT03459079] | Phase 2 | 54 participants (Anticipated) | Interventional | 2018-08-14 | Recruiting | ||
| Interfacing Adiposity, Sleep Apnea, and Insulin Resistance[NCT02192684] | 45 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| The Effect of PPARgamma Stimulation on Glucose Metabolism, Insulin Resistance, Growth Hormone and Cortisol on Women Suffering From Polycystic Ovary Syndrome[NCT00145340] | Phase 4 | 30 participants | Interventional | 2002-09-30 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes[NCT00598013] | 83 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial[NCT02347501] | Phase 2 | 118 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects[NCT01090752] | Phase 4 | 16 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis[NCT01950884] | Phase 4 | 45 participants (Anticipated) | Interventional | 2013-10-31 | Enrolling by invitation | ||
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
| Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of Non-alcoholic Fatty Liver: a Randomized Clinical Trial[NCT04450875] | 121 participants (Actual) | Interventional | 2015-03-24 | Completed | |||
| Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)[NCT00063622] | Phase 3 | 247 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Single-arm, Open-label Clinical Study to Evaluate the Effect of SIM01 in Female Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT05885373] | 40 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | |||
| An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease[NCT01720719] | Phase 4 | 120 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Exercise and Pioglitazone for HIV-Metabolic Syndromes[NCT00639457] | 44 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome[NCT00656851] | 24 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients[NCT00140244] | Phase 2 | 7 participants (Actual) | Interventional | 2001-12-31 | Completed | ||
| A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.[NCT01157975] | Phase 2 | 0 participants (Actual) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was completed in another site) | ||
| The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study[NCT02765399] | Phase 4 | 23 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Role of Exenatide in Treatment of NASH-a Pilot Study[NCT00650546] | Phase 2/Phase 3 | 8 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282] | Phase 2 | 184 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome[NCT00926341] | Phase 4 | 110 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| The Impact of Brief Primary Care Counseling and Novel Physiological Measures on Patient Physical and Emotional Health[NCT00534482] | 950 participants (Anticipated) | Interventional | 2007-07-31 | Completed | |||
| Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)[NCT00227110] | Phase 4 | 55 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial[NCT00868933] | 159 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis[NCT01210989] | 60 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| [NCT00870012] | 20 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206] | Phase 4 | 34 participants (Actual) | Interventional | 2017-11-08 | Completed | ||
| Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia[NCT00331487] | Phase 3 | 719 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| The Effects of Rosiglitazone on Cognition in Patients With MCI[NCT00242593] | Phase 2 | 120 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
The blood sample for determining of 2-h PG, was taken two hours after the ingestion of the drink with 75 g dextrose and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 6.83 |
| Gymnema Sylvestre | 7.22 |
The estimation for AUCG was calculated from parameters obtained during the 2 hours oral glucose tolerant test (OGTT) with 75 g dextrose by trapezoidal integration. The value was expressed mmol/L/min. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L/min (Mean) |
|---|---|
| Placebo | 965 |
| Gymnema Sylvestre | 914 |
The estimation for AUCI was calculated from parameters obtained during the 2 hours oral glucose tolerant test (OGTT) with 75 g dextrose by trapezoidal integration. The value was expressed on pmol/L/min. (NCT02370121)
Timeframe: week 12
| Intervention | pmol/L/min (Mean) |
|---|---|
| Placebo | 90816 |
| Gymnema Sylvestre | 60468 |
The BMI was calculated by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres. (NCT02370121)
Timeframe: week 12
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 30.70 |
| Gymnema Sylvestre | 30.43 |
The BW was evaluated after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal. (NCT02370121)
Timeframe: week 12
| Intervention | kg (Mean) |
|---|---|
| Placebo | 80.3 |
| Gymnema Sylvestre | 77.9 |
The DBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg. (NCT02370121)
Timeframe: week 12
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 83 |
| Gymnema Sylvestre | 78 |
The blood sample for determining of FPG, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 5.00 |
| Gymnema Sylvestre | 4.83 |
The first phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'). (NCT02370121)
Timeframe: week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 1805 |
| Gymnema Sylvestre | 1366 |
The blood sample for determining of HDL-C, was taken after an overnight fast and was evaluated by colorimetric method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 1.03 |
| Gymnema Sylvestre | 1.08 |
The insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. (NCT02370121)
Timeframe: week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 2.5 |
| Gymnema Sylvestre | 4.1 |
The blood sample for determining of LDL-C, was taken after an overnight fast and was calculated by Friedewald formula. The value was expressed on mmol/L. (NCT02370121)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 2.77 |
| Gymnema Sylvestre | 2.69 |
The SBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg. (NCT02370121)
Timeframe: week 12
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | 122 |
| Gymnema Sylvestre | 121 |
The blood sample for determining of TC, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 5.04 |
| Gymnema Sylvestre | 4.55 |
The total insulin secretion was calculated by the insulinogenic index (ΔABC insulin / ΔABC glucose). (NCT02370121)
Timeframe: Week 12
| Intervention | unitless (Mean) |
|---|---|
| Placebo | 0.95 |
| Gymnema Sylvestre | 0.59 |
The blood sample for determining of TGs, was taken after an overnight fast and was evaluated by spectrophotometry method. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 2.79 |
| Gymnema Sylvestre | 1.70 |
The blood sample for determining the VLDL, was taken after an overnight fast and was calculated as triglycerides/5. The value was expressed on mmol/L. (NCT02370121)
Timeframe: week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.56 |
| Gymnema Sylvestre | 0.35 |
The WC was evaluated after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. (NCT02370121)
Timeframe: Week 12
| Intervention | cm (Mean) |
|---|---|
| Placebo | 101 |
| Gymnema Sylvestre | 96 |
(NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | mg/dl (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 8.1 |
| Pioglitazone Phase After 8 Weeks | 5.02 |
| Placebo Phase Baseline | 7.7 |
| Placebo Phase wk After 8 Weeks | 8.25 |
A measure of disease activity based upon tender joint count of 28 joints, swollen joint count of 28 joints, erythrocyte sedimentation rate, and global disease activity (GH) as reported by participant. Calculation is as follows: DAS28=0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR) + 0.014*GH (NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 4.40 |
| Pioglitazone Phase After 8 Weeks | 4.03 |
| Placebo Phase Baseline | 4.57 |
| Placebo Phase wk 8/20 | 4.48 |
sed rate (NCT00763139)
Timeframe: baseline and after 8 weeks on either placebo or pioglitazone
| Intervention | mm/hr (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 18.5 |
| Pioglitazone Phase After 8 Weeks | 17 |
| Placebo Phase Baseline | 19.5 |
| Placebo Phase After 8 Weeks | 18.88 |
Homa is a measure of insulin sensitivity, using glucose measured in mmol/L and insulin measured in milliUnits per liter (mU/L) Calculated using the formula Glucose * Insulin/22/5 (NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 2.83 |
| Pioglitazone Phase After 8 Weeks | 2.44 |
| Placebo Phase Baseline | 2.38 |
| Placebo Phase wk 8/20 | 3.11 |
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 1 |
| Placebo | 3 |
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Baseline and Month 12.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.69 |
| Placebo | -0.14 |
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Month 12 and Month 18.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.14 |
| Placebo | 0.04 |
The change between the fasting plasma glucose value collected at each time frame indicated. (NCT00708175)
Timeframe: Baseline and Month 12; Month 12 and Month 18.
| Intervention | mg/dL (Least Squares Mean) | |
|---|---|---|
| Baseline to Month 12 (n=57; n=61) | Month 12 to Month 18 (n=54; n=57) | |
| Pioglitazone | -2.8 | 0.4 |
| Placebo | 6.0 | -1.0 |
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) | |
|---|---|---|
| Double-Blind Period (n=76; n=75) | Follow-up Period (n=63; n=59) | |
| Pioglitazone | 1 | 0 |
| Placebo | 7 | 1 |
Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -4.0 |
| Pioglitazone | -10.7 |
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | matsuda index (Mean) |
|---|---|
| Placebo | 0.7 |
| Pioglitazone | 3.6 |
Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | nmol (Mean) |
|---|---|
| Placebo | 35 |
| Pioglitazone | 25 |
carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | percentage of intima (Mean) |
|---|---|
| Placebo | 1.7 |
| Pioglitazone | 3.2 |
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.1 |
| Pioglitazone | 5.0 |
"The CGI-BP asks the clinician one question: Considering your total clinical experience with this particular population, how mentally ill is the patient at this time? which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients." (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -1.9 |
The QIDS-SR16 is a 16-item, self report assessment. Total scores can range from 0 to 27, with higher scores indicating a worse outcome (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -7.1 |
Inventory of Depressive Symptoms-Clinician rated, 30 item (IDS-C30) score change from baseline to study endpoint. IDS-C30 total scores can range from 0 to 84, with higher scores indicating a worse outcome (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | -16.5 |
A participant is considered in remission if their total score on the MADRS is > 7, their total score on the QIDS-SR16 > 6 and/or their total score on the IDS-CR is > 12 at Week 8. (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 8 |
A participant is considered to have responded if their total score on either the MADRS or QIDS-SR16 decreases by at least 50% between their Week 0 visit and Week 8 visit. (NCT00835120)
Timeframe: Week 0 - Week 8
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 13 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
Body fat is reported as a percentage of body weight. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage of body weight (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 1.73 |
| Placebo | -0.01 |
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 0.37 |
| Placebo | -0.21 |
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -19.96 |
| Placebo | 8.39 |
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -1.13 |
| Placebo | -0.34 |
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.35 |
| Placebo | 0.19 |
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL). (NCT00443755)
Timeframe: Baseline, 3 month
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.13 |
| Placebo | 0.18 |
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | microIU/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -8.13 |
| Placebo | 1.38 |
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | micromols/kg of FFM/minute (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 17.95 |
| Placebo | 1.68 |
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 9.10 |
| Placebo | 0.46 |
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.19 |
| Placebo | -0.15 |
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.99 |
| Placebo | -1.42 |
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 14.00 |
| Placebo | -18.62 |
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -34.17 |
| Placebo | 8.15 |
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Triglycerides | HDL-C-Cholesterol | Non-HDL-Cholesterol | |
| Insulin Sensitizer Therapy | -15.58 | 4.33 | -7.50 |
| Placebo | 17.77 | -0.31 | 4.62 |
The HDRS-21 was administered at baseline and at the end of 12 weeks, and the mean difference between the two time points was calculated. The HDRS-21 is scored on a scale from 0 to 21, where 0 is the lowest level of depression severity and 21 is the highest level of depression severity. (NCT01559857)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Pio - IS | -4.45 |
| Placebo - IS | -3.57 |
| Pio - IR | -1.71 |
| Placebo - IR | -3.57 |
The fasting plasma insulin measurements taken at baseline are shown in the data table below. (NCT01559857)
Timeframe: Baseline
| Intervention | uIU/mL (Mean) |
|---|---|
| Pio - IS | 10.61 |
| Placebo - IS | 9.18 |
| Pio - IR | 13.98 |
| Placebo - IR | 14.12 |
The HDRS-21 was used to screen for unremitted depression. The HDRS-21 is scored on a scale from 0 to 21, where 0 is the lowest level of depression severity and 21 is the highest level of depression severity. Unremitted depression is characterized by a score of ≥7. The HDRS-21 scores at baseline are shown in the data table below. (NCT01559857)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Pio - IS | 15.22 |
| Placebo - IS | 13.67 |
| Pio - IR | 19.22 |
| Placebo - IR | 13.25 |
We calculated average drug compliance based on the number of remained drugs at each follow-up. (NCT02796664)
Timeframe: At twelve months after randomization.
| Intervention | percentage of drug compliance (Mean) |
|---|---|
| Ginseng | 97.4 |
| Placebo | 97.8 |
Presence of other cerebro-cardiovascular morbidity or mortality assessed by aggravation of patient status (modified Rankin Scale). The modified Rankin Scale is ranging from 0 to 5. The higher scale indicates the worse outcome. (NCT02796664)
Timeframe: Twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| mRS 0 | mRS 1 | mRS 2 | mRS 3 | mRS 4 | mRS 5 | |
| Ginseng | 21 | 5 | 0 | 2 | 0 | 0 |
| Placebo | 22 | 1 | 0 | 1 | 0 | 0 |
The 1-year composite of cerebral ischemic stroke and transient ischemic attack downstream to an atherosclerotic lesion (NCT02796664)
Timeframe: Twelve months after randomization.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Ischemic stroke | Transient ischemic attack | |
| Ginseng | 0 | 0 |
| Placebo | 0 | 1 |
The changes in volumetric blood flow (ml/sec) in intracranial vessels assessed by quantitative magnetic resonance angiography with noninvasive optimal vessel analysis. (NCT02796664)
Timeframe: At randomization and twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The flow change in steno-occlusive lesion72501839 | The flow change in steno-occlusive lesion72501838 | The flow change in collateral vessel72501838 | The flow change in collateral vessel72501839 | |||||||||
| Improved | No change | Aggravated | ||||||||||
| Ginseng | 4 | |||||||||||
| Placebo | 5 | |||||||||||
| Ginseng | 17 | |||||||||||
| Placebo | 18 | |||||||||||
| Placebo | 1 | |||||||||||
| Ginseng | 7 | |||||||||||
| Placebo | 7 | |||||||||||
| Placebo | 9 | |||||||||||
| Placebo | 8 | |||||||||||
The changes of white matter hyperintensities, assessed by the Fazekas scale using brain magnetic resonance imaging. The Fazekas scale is a 4 point white matter disease severity scale with values ranging from 0 to 3. It quantifies the amount of white matter T2 hyperintense lesions each in periventricular white matter and deep white matter. Higher scales mean a worse white matter status. In the region of the periventricular white matter, 0 means absence of the lesion; 1, caps or pencil-thin lining lesion; 2, smooth halo lesion; 3, irregular high intense signal extending into the deep shite matter. In the region of the deep white matter, 0 means absence of the lesion; 1, punctate foci lesions; 2, beginning confluence; 3, large confluent hyperintense areas. (NCT02796664)
Timeframe: At randomization and twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Periventricular white matter72501836 | Periventricular white matter72501837 | Deep white matter72501837 | Deep white matter72501836 | |||||||||||||
| Fazekas scale 3 | Fazekas scale 0 | Fazekas scale 1 | Fazekas scale 2 | |||||||||||||
| Placebo | 11 | |||||||||||||||
| Placebo | 10 | |||||||||||||||
| Ginseng | 2 | |||||||||||||||
| Ginseng | 9 | |||||||||||||||
| Placebo | 6 | |||||||||||||||
| Ginseng | 15 | |||||||||||||||
| Placebo | 15 | |||||||||||||||
| Ginseng | 3 | |||||||||||||||
| Placebo | 2 | |||||||||||||||
| Ginseng | 1 | |||||||||||||||
| Placebo | 1 | |||||||||||||||
Suppression of free fatty acids by low dose insulin (i.e., percentage of reduction of plasma FFA with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((plasma FFA without insulin - plasma FFA with insulin infusion)/plasma FFA without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of FFA (Mean) |
|---|---|
| Placebo | 46.1 |
| Pioglitazone | 65.9 |
Suppression of endogenous glucose production (Supp EGP) by low dose insulin (i.e., percentage of reduction of EGP with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((EGP without insulin - EGP with insulin infusion)/EGP without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of EGP (Mean) |
|---|---|
| Placebo | 37.7 |
| Pioglitazone | 55.3 |
Liver fat content was calculated as the fat fraction: 100*(area under the curve [AUC] of fat peak / [AUC of fat peak + AUC of water peak]). (NCT00994682)
Timeframe: 18 months
| Intervention | percentage of fat in liver (Mean) |
|---|---|
| Placebo | 11 |
| Pioglitazone | 7 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT00994682)
Timeframe: At 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Pioglitazone | 29 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Pioglitazone | 26 |
Number of patients with osteoporotic fractures (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pioglitazone | 0 |
| Placebo | 0 |
Rate of glucose disappearance (Rd) during high-dose insulin infusion. The rate of plasma glucose disappearance was calculated using Steele's non-steady-state equation. (NCT00994682)
Timeframe: 18 months
| Intervention | mg/kgLBM/min (Mean) |
|---|---|
| Placebo | 5.4 |
| Pioglitazone | 9.6 |
Total body fat measured by dual-energy x-ray absorptiometry (DXA) (NCT00994682)
Timeframe: Months 18
| Intervention | Percentage of body weight that is fat (Mean) |
|---|---|
| Placebo | 36 |
| Pioglitazone | 36 |
(NCT00994682)
Timeframe: Months 18 and 36
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| BMI Month 18 | BMI Month 36 | |
| Pioglitazone | 34.6 | 35.2 |
| Placebo | 34.6 | 36.7 |
Bone mineral density measured at the levels of spine, femoral neck, hip, and wrist by DXA. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | g/cm^2 (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Spine BMD at month 18 | Femoral Neck BMD at month 18 | Hip BMD at month 18 | Wrist BMD at month 18 | Spine BMD at month 36 | Femoral Neck BMD at month 36 | Hip BMD at month 36 | Wrist BMD at month 36 | |
| Pioglitazone | 1.04 | 0.84 | 1.05 | 0.76 | 1.06 | 0.84 | 1.02 | 0.75 |
| Placebo | 1.10 | 0.86 | 1.05 | 0.78 | 1.10 | 0.84 | 1.06 | 0.77 |
Homeostatic model assessment of insulin resistance (HOMA-IR) is a method for assessing insulin resistance (IR) from basal fasting plasma glucose (FPG) and fasting plasma insulin (FPI). It is calculated as (FPG x FPI)/405. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Arbitrary units (Mean) | |
|---|---|---|
| HOMA-IR month 18 | HOMA-IR month 36 | |
| Pioglitazone | 1.4 | 1.6 |
| Placebo | 4.3 | 2.3 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal, 1A = Mild, zone 3, perisinusoidal delicate fibrosis; 1B = Moderate, zone 3, perisinusoidal dense fibrosis; 1C = Portal/periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis" (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 35 | 25 | 25 | 20 |
| Placebo | 13 | 11 | 12 | 13 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| ALT at month 18 | AST at month 18 | ALT at month 36 | AST at month 36 | |
| Pioglitazone | 27 | 29 | 27 | 27 |
| Placebo | 44 | 38 | 32 | 30 |
Mean change in individual scores compared to baseline. Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Baseline and Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | -1.1 | -0.6 | -0.6 | -0.5 |
| Placebo | -0.2 | -0.1 | -0.2 | 0 |
Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Month 36
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 0.97 | 0.81 | 0.22 | 0.66 |
| Placebo | 1.56 | 1.30 | 0.33 | 0.89 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | μg/ml (Mean) | |
|---|---|---|
| Adiponectin month 18 | Adiponectin month 36 | |
| Pioglitazone | 22.8 | 24.2 |
| Placebo | 9.1 | 24.0 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |
|---|---|---|
| CK-18 month 18 | CK-18 month 36 | |
| Pioglitazone | 186 | 151 |
| Placebo | 314 | 245 |
Number of patients developing T2DM and number of patients regressing to NGT among patients with prediabetes (IFG/IGT). (NCT00994682)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients developing T2DM | Patients regressing to NGT | |
| Pioglitazone | 1 | 10 |
| Placebo | 2 | 1 |
To evaluate the effects of pioglitazone versus placebo on AHI in patients with OSA. (NCT02192684)
Timeframe: 8 weeks
| Intervention | AHI events/hour (Median) |
|---|---|
| Pioglitazone | 35.8 |
| Placebo | 34.4 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | µg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | -0.2 |
| Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmHg (Median) |
|---|---|
| Sitagliptin | 4 |
| Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | 0.1 |
| Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 3 |
| Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 9.5 |
| Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | kg (Median) |
|---|---|
| Sitagliptin | -0.5 |
| Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Gliclazide | -1.12 |
| Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Sitagliptin | 3.41 |
| Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | -0.07 |
| Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 6 |
| Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
| Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
| Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PASI 50 | PASI 75 | PASI 90 | |
| Gliclazide | 1 | 0 | 0 |
| Sitagliptin | 1 | 0 | 0 |
24 hour blood pressure measurements were performed after each treatment/diet phase (NCT01090752)
Timeframe: march 2009
| Intervention | mmHg (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 128 |
| Placebo Low Salt/High Salt | 129 |
At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF (NCT01090752)
Timeframe: 2008
| Intervention | ml/min/1.73m2 (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 68.0 |
| Placebo Low Salt/High Salt | 62.4 |
At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances (NCT01090752)
Timeframe: 2007
| Intervention | ml/min (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 1.05 |
| Placebo Low Salt/High Salt | 1.18 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score, which indicates improvement in fibrosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 33 |
| Placebo | 22 |
Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning. This secondary outcome measure is the number of participants that experienced a decrease in hepatocellular ballooning score, which indicates improvement in hepatocellular ballooning. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 31 |
| Vitamin E | 40 |
| Placebo | 21 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score, which indicates improvement in lobular inflammation. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 41 |
| Vitamin E | 43 |
| Placebo | 25 |
Total nonalcoholic fatty liver disease (NAFLD) activity was assessed on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (assessed on a scale of 0 to 3), lobular inflammation (assessed on a scale of 0 to 3), and hepatocellular ballooning (assessed on a scale of 0 to 2). The primary outcome was an improvement in histological findings from baseline to 96 weeks, which required an improvement by 1 or more points in the hepatocellular ballooning score; no increase in the fibrosis score; and either a decrease in the activity score for nonalcoholic fatty liver disease to a score of 3 or less or a decrease in the activity score of at least 2 points, with at least a 1-point decrease in either the lobular inflammation or steatosis score. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 27 |
| Vitamin E | 36 |
| Placebo | 16 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score, which indicates improvement in steatosis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 48 |
| Vitamin E | 43 |
| Placebo | 22 |
The criteria for nonalcoholic steatohepatitis was definite or possible steatohepatitis (assessed by a pathologist) with an activity score of 5 or more, or definite steatohepatitis (confirmed by two pathologists) with an activity score of 4. This secondary outcome measure is the number of participants who met this definition at baseline and did not meet this definition after 96 weeks of treatment and thus had a resolution of steatohepatitis. (NCT00063622)
Timeframe: baseline and 96 weeks
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 33 |
| Vitamin E | 29 |
| Placebo | 15 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 2101 | 2164 |
| Pioglitazone + Exercise Training | 1877 | 1905 |
Percentage of blood volume that is red cells (NCT00639457)
Timeframe: Baseline and Week 16
| Intervention | % red cells (Mean) | |
|---|---|---|
| Baseline Hematocrit | Week 16 Hematocrit | |
| Pioglitazone | 39.9 | 39.6 |
| Pioglitazone + Exercise Training | 40.7 | 39.7 |
(NCT00639457)
Timeframe: Baseline and Week 16
| Intervention | g/L (Mean) | |
|---|---|---|
| Baseline Hemoglobin | Week 16 Hemoglobin | |
| Pioglitazone | 13.8 | 13.7 |
| Pioglitazone + Exercise Training | 13.8 | 13.6 |
ability of insulin to suppress hepatic glucose production = hepatic insulin sensitivity (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | percent suppression (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 32 | 40 |
| Pioglitazone + Exercise Training | 37 | 42 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | percent of water (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 12.1 | 10.7 |
| Pioglitazone + Exercise Training | 8.0 | 5.5 |
Insulin-mediated glucose disposal rate per kg of fat free mass per min (NCT00639457)
Timeframe: Baseline and week16
| Intervention | µmol glucose/kg FFM/min (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 30 | 37 |
| Pioglitazone + Exercise Training | 34 | 48 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| Baseline ALT | Week 16 ALT | Baseline AST | Week 16 AST | |
| Pioglitazone | 38 | 39 | 34 | 30 |
| Pioglitazone + Exercise Training | 34 | 32 | 27 | 27 |
E/A ratio; ratio of the early (E) to late (A) ventricular filling velocities (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | ratio (Mean) | |
|---|---|---|
| Baseline E/A ratio | Week 16 E/A ratio | |
| Pioglitazone | 1.3 | 1.4 |
| Pioglitazone + Exercise Training | 1.2 | 1.4 |
Diastolic blood pressure; vascular pressure during ventricular relaxation (diastole) (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline DBP | Week 16 DBP | |
| Pioglitazone | 65 | 67 |
| Pioglitazone + Exercise Training | 68 | 61 |
Deceleration time; time from the peak of early diastolic filling to baseline (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline DT | Week 16 DT | |
| Pioglitazone | 204 | 193 |
| Pioglitazone + Exercise Training | 214 | 190 |
Time required to empty the left ventricle into the aorta (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | msec (Mean) | |
|---|---|---|
| Baseline LV ejection time | Week 16 LV ejection time | |
| Pioglitazone | 296 | 294 |
| Pioglitazone + Exercise Training | 281 | 305 |
Systolic blood pressure; peak vascular pressure during ventricular contraction (NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline SBP | Week 16 SBP | |
| Pioglitazone | 114 | 114 |
| Pioglitazone + Exercise Training | 121 | 114 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | µg/mL (Mean) | |
|---|---|---|
| Baseline serum adiponectin | Week 16 serum adiponectin | |
| Pioglitazone | 4.7 | 7.0 |
| Pioglitazone + Exercise Training | 4.8 | 6.5 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | mM/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Triglycerides | Week 16 Triglycerides | Baseline Total Cholesterol | Week 16 Total cholesterol | Baseline LDL cholesterol | Week 16 LDL cholesterol | Baseline HDL cholesterol | Week 16 HDL cholesterol | |
| Pioglitazone | 2.3 | 2.5 | 4.9 | 4.6 | 2.8 | 2.5 | 0.99 | 0.98 |
| Pioglitazone + Exercise Training | 2.1 | 1.8 | 4.7 | 4.5 | 2.7 | 2.6 | 1.06 | 1.09 |
(NCT00639457)
Timeframe: Baseline and week 16
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Pioglitazone | 1933 | 1970 |
| Pioglitazone + Exercise Training | 1890 | 1746 |
fasting plasma glucose, insulin concentrations and HOMA-insulin resistance (NCT00656851)
Timeframe: Week 0 and 16
| Intervention | mg/dL µU/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| glucose (mg/dL) wk 0 | glucose wk 16 | insulin (µU/mL) wk 0 | insulin wk 16 | HOMA-IR wk 0 | HOMA-IR wk 16 | |
| Exercise Training | 91.9 | 86.8 | 14.8 | 11.8 | 3.3 | 2.6 |
| Pioglitazone | 102 | 95.3 | 20.5 | 11.4 | 6.1 | 2.8 |
fasting serum triglycerides, LDL-, and HDL-cholesterol concentrations (NCT00656851)
Timeframe: Week 0 and 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| triglycerides wk 0 | triglycerides wk 16 | LDL-cholesterol wk 0 | LDL-cholesterol wk 16 | HDL-cholesterol wk 0 | HDL-cholesterol wk 16 | |
| Exercise Training | 185 | 159 | 112 | 90 | 38.1 | 39.8 |
| Pioglitazone | 199 | 182 | 115 | 97 | 38.9 | 38.8 |
"Echocardiographic quantification of (E/A) early to late diastolic filling velocity. Aria transfer blood to the ventricles in 2 steps:~blood collected in the atria falls into the ventricles when the atrioventricular valves opens. In the left heart, the velocity at which the blood moves during this initial action is called the early or E filling velocity.~residual blood in the atria, is emptied during diastole by atrial contraction. The velocity of the blood during atrial contraction is the A (for atrial) filling velocity. These are expressed as a ratio (E/A). If A exceeds E velocity (ratio <1.0) this is a clinical marker of diastolic dysfunction. This can occur when the left ventricular wall becomes so stiff as to impair proper filling, which can lead to diastolic heart failure." (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | ratio (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 1.4 | 1.5 |
| Pioglitazone | 1.4 | 1.4 |
Echocardiographic quantification of E' wall velocity during systole averaged at the lateral wall and septum (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | cm/sec (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 13.1 | 13.6 |
| Pioglitazone | 12.7 | 12.8 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid esterification as a % of total fatty acid extraction (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (% of total fatty acid extraction) (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 4 | 7 |
| Pioglitazone | 7 | 4 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid oxidation rate. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol palmitate/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 106.3 | 97.5 |
| Pioglitazone | 92.4 | 110.1 |
Radio-tracer (11C-palmitate) and positron emission tomography quantification of myocardial fatty acid utilization rate. The rate at which palmitate exits the blood, enters the muscle cells in the left ventricle, and is metabolized (oxidation, re-esterification). (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol palmitate/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 119.8 | 130.4 |
| Pioglitazone | 119.3 | 129.3 |
Radio-tracer (11C-glucose) and positron emission tomography quantification of myocardial glucose utilization rate. The rate at which glucose exits the blood, enters the muscle cells in the left ventricle, and is metabolized (ATP generation, glycolysis, glycogenolysis, or lactate production). Total glucose utilization rate in the left ventricle of the heart. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol glucose/g heart muscle/min (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 106.7 | 87.2 |
| Pioglitazone | 109.6 | 109.1 |
Radio-tracer (11C-glucose) and positron emission tomography quantification of myocardial glucose utilization rate per unit of plasma insulin. Total glucose utilization rate in the left ventricle of the heart expressed per unit of the circulating plasma insulin concentration. (NCT00656851)
Timeframe: Weeks 0 and 16
| Intervention | (nmol glucose/g heart muscle/min/µU insu (Mean) | |
|---|---|---|
| Week 0 | Week 16 | |
| Exercise Training | 11.9 | 21.7 |
| Pioglitazone | 14.9 | 15.7 |
percent change in mean blood pressure (NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | percentage change of mean blood pressure (Least Squares Mean) |
|---|---|
| r-MetHuLeptin | 3.2 |
| Placebo | -6.7 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | cells/mcl (Mean) |
|---|---|
| r-MetHuLeptin | 556.6 |
| Placebo | 637.2 |
Fibrinogen (NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mg/dL (Mean) |
|---|---|
| r-MetHuLeptin | 252.2 |
| Placebo | 294.4 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mEq/liter (Mean) |
|---|---|
| r-MetHuLeptin | 0.45 |
| Placebo | 0.61 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mg/dl (Mean) |
|---|---|
| r-MetHuLeptin | 91 |
| Placebo | 95.6 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | percentage of liver volume (Mean) |
|---|---|
| r-MetHuLeptin | 4.02 |
| Placebo | 4.01 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mcIU/ml (Mean) |
|---|---|
| r-MetHuLeptin | 11.6 |
| Placebo | 20.3 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | units on a scale (Mean) |
|---|---|
| r-metHuLeptin | 2.52 |
| Placebo | 4.56 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | pg/ml (Mean) |
|---|---|
| r-MetHuLeptin | 1.65 |
| Placebo | 2.14 |
lean body mass (NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | kg (Mean) |
|---|---|
| r-MetHuLeptin | 58.6 |
| Placebo | 61.6 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mg/dl (Mean) |
|---|---|
| r-MetHuLeptin | 113 |
| Placebo | 105.7 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | copies/ml (Mean) |
|---|---|
| r-MetHuLeptin | 11345 |
| Placebo | 12367 |
(NCT00140244)
Timeframe: At the end of each two month intervention
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| total cholesterol | low density lipoprotein cholesterol | triglycerides | high density lipoprotein cholesterols | Free fatty acids | |
| Placebo | 219.7 | 105.7 | 520.5 | 29.96 | 0.61 |
| r-MetHuLeptin | 228.8 | 113.0 | 409.0 | 35 | 0.45 |
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | μg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | sec (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
| Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
| Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
| Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
Before vs after intervention (Liraglutide or placebo): Change in body weight. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 98.6 | 96.1 |
| Placebo | 92.0 | 89.8 |
Before vs after intervention (Liraglutide or placebo): apolipoprotein CIII concentration in plasma measured by using turbidimetric immunoassay. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 12.0 | 9.9 |
| Placebo | 9.7 | 8.6 |
Before vs after intervention (Liraglutide or placebo): Direct apoB48 clearance rates in isolated chylomicrons and measured by liquid chromatography - mass spectrometry and calculated by multicompartmental modeling assay. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mg/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 106 | 3.8 |
| Placebo | 20 | 17 |
Before vs after intervention (Liraglutide or placebo): concentration of fasting plasma glucose measured using the hexokinase method. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 8.3 | 6.4 |
| Placebo | 6.5 | 6.4 |
Before vs after intervention (Liraglutide or placebo): Change in B -Hemoglobiini-A1c level in plasma. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | HbA1c % (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 7.0 | 6.4 |
| Placebo | 6.3 | 6.4 |
Before vs after intervention (Liraglutide or placebo): Hepatic DNL is calculated from enrichment of deuterated water ingested during the kinetic study at specified time points (0, 4 and 8 hrs.). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | μmol/L (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 15.4 | 19.1 |
| Placebo | 12.6 | 13.8 |
Before vs after intervention (Liraglutide or placebo): Concentration of insulin level in plasma measured using electrochemiluminescence. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after16 weeks
| Intervention | μU/mL (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 13.9 | 14.5 |
| Placebo | 13.8 | 14.1 |
Before vs after intervention (Liraglutide or placebo): mean liver fat content was measured by magnetic resonance imaging. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | fat % (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 14.8 | 10.7 |
| Placebo | 16.1 | 13.9 |
Before vs after intervention (Liraglutide or placebo): Matsuda index was calculated for assessment of insulin sensitivity in plasma at time points 0, 30, 60 and 120 minutes using formula 10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during oral glucose tolerance test]. The Matsuda index is considered to be the gold standard to determine insulin sensitivity without glucose clamp studies (Matsuda M, DeFronzo RA. Diabetes Care. 22:1462-70). Subjects who don't have insulin resistance have values of Matsuda Index of 2.5 or higher (Kerman WN et al. Stroke 34:1431;2003). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | index (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 2.5 | 3.5 |
| Placebo | 3.1 | 3.1 |
Before vs after intervention (Liraglutide or placebo): subcutaneous adipose tissue area measured by magnetic resonance imaging (MRI). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 4043 | 3792 |
| Placebo | 5400 | 5161 |
Before vs after intervention (Liraglutide or placebo): systolic blood pressure measurements. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 135 | 139 |
| Placebo | 145 | 137 |
Before vs after intervention (Liraglutide or placebo): visceral adipose tissue area measured by magnetic resonance imaging (MRI). Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | cm3 (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 3403 | 3185 |
| Placebo | 2710 | 2600 |
Before vs after intervention (Liraglutide or placebo): Change in apoB48 chylomicron fractional transfer rate to VLDL1 isolated from plasma by ultracentrifugation and by liquid chromatography/mass spectrometry and calculated with multicompartmental modeling assay. So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | pools/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 12 | 26 |
| Placebo | 34 | 30 |
Before vs after intervention (Liraglutide or placebo): Change in chylomicron fractional direct clearance rates of apoB48 measured from plasma by liquid chromatography - mass spectrometry with multicompartmental modeling assay. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | pools/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 9 | 0.8 |
| Placebo | 4.4 | 3.2 |
Before vs after intervention (Liraglutide or placebo): Change in chylomicron-apoB48 transfer rates to VLDL1 isolated from plasma by ultracentrifugation and measured using multicompartmental modeling. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mg/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 127 | 110 |
| Placebo | 170 | 150 |
Before vs after intervention (Liraglutide or placebo): Change in VLDL2-apoB100 fractional catabolic rates measured from isolated VLDL2 from plasma by ultracentrifugation and measured using mathematical modeling. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (JCI 1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. DOM 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | pools/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 6.7 | 5.6 |
| Placebo | 4.5 | 5.1 |
Before vs after intervention (Liraglutide or placebo): Change in mean production rate of ApoB48 in chylomicrons isolated from plasma samples and measured by multicompartmental modeling assay. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (JCI 1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mg/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 284 | 113 |
| Placebo | 190 | 160 |
Before vs after intervention (Liraglutide or placebo): Change in triglycerides fractional catabolic rates in isolated chylomicrons from plasma samples measured by multicompartmental modeling assay. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (JCI 1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. DOM 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | pools/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 33 | 46 |
| Placebo | 64 | 59 |
Before vs after intervention (Liraglutide or placebo): ApoB48 total production in plasma measured by using multicompartmental modeling. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (JCI 63:1262;1979) and have been widely used over 30yrs. So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 285:562;2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. Diabetes Obes Metab. 23:1191; 2021. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mg/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 490 | 329 |
| Placebo | 570 | 530 |
Before vs after intervention (Liraglutide or placebo): Change in VLDL1 production rates measured from isolated VLDL from plasma samples by ultracentrifugation and measured using mathematical modeling. The power of mathematical modelling to describe the metabolic pathways of lipid and lipoprotein metabolism was demonstrated by Zech L et al (JCI 1979). So far few studies have focused on the modelling of apo B48 and apo B100 after a meal that is more physiological than the fasting state (Björnson E et al. JIM 2019). Production rates for apo B48, apo B100 and triglycerides in chylomicrons, VLDL1 and VLDL2 were derived from samples taken before and after the tracer injection and after the meal at 0, 30, 45, 60, 75, 90,120, 150 min and at 3, 4, 5, 6, 8, 10, 24 hrs and averages for 24 hrs. Analysis of tracer/ tracee curves of stable isotopes was used to derived the estimates of kinetic parameters using a new mathematical modeling per day. Results from Taskinen et al. DOM 2021. (NCT02765399)
Timeframe: Baseline and after16 weeks
| Intervention | g/day (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 51 | 35 |
| Placebo | 43 | 35 |
Before vs after intervention (Liraglutide or placebo): postprandial plasma TG summary measured using the trapezoidal rule and expressed as AUC (at fasting and at 0.5, 1, 2, 3, 4, 6 and 8 hours) after oral fat tolerance test. Results from Matikainen et al. Diabetes Obes Metab 21:84-94; 2019. (NCT02765399)
Timeframe: Baseline and after 16 weeks
| Intervention | mmol/l per h (Mean) | |
|---|---|---|
| Baseline | 16 weeks | |
| Liraglutide | 22.0 | 17.1 |
| Placebo | 17.5 | 19.0 |
The NAFLD Activity Score (NAS) is an underweight sum of steatosis (score 0-3), inflammation (score 0-3), ballooning scores (0-2). The NAS can range from 0-8 with the higher score indicating more aggressive disease. (NCT00650546)
Timeframe: Between baseline and 28 weeks of treatment with exenatide, sub q, 5-10 mcq.
| Intervention | units on a scale (Mean) |
|---|---|
| Individuals Who Recieved Treatment With Exenatide | -1.5 |
Number of patients with liver histology improved with exenatide. The improvement of liver histology was defined as (1) no worsening of the fibrosis score, (11) improved score by at least one point in hepatocyte ballooning, and (111) either (a) improvement in NAS (NAFLD Activity Score) by two points spread across as least two of the three NAS components, or by (B)post-treatment NAS<3. (NCT00650546)
Timeframe: between baseline and 24-28 weeks after initiating treatment
| Intervention | participants (Number) |
|---|---|
| Treatment With Exenatide | 8 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Pioglitazone Group | 1.02 |
| Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
| Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
| Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
| Intervention | % Change (Mean) | |||
|---|---|---|---|---|
| % Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
| Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
| Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
121 reviews available for pioglitazone and Insulin Resistance
| Article | Year |
|---|---|
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metform | 2022 |
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin Re | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.
Topics: Glycated Hemoglobin; Humans; Insulin; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglit | 2022 |
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review.
Topics: Adult; Critical Illness; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone | 2023 |
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Insul | 2023 |
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin Resistance | 2023 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Thiazolidinediones: the Forgotten Diabetes Medications.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitaz | 2019 |
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Live | 2020 |
Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Insuli | 2021 |
Pharmacological approach for drug repositioning against cardiorenal diseases.
Topics: Angiotensin Receptor Antagonists; Cardiovascular Diseases; Drug Repositioning; Humans; Insulin Resis | 2017 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hypergl | 2018 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; I | 2017 |
Updates in Stroke Treatment.
Topics: Acute Disease; Atrial Fibrillation; Brain Ischemia; Glucose Intolerance; Humans; Hypoglycemic Agents | 2018 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
Pathophysiology of Diabetic Dyslipidemia.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Diabetes | 2018 |
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Non-al | 2018 |
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitu | 2019 |
Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insul | 2019 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Topics: Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
Treatment of non-alcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Inflammation; Insulin Resistance; Life Style; Liver Transplantation; M | 2013 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb | 2013 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistanc | 2015 |
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; I | 2016 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; In | 2017 |
PPAR-γ Agonists for the Treatment of Major Depression: A Review.
Topics: Antidepressive Agents; Biomarkers; Blood Glucose; Depressive Disorder, Major; Fasting; Glucose Toler | 2017 |
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Prediabeti | 2017 |
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Edema; Fractures, Bone; Humans; Hypoglycemic Age | 2017 |
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-al | 2017 |
Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.
Topics: Adipose Tissue; Apolipoproteins; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Humans; Hy | 2008 |
[Pioglitazone effects on blood pressure in patients with metabolic syndrome].
Topics: Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Meta-Analys | 2008 |
Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
[Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
Topics: Animals; Arteriosclerosis; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2009 |
[Relationship between insulin resistance and bone metabolism].
Topics: Adipokines; Animals; Bone and Bones; Carbohydrate Metabolism; Fractures, Bone; Humans; Hypoglycemic | 2009 |
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia | 2010 |
Pioglitazone and mechanisms of CV protection.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angi | 2010 |
[Glycemic control and cardiovascular benefit: What do we know today?].
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2010 |
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglyc | 2010 |
[Dementia and insulin resistance in patients with diabetes mellitus].
Topics: Animals; Dementia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Piogl | 2010 |
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistanc | 2010 |
Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2010 |
Pioglitazone: beyond glucose control.
Topics: Adipose Tissue; Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Ty | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Th | 2010 |
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Diseas | 2011 |
Review of approved pioglitazone combinations for type 2 diabetes.
Topics: Anti-Inflammatory Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Human | 2011 |
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.
Topics: Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Pr | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; | 2011 |
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Topics: Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Ins | 2012 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Pioglitazone--where do we stand in India?
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela | 2012 |
Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.
Topics: Androgens; Blood Glucose; Body Weight; Female; Humans; Insulin; Insulin Resistance; Pioglitazone; Po | 2012 |
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcohol | 2013 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; | 2002 |
[Adverse effects of oral hypoglycemic agents].
Topics: Acarbose; Administration, Oral; Biguanides; Cyclohexanes; Drug Interactions; Glycoside Hydrolase Inh | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Ins | 2002 |
[Glitazone--a new drug for type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secreti | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2002 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglyce | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T | 2002 |
[Perspective for development of insulin sensitizers].
Topics: Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic a | 2002 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Anima | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemod | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resi | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
Effects of the thiazolidinediones on cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hypoglyc | 2002 |
Metabolic improvement and abdominal fat redistribution in Werner syndrome by pioglitazone.
Topics: Abdomen; Adipose Tissue; Body Constitution; Female; Glucose; Glucose Tolerance Test; Humans; Hyperli | 2004 |
[Glucose-independent impact of the glitazones on the cardiovascular outcome].
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Thera | 2005 |
[Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Topics: Acarbose; Cyclohexanes; Fasting; Glucose Intolerance; Glycation End Products, Advanced; Humans; Hype | 2005 |
The Clinical Significance of PPAR Gamma Agonism.
Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Melli | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli | 2005 |
Pioglitazone: a review of its use in type 2 diabetes mellitus.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug T | 2006 |
A meta-analysis of the effect of thiazolidinediones on blood pressure.
Topics: Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Hypoglycemic Agents; Insulin Resista | 2006 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D | 2005 |
[PPAR and NASH].
Topics: Acyl-CoA Oxidase; Animals; Cytokines; Fatty Liver; Gene Deletion; Humans; Inflammation Mediators; In | 2006 |
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit | 2006 |
The role of PPARs in the microvascular dysfunction in diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Mi | 2006 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Metformin and pioglitazone: Effectively treating insulin resistance.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; | 2006 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie | 2006 |
[Werner's syndrome].
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemi | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
[Therapy with glitazones--a risk for cardiovascular disease?].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Contraindications; Diabetes Mellitus, Type 2; Dyslipidemi | 2007 |
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Topics: Biomarkers; Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
Vaspin: a novel serpin with insulin-sensitizing effects.
Topics: Adipose Tissue; Animals; Gene Expression Profiling; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2008 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose | 1995 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
[Preclinical studies of pioglitazone (AD-4833)].
Topics: Animals; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Hypoglycemic Agents; Insul | 1997 |
[Clinical efficacy of Pioglitazone (AD-4833)].
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; H | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrola | 1997 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metaboli | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, | 2000 |
[Obesity, insulin resistance and the implication of thiazolidinediones].
Topics: Adipose Tissue; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
[Insulin-sensitizing agents and hypertension].
Topics: Animals; Chromans; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thia | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemi | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimeri | 2001 |
Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Education, Continuing; Female; Humans; Hypoglycemic | 2001 |
[Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Re | 2001 |
Actos (pioglitazone): a new treatment for type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug The | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship | 2001 |
Pioglitazone: mechanism of action.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Nuclear Proteins; Pioglitazone; Rece | 2001 |
[A trend of insulin sensitizer which is under development].
Topics: Animals; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Design; Humans; Hypoglycemic | 2001 |
[Pharmacological effects of a thiazolidinedione derivative, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Insulin | 2001 |
[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, | 2001 |
Current treatment of insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; | 2000 |
New solutions for type 2 diabetes mellitus: the role of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Insulin Resi | 2002 |
[Against insulin resistance. Insulin sensitizers].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin R | 2002 |
New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insuli | 1992 |
182 trials available for pioglitazone and Insulin Resistance
| Article | Year |
|---|---|
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated | 2022 |
Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Extracellular Vesicles; Gene Expression Regulation; Human | 2022 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity.
Topics: Adult; Animals; Cell Line; Clusterin; Disease Models, Animal; Female; Glucose; Glucose Clamp Techniq | 2020 |
Adherence to study drug in a stroke prevention trial"?>.
Topics: Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin Resi | 2020 |
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Exenatide; Female; Glycated Hemoglobin; Gl | 2021 |
Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazo | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
Topics: Cognition; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic At | 2018 |
Taking care of volunteers in a stroke trial: a new assisted-management strategy.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Biomarkers; Blood Coagulation; Blood Pressu | 2016 |
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
Topics: Aged; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistanc | 2017 |
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
Topics: Aged; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, | 2018 |
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
Topics: Aged; Aged, 80 and over; Australia; Double-Blind Method; Europe; Female; Heart Failure; Hospitalizat | 2018 |
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemo | 2019 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Edema; Fema | 2013 |
Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fe | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cyclohexanes; Diabetes Mellitus, Ty | 2013 |
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Human | 2013 |
Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adult; Animals; Disease Models, Animal; Dyslipidemias; Fenofibrate; Humans | 2014 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cross-Ov | 2013 |
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Topics: Adiposity; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Double- | 2013 |
Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.
Topics: Adult; Anti-Inflammatory Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; | 2013 |
Change in serum PEDF level after pioglitazone treatment is independently correlated with that in HOMA-IR.
Topics: Aged; Cardiovascular Diseases; Eye Proteins; Female; Homeostasis; Humans; Hypoglycemic Agents; Insul | 2014 |
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Hepaci | 2014 |
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Topics: Adiponectin; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.
Topics: Adolescent; Adult; Affect; Aged; Bipolar Disorder; Blood Glucose; C-Reactive Protein; Female; Humans | 2014 |
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hy | 2014 |
PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia.
Topics: Biomarkers; C-Reactive Protein; Cross-Over Studies; District of Columbia; Double-Blind Method; Endot | 2014 |
Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Double-Blind Method; E | 2014 |
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Topics: Adiponectin; Adolescent; C-Reactive Protein; Female; Fibrinogen; Hirsutism; Humans; Hyperandrogenism | 2014 |
The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
Topics: Blood Glucose; Body Mass Index; Drug Monitoring; Female; Follow-Up Studies; Glucose Intolerance; Glu | 2014 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination | 2014 |
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
Topics: Adipokines; Adipose Tissue; Adult; Body Composition; Cross-Over Studies; Double-Blind Method; Fastin | 2014 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
Topics: Adult; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; H | 2014 |
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fast | 2015 |
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Toleranc | 2015 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose C | 2015 |
Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.
Topics: Baroreflex; Blood Glucose; Blood Pressure; Carbohydrates; Double-Blind Method; Female; Glucose; Gluc | 2015 |
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
Topics: Adiponectin; Adult; Ceramides; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Res | 2015 |
Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial.
Topics: Adult; Asia, Southeastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Rel | 2015 |
Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Diabetes Mellitus, Type 2; Female; Glucose Intoleran | 2015 |
Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response.
Topics: Adjuvants, Pharmaceutic; Adult; Age Factors; Antidepressive Agents; Blood Glucose; Depressive Disord | 2015 |
Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study.
Topics: Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insu | 2016 |
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insu | 2016 |
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insu | 2016 |
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insu | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2016 |
Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study.
Topics: Blood Glucose; Fasting; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; | 2016 |
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Do | 2016 |
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
Topics: Accidental Falls; Aged; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; I | 2017 |
Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Topics: Acute Coronary Syndrome; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 2017 |
Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
Topics: Adenosine Triphosphate; Adult; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Fem | 2017 |
Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
Topics: Adult; Biopsy; Double-Blind Method; Female; Glucose; Glycogen; Glycogen Synthase; Humans; Hypoglycem | 2008 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; H | 2008 |
Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease.
Topics: Adiponectin; Aged; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Coronary Artery Di | 2008 |
Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-HS-Glycoprotein; Blood Proteins; Diabetes Mellitus, Type 2; Exercise; Exercise Therapy | 2008 |
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2008 |
Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glyc | 2008 |
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
Topics: Adiponectin; Adult; Aged; Benzamides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated | 2008 |
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cyclobutanes | 2008 |
Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.
Topics: Adult; Aged; Hormone Replacement Therapy; Human Growth Hormone; Humans; Insulin; Insulin Resistance; | 2009 |
[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2008 |
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic | 2009 |
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
Topics: Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus; Double-Blind Met | 2009 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double | 2009 |
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Menstr | 2009 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mel | 2009 |
Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brachial Arte | 2009 |
Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combin | 2009 |
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.
Topics: Adipocytes; Adiponectin; Adult; Aged; CD36 Antigens; Cell Line; Coculture Techniques; Down-Regulatio | 2009 |
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycation En | 2010 |
Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia.
Topics: Adipose Tissue; Adrenal Hyperplasia, Congenital; Adult; Blood Pressure; Cross-Over Studies; Female; | 2009 |
Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.
Topics: Adipocytes; Adrenal Hyperplasia, Congenital; Adult; Cross-Over Studies; Glucose Clamp Technique; Hum | 2009 |
Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.
Topics: Adiponectin; Adult; Atherosclerosis; Carotid Arteries; Disease Progression; Female; Glucose Intolera | 2010 |
Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.
Topics: Acarbose; Adipokines; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up | 2009 |
Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chro | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes.
Topics: Age of Onset; Body Fat Distribution; Chromatography, Gel; Chromatography, High Pressure Liquid; Diab | 2010 |
Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Blotting, Western; Body Mass Index; Cells, Cultured; Cocult | 2010 |
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Topics: Analysis of Variance; Blood Pressure; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypo | 2010 |
Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis.
Topics: Adiponectin; Adult; Aged; Anemia; Blood Pressure; C-Reactive Protein; Calcitriol; Diabetes Mellitus, | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2010 |
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adolescent; Adult; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Humans; | 2011 |
Withdrawal of pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Alkaline Phosphatase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch | 2010 |
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; Heart Function | 2010 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.
Topics: Adiposity; Adolescent; Adult; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Female | 2011 |
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2011 |
Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
Topics: Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Mass Index; Drug Ther | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; | 2011 |
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Topics: Administration, Oral; Biomarkers; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; G | 2011 |
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Stu | 2012 |
Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Baroreflex; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insul | 2012 |
Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Topics: Adult; Antiviral Agents; Blood Glucose; Chemical and Drug Induced Liver Injury; Cytokines; Female; G | 2012 |
Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Female | 2012 |
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administratio | 2012 |
Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Drug Therapy, Combination; Gluc | 2012 |
Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
Topics: Adult; Area Under Curve; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Endotheliu | 2013 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up | 2003 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type | 2003 |
Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
Topics: Aged; Blood Glucose; Brain Ischemia; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; In | 2003 |
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Body Con | 2003 |
Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
Topics: Arteriosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; | 2003 |
Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.
Topics: Adipocytes; Adipose Tissue; Adult; Body Composition; Diet, Reducing; Exercise; Female; Humans; Hypog | 2003 |
Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.
Topics: Adult; Case-Control Studies; Dose-Response Relationship, Drug; Estradiol; Female; Follicle Stimulati | 2003 |
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Glucose Tolerance Tes | 2004 |
Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Androst | 2004 |
Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fem | 2004 |
Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypo | 2004 |
Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.
Topics: Aged; Animals; Blood Glucose; Body Weight; Cyclopentanes; Diabetes Mellitus, Type 2; Dietary Fats; D | 2004 |
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; | 2004 |
Pioglitazone reduces blood pressure in non-dipping diabetic patients.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2004 |
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Re | 2004 |
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
Topics: Adult; Double-Blind Method; Female; Glucose Intolerance; Hormones; Humans; Hyperandrogenism; Insulin | 2004 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Body Mass Index; Body Size; Gene Expression Regulati | 2005 |
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, N | 2004 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resis | 2004 |
Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Femal | 2005 |
Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
Topics: Acarbose; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Typ | 2002 |
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide.
Topics: Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Sc | 2005 |
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
Topics: Aged; Cardiovascular Diseases; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Humans; Hypergly | 2005 |
Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hy | 2005 |
Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Chemokin | 2005 |
Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.
Topics: Adiponectin; Aged; Blood Glucose; Blood Pressure; Diastole; Echocardiography; Female; Glucose Tolera | 2005 |
Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
Topics: Absorptiometry, Photon; Adult; Area Under Curve; Body Composition; Cholinesterase Inhibitors; Double | 2005 |
Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Humans; Hypoglycemic Agents; Insulin Resistance; In | 2005 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Atherosclerosis; Biomarkers; Body Weight; Cholesterol, HDL; Cholesterol, L | 2006 |
Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size.
Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Exercise Therapy; Female; Humans; Insulin Resi | 2006 |
Effects of pioglitazone in familial combined hyperlipidaemia.
Topics: Alanine Transaminase; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Humans; Hyperlip | 2006 |
Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension.
Topics: Aged; Area Under Curve; Blood Glucose; Brachial Artery; Endothelium, Vascular; Female; Humans; Hyper | 2005 |
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hispanic or Latino; Hu | 2006 |
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Female | 2006 |
Pioglitazone treatment improves nitrosative stress in type 2 diabetes.
Topics: Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Foot; Glycated Hemoglobi | 2006 |
Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans | 2006 |
Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nones | 2006 |
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.
Topics: Aged; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, | 2006 |
Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Double-Blind Method; Fasting; Female; Glucose Clamp Technique; Hormones; Human | 2006 |
Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.
Topics: Absorptiometry, Photon; Adiponectin; Adult; Body Composition; C-Reactive Protein; Diet, Reducing; Ex | 2006 |
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypo | 2006 |
Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy.
Topics: Adult; Blood Glucose; Body Mass Index; Chi-Square Distribution; Data Interpretation, Statistical; Di | 2006 |
Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administrati | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli | 2006 |
Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hy | 2006 |
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Sche | 2007 |
Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.
Topics: Aged; Atherosclerosis; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucose; Hom | 2007 |
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
Topics: Adiponectin; Cardiovascular Diseases; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglyce | 2007 |
Retinol binding protein-4 levels and clinical features of type 2 diabetes patients.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Age | 2007 |
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Topics: Adiponectin; Aged; Aldosterone; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Fa | 2007 |
Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; | 2007 |
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent | 2007 |
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Topics: Adiponectin; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, | 2007 |
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fatty Acids, Nonesterified; Glycated | 2007 |
Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; | 2007 |
Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hyp | 2008 |
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.
Topics: Antigens, CD; Atherosclerosis; Biomarkers; Blood Glucose; Body Composition; C-Reactive Protein; Dipe | 2008 |
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Topics: Aged; Asian People; Blood Glucose; Case-Control Studies; Demography; Diabetes Mellitus, Type 2; Drug | 2007 |
Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Growth Disorders; Hormon | 2008 |
A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adiponectin; Androsterone; Blood Glucose; Denmark; Etiocholan | 2009 |
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Techniqu | 1997 |
Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Huma | 1998 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Met | 2001 |
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitu | 2002 |
362 other studies available for pioglitazone and Insulin Resistance
| Article | Year |
|---|---|
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
Topics: Animals; Dogs; Half-Life; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Magnetic R | 1996 |
Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists.
Topics: Adipocytes; Adipogenesis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; C | 2006 |
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Bio | 2011 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Tra | 2016 |
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR | 2018 |
TRIB3 Is Highly Expressed in the Adipose Tissue of Obese Patients and Is Associated With Insulin Resistance.
Topics: Adipocytes; Adult; Cell Cycle Proteins; Cells, Cultured; Coculture Techniques; Diabetes Mellitus, Ty | 2022 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag | 2021 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Sub | 2022 |
Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice.
Topics: Animals; Blood Glucose; Diet, High-Fat; Dose-Response Relationship, Drug; Insulin Resistance; Interl | 2022 |
Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.
Topics: Adiponectin; Animals; Cytokines; Diet, High-Fat; Glucose; Insulin Resistance; Interleukin-10; Liver; | 2022 |
Role of insulin resistance and the gut microbiome on urine oxalate excretion in ob/ob mice.
Topics: Animals; Anti-Bacterial Agents; Gastrointestinal Microbiome; Hyperoxaluria; Hyperphagia; Insulin Res | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
Topics: Adiponectin; Adult; Diabetes Mellitus; East Asian People; Female; Humans; Insulin Resistance; Lipody | 2023 |
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.
Topics: Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insu | 2023 |
In Vitro and In Vivo Validation of GATA-3 Suppression for Induction of Adipogenesis and Improving Insulin Sensitivity.
Topics: Adipogenesis; Animals; Antioxidants; Catalase; Diabetes Mellitus, Type 2; DNA, Catalytic; Humans; In | 2022 |
Ameliorative effect of selenium yeast in combination with pioglitazone on diabetes outcomes in streptozotocin-induced.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resist | 2022 |
Anti-diabetic effect of cotreatment with resveratrol and pioglitazone in diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; Li | 2023 |
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
Topics: Animals; Female; Hepatocyte Nuclear Factors; Humans; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin | 2023 |
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Phosphatidate Phosphatase; Piogl | 2023 |
Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity.
Topics: Animals; Cachexia; Hypoglycemic Agents; Insulin; Insulin Resistance; Neoplasms; Pioglitazone; Rats; | 2023 |
Impact of discontinuation of fish oil after pioglitazone-fish oil combination therapy in diabetic KK mice.
Topics: Adiponectin; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Body Weight; Cell Differentiatio | 2020 |
MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2020 |
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Topics: Anti-Inflammatory Agents; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COV | 2020 |
Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diet, High-Fat; Hyperinsuli | 2020 |
Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Body Weight; Catechol O-Methyltransferase; Diet, Hi | 2020 |
Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Huma | 2020 |
Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor.
Topics: Animals; Brassicaceae; Diet, High-Fat; Glucosinolates; Insulin Resistance; Leptin; Liver; Male; NF-E | 2021 |
Are thiazolidinediones a preferred drug treatment for type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pharmaceutical Preparati | 2021 |
Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism.
Topics: Acetanilides; Adipose Tissue, Beige; Drug Synergism; Female; Glucose; Glucose Tolerance Test; Humans | 2021 |
Suppression of Myocardial Hypoxia-Inducible Factor-1α Compromises Metabolic Adaptation and Impairs Cardiac Function in Patients With Cyanotic Congenital Heart Disease During Puberty.
Topics: Animals; Disease Models, Animal; Fatty Acids; Glucose; Glycolysis; Heart Defects, Congenital; Humans | 2021 |
Pioglitazone rescues high-fat diet-induced depression-like phenotypes and hippocampal astrocytic deficits in mice.
Topics: Animals; Anxiety; Astrocytes; Blood Glucose; Depression; Diet, High-Fat; Hippocampus; Hypoglycemic A | 2021 |
The role of pioglitazone in antioxidant, anti-inflammatory, and insulin sensitivity in a high fat-carbohydrate diet-induced rat model of insulin resistance.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carbohydrates; Diabetes Mellitus, Type 2; Diet, Hig | 2021 |
Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues.
Topics: Adipose Tissue; Animals; beta-Arrestin 2; Diet, High-Fat; Disease Models, Animal; Fructose; Hypoglyc | 2021 |
Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Non-alcoholic Fat | 2021 |
Intensive Medical Management to Prevent Large and Small Artery Atherothrombotic Stroke: Time to Expand the Horizon.
Topics: Eicosapentaenoic Acid; Folic Acid; Glucagon-Like Peptide-1 Receptor; Humans; Hyperlipidemias; Hypogl | 2021 |
Synthesis of a novel glibenclamide-pioglitazone hybrid compound and its effects on glucose homeostasis in normal and insulin-resistant rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glyburide; Home | 2021 |
Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; In | 2017 |
Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial.
Topics: Brain Ischemia; Humans; Insulin Resistance; Ischemic Attack, Transient; Pioglitazone; Stroke | 2017 |
Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARγ.
Topics: Adipokines; Animals; CD36 Antigens; Cholesterol; Diet, High-Fat; Endocytosis; Endothelial Cells; Gen | 2017 |
Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.
Topics: Animals; Behavior, Animal; Blood Glucose; Corticosterone; Curcumin; Depression; Disease Models, Anim | 2017 |
Pioglitazone ameliorates Aβ42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3β activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Diet; Glycogen Synthase Kinase 3 beta; Insulin Re | 2017 |
Effects of Lactobacillus casei CCFM419 on insulin resistance and gut microbiota in type 2 diabetic mice.
Topics: Animals; Bacteroides; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2017 |
New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations: Reduction of Acute Coronary Events With Pioglitazone.
Topics: Brain Ischemia; Cardiovascular Diseases; Diabetes Mellitus; Humans; Insulin Resistance; Ischemic Att | 2017 |
The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Topics: Acetophenones; Adipose Tissue; Animals; Anion Transport Proteins; Diet, High-Fat; Hypoglycemic Agent | 2017 |
Long-term rates of mitochondrial protein synthesis are increased in mouse skeletal muscle with high-fat feeding regardless of insulin-sensitizing treatment.
Topics: Animals; Diet, High-Fat; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metab | 2017 |
Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cholesterol; Combined Modality Therapy; Diabetes Mellitus, Experimental; Dia | 2018 |
Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone Hydrochloride?
Topics: Brain Ischemia; Humans; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Piogl | 2017 |
Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
Topics: Brain Ischemia; Diabetes Mellitus; Humans; Insulin Resistance; Ischemic Attack, Transient; Pioglitaz | 2017 |
Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
Topics: Brain Ischemia; Diabetes Mellitus; Humans; Insulin Resistance; Ischemic Attack, Transient; Pioglitaz | 2017 |
Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
Topics: Brain Ischemia; Diabetes Mellitus; Humans; Insulin Resistance; Ischemic Attack, Transient; Pioglitaz | 2017 |
Oral pioglitazone ameliorates fructose-induced peripheral insulin resistance and hippocampal gliosis but not restores inhibited hippocampal adult neurogenesis.
Topics: Administration, Oral; Adult Stem Cells; Animals; Fructose; Gliosis; Hippocampus; Hypoglycemic Agents | 2018 |
Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Gene Deletion; Gene Expression Prof | 2018 |
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; I | 2017 |
Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance.
Topics: Animals; Animals, Genetically Modified; Body Weight; Disease Models, Animal; Female; Hypoglycemic Ag | 2018 |
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
Topics: Adipose Tissue; Amino Acids, Branched-Chain; Animals; Citric Acid Cycle; Diet; Female; Fructose; Hum | 2018 |
Modulation of brain insulin signaling in Alzheimer's disease: New insight on the protective role of green coffee bean extract.
Topics: Alzheimer Disease; Animals; Brain; Coffee; Hippocampus; Insulin; Insulin Resistance; Male; Neuroprot | 2020 |
Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association.
Topics: Anticholesteremic Agents; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; In | 2018 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Early life adversity blunts responses to pioglitazone in depressed, overweight adults.
Topics: Adult; Adverse Childhood Experiences; Antidepressive Agents; Child; Depressive Disorder, Treatment-R | 2019 |
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver | 2019 |
Pioglitazone Ameliorates Atorvastatin-Induced Islet Cell Dysfunction through Activation of FFA1 in INS-1 Cells.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Line; Homeodomain Proteins | 2019 |
Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet.
Topics: Adiponectin; Animals; Diet, High-Fat; Disease Models, Animal; Fibroblast Growth Factors; Gene Knocko | 2019 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted | 2012 |
Pioglitazone ameliorates intracerebral insulin resistance and tau-protein hyperphosphorylation in rats with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycogen Synthas | 2013 |
Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats.
Topics: Analysis of Variance; Animals; Brain Diseases; Fructose; Hyperinsulinism; Insulin; Insulin Resistanc | 2013 |
Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2.
Topics: Clinical Trials as Topic; Computer Simulation; Diabetes Mellitus, Type 2; Homeostasis; Humans; Insul | 2013 |
Streptozotocin diabetes and insulin resistance impairment of spermatogenesis in adult rat testis: central vs. local mechanism.
Topics: Animals; Diabetes Mellitus, Experimental; Infertility, Male; Insulin; Insulin Resistance; Male; Panc | 2012 |
Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Topics: Adipocytes; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 2013 |
Circadian-clock system in mouse liver affected by insulin resistance.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Circadian Rhythm; Diabetes Mellitus, Experime | 2013 |
Effect of a deacyl gymnemic acid on glucose homeostasis & metabolic parameters in a rat model of metabolic syndrome.
Topics: Animals; Blood Glucose; Body Weight; Disease Models, Animal; Female; Fructose; Glucose; Glucose Tole | 2013 |
Pioglitazone does not improve insulin signaling in mice with GH over-expression.
Topics: Animals; Blood Glucose; Disease Models, Animal; Growth Hormone; Hyperinsulinism; Hypoglycemic Agents | 2013 |
Pioglitazone-induced increase in the stearoyl-CoA desaturation index and fat accumulation in rat muscles are not related to lipoprotein lipase activity.
Topics: Adipose Tissue; Administration, Oral; Animals; Fatty Acids; Glucose Intolerance; Glucose Tolerance T | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pr | 2013 |
HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Fasting; Female; Glucose | 2014 |
Assessment of pharmacokinetic interaction of spirulina with glitazone in a type 2 diabetes rat model.
Topics: Animals; Dexamethasone; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, | 2013 |
Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone.
Topics: Adipose Tissue; Animals; Cell Count; Diet, High-Fat; Flow Cytometry; Gene Expression Profiling; Gene | 2013 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; D | 2014 |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expres | 2014 |
Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Diet, High-Fat; Fatty Liver; Gene Expressi | 2014 |
Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 2.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Mal | 2014 |
MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes.
Topics: Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Female; Hepatocyte Nuclear Factor 3-beta; Huma | 2014 |
Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat.
Topics: Adipose Tissue, White; Animals; Benzamides; Carrier Proteins; Diabetes Mellitus, Type 2; Drug Therap | 2014 |
Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Ce | 2014 |
Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Glucose | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.
Topics: Adipocytes; Adipose Tissue; Adult; Elastin; Female; Fish Oils; Humans; Inflammation; Insulin Resista | 2014 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Ca | 2014 |
The endothelial protective effects of pioglitazone on insulin resistance in endothelial cells.
Topics: Apoptosis; Caspase 3; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Enzyme Activation; | 2014 |
Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice.
Topics: Animals; Blood Glucose; Diet, High-Fat; Gene Expression Regulation; Humans; Insulin Resistance; Intr | 2014 |
DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Topics: Adamantane; Animals; Blood Glucose; Cholesterol; Dendritic Spines; Diet, High-Fat; Dipeptidyl-Peptid | 2014 |
L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Topics: 3T3-L1 Cells; Adipose Tissue, White; Animals; Binding, Competitive; Blotting, Western; Cyclin-Depend | 2015 |
Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Weight; | 2015 |
Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats.
Topics: Adipose Tissue; Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Hypoglycemic Agents; I | 2015 |
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Topics: Alanine Transaminase; Aldehydes; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Body We | 2015 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty A | 2015 |
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
Topics: 3-Mercaptopropionic Acid; Animals; Blood Glucose; Cell Line; Cell Survival; Diabetes Mellitus, Exper | 2015 |
Mitoflash altered by metabolic stress in insulin-resistant skeletal muscle.
Topics: Animals; Bacterial Proteins; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Lumine | 2015 |
Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys.
Topics: Animals; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Macaca mulatta; Male; Obesity; Pi | 2015 |
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.
Topics: Animals; Bombyx; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Drug Evaluation, | 2015 |
[Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
Topics: Caloric Restriction; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistance; Lamin Type | 2015 |
Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARδ, PPARγ, and RXR.
Topics: Acrolein; Adipocytes; Cinnamomum zeylanicum; Drug Synergism; Energy Metabolism; Fatty Acids; Gene Ex | 2015 |
MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation.
Topics: 3' Untranslated Regions; Adipocytes; Animals; Bone Marrow; Chromatin Immunoprecipitation; Diet, High | 2015 |
4-Hydroxyisoleucine ameliorates an insulin resistant-like state in 3T3-L1 adipocytes by regulating TACE/TIMP3 expression.
Topics: 3T3-L1 Cells; ADAM Proteins; ADAM17 Protein; Adipocytes; Animals; Deoxyglucose; Dose-Response Relati | 2015 |
Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Topics: Animals; Diet, High-Fat; Fatty Liver; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents | 2016 |
Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
Topics: Actins; Adipocytes, White; Adipose Tissue, White; Adiposity; Animals; Anti-Infective Agents; Cell Pr | 2016 |
Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Causality; Diabetes Mellitus, Type 2; Dietary Fat | 2016 |
PPARγ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Composition; Cell Proliferation; Cell Size; | 2016 |
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Insulin; I | 2016 |
Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabeti | 2016 |
The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone.
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Multicenter Studies as | 2016 |
Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Female; Glucose Tolerance | 2016 |
Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning?
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Prediabetic State; Stroke | 2016 |
Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Drug Therapy, Combination; Fructose; Hypoglycemic | 2016 |
Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
Topics: Adipocytes; Adipose Tissue; Animals; Animals, Genetically Modified; Blood Glucose; Body Composition; | 2016 |
Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.
Topics: Amyloid beta-Peptides; Animals; Cognition; Down-Regulation; Drug Therapy, Combination; Exenatide; Fr | 2016 |
Effect of pioglitazone on metabolic features in endotoxemia model in obese diabetic db/db mice.
Topics: Adipogenesis; Adipose Tissue, White; Animals; Blood Glucose; Diabetes Mellitus; Endotoxemia; Female; | 2017 |
[Is Pioglitazone blessing or curse?].
Topics: Anemia; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Th | 2016 |
Protective effects of fish oil and pioglitazone on pancreatic tissue in obese KK mice with type 2 diabetes.
Topics: Animals; Apoptosis; Cytokines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy | 2016 |
Pioglitazone improves insulin sensitivity and reduces weight loss in Walker-256 tumor-bearing rats.
Topics: Animals; Cachexia; Insulin Resistance; Male; Pioglitazone; Rats; Rats, Wistar; Thiazolidinediones; W | 2017 |
Appropriate Insulin Level in Selecting Fortified Diet-Fed, Streptozotocin-Treated Rat Model of Type 2 Diabetes for Anti-Diabetic Studies.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dis | 2017 |
Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Hypoglyc | 2017 |
Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cholesterol, H | 2017 |
Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.
Topics: Adiponectin; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mitoch | 2008 |
Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers.
Topics: Alanine Transaminase; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; E-Sel | 2008 |
Fatty acid metabolism in patients with PPARgamma mutations.
Topics: Adipose Tissue; Adult; Amino Acid Substitution; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, | 2008 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fa | 2008 |
The effects of hydroxycinnamic acid derivatives on adiponectin secretion.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Caffeic Acids; Coumaric Acids; Curcumin; Diabetes Me | 2009 |
The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Diabetes Mellitus, Type 2; Enzyme-Lin | 2008 |
Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
Topics: Adolescent; Cabergoline; Conduct Disorder; Dopamine Agonists; Drug Therapy, Combination; Ergolines; | 2008 |
[Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance].
Topics: Adipose Tissue; Animals; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice | 2008 |
Effect of Tectona grandis Linn. on dexamethasone-induced insulin resistance in mice.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Dexamethasone; Diabetes Mellitus, Type 2; Diaphra | 2009 |
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Topics: Abdominal Fat; Adiposity; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fenofibrate; H | 2009 |
Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
Topics: Acanthosis Nigricans; Adolescent; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; | 2008 |
Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice.
Topics: Adipokines; Animals; Blood Glucose; Diabetes Complications; Hepatectomy; Hypoglycemic Agents; Insuli | 2009 |
Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Fem | 2009 |
Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
Topics: Adipose Tissue; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
Topics: Adult; Antiviral Agents; Chemotherapy, Adjuvant; Drug Administration Schedule; Hepatitis C, Chronic; | 2009 |
Pioglitazone: more than just an insulin sensitizer.
Topics: Animals; Fatty Liver; Hepatectomy; Hypoglycemic Agents; Insulin Resistance; Liver Regeneration; Obes | 2009 |
Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers.
Topics: Cardiovascular Diseases; Cholesterol; Fasting; Female; Humans; Hypertriglyceridemia; Hypoglycemic Ag | 2009 |
A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Homeostasis; Hom | 2009 |
Evidence against a direct role of klotho in insulin resistance.
Topics: Animals; Cell Line; Dietary Fats; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expre | 2010 |
Pioglitazone reduces ER stress in the liver: direct monitoring of in vivo ER stress using ER stress-activated indicator transgenic mice.
Topics: Adiponectin; Adipose Tissue; Animals; Cell Size; Diabetes Mellitus, Experimental; DNA-Binding Protei | 2009 |
Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI.
Topics: Adipocytes; Adult; Alleles; Asian People; Body Mass Index; Cell Line; Cells, Cultured; Chi-Square Di | 2010 |
Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibrosis; Hypoglycemic A | 2009 |
Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Diet, Atherogenic; Dietary Fats; Hypoglycem | 2009 |
Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue.
Topics: Adipogenesis; Adult; Aged; Blood Glucose; Cell Count; Cell Size; Humans; Hypoglycemic Agents; Insuli | 2010 |
Long-term pioglitazone treatment augments insulin sensitivity and PKC-epsilon and PKC-theta activation in skeletal muscles in sucrose fed rats.
Topics: Animals; Animals, Congenic; Blood Glucose; CD36 Antigens; Dietary Sucrose; Disease Models, Animal; G | 2010 |
Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation.
Topics: Animals; Brain; Drinking; Fructose; Gene Expression Regulation, Enzymologic; Glycation End Products, | 2010 |
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
Topics: Acyl Coenzyme A; Adult; Aged; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Digly | 2010 |
Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome.
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrom | 2010 |
Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats.
Topics: Animals; Curcumin; Dietary Carbohydrates; Extracellular Signal-Regulated MAP Kinases; Fatty Liver; F | 2010 |
Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation.
Topics: Administration, Oral; Animals; Cholesterol, Dietary; Dietary Carbohydrates; Disease Models, Animal; | 2010 |
Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Glucose Tolerance Test; Hypertension; Hypoglycemic Ag | 2010 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitu | 2010 |
Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with α-glucosidase inhibitor.
Topics: Action Potentials; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase | 2010 |
S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats.
Topics: Animals; Cell Line; Glucose; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Ag | 2010 |
Generation, validation and humanisation of a novel insulin resistant cell model.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; | 2010 |
Antidiabetic effects of total flavonoids from Litsea Coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Antioxidants; Body Weight; C-Reactive Protein; Diabetes Mellitus, Experimental; Dietary Fat | 2010 |
Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation.
Topics: Animals; Hepatitis; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance | 2010 |
Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
Topics: Body Mass Index; Cell Respiration; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; H | 2010 |
Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
Topics: Adult; Aged; Body Mass Index; Body Weight; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyc | 2010 |
Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia.
Topics: Animals; Apoptosis; Castration; Cell Proliferation; Dietary Fats; Disease Models, Animal; Glucose To | 2010 |
Improvement of psoriatic arthritis by pioglitazone treatment in a type 2 diabetic patient.
Topics: Arthritis, Psoriatic; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hu | 2010 |
Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study.
Topics: Blood Flow Velocity; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dias | 2010 |
Insulin resistance secondary to a high-fat diet stimulates longitudinal bone growth and growth plate chondrogenesis in mice.
Topics: Animals; Blotting, Western; Bone Development; Cell Differentiation; Cell Proliferation; Cells, Cultu | 2011 |
Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Adipose Tissue; Bicycling; Body Mass Index; Female; Hu | 2011 |
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Dipeptidyl-Peptida | 2011 |
Insulin resistance is not conserved in myotubes established from women with PCOS.
Topics: Adult; Cell Differentiation; Female; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agent | 2010 |
Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue, White; Animals; Apolipoproteins E; Atheroscle | 2011 |
Angelica acutiloba root attenuates insulin resistance induced by high-fructose diet in rats.
Topics: Angelica; Animals; Body Weight; Fructose; Glucose Tolerance Test; Glucose Transporter Type 4; Glycog | 2011 |
The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice.
Topics: Alleles; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; Diabetes | 2011 |
The effects of an arabinogalactan-protein from the white-skinned sweet potato (Ipomoea batatas L.) on blood glucose in spontaneous diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Female; Glucose Tolerance Test; H | 2011 |
Insulin sensitizers in nonalcoholic steatohepatitis.
Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Non | 2011 |
Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; AMP-Activated Protein Kinases; Animals; Deoxyglucose; Hypoglycemic Agents; | 2011 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |
Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Topics: Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Down-Regulation; Drinking; Fructose; | 2011 |
Ocular blood flow analysis detects microvascular abnormalities in impaired glucose tolerance.
Topics: Adult; Aged; Blood Glucose; Eye; Fasting; Female; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2011 |
Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglyce | 2011 |
Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Topics: Animals; Blood Vessels; Disease Models, Animal; Disease Progression; Dyslipidemias; Hyperinsulinism; | 2011 |
Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Topics: Adiponectin; Adipose Tissue; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bip | 2011 |
Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance.
Topics: Cholesterol, HDL; Coronary Artery Disease; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglita | 2011 |
Cinnamaldehyde protects from the hypertension associated with diabetes.
Topics: Acetylcholinesterase; Acrolein; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cal | 2011 |
Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gene Frequency; Genotype; Humans; Hypo | 2011 |
The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats.
Topics: Adiponectin; Animals; Body Mass Index; Insulin; Insulin Resistance; Male; Pioglitazone; PPAR gamma; | 2012 |
Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Anthropometry; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Ge | 2012 |
PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue.
Topics: 3T3-L1 Cells; Adipokines; Adipose Tissue; Animals; Dexamethasone; Diet, High-Fat; Granulins; Insulin | 2012 |
Which is the eligible patient to be treated with pioglitazone? The expert view.
Topics: Algorithms; Animals; Atherosclerosis; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Type 2; | 2011 |
Beneficial impact of Zingiber zerumbet on insulin sensitivity in fructose-fed rats.
Topics: Animals; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Plant Extracts; Rats | 2012 |
Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Topics: Adolescent; Adult; Aged; Female; Fenofibrate; Genome-Wide Association Study; Glucose; Humans; Hypogl | 2012 |
NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile.
Topics: Adipocytes; Adipogenesis; Animals; Body Weight; Glucose Tolerance Test; Insulin Resistance; Male; Me | 2012 |
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Topics: 3T3-L1 Cells; Animals; Binding, Competitive; Cells, Cultured; Female; Gene Expression; Glycolysis; H | 2012 |
Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system.
Topics: Anhedonia; Animals; Antidepressive Agents; Arcuate Nucleus of Hypothalamus; Chronic Disease; Cortico | 2013 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
Pioglitazone safe, so save.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2012 |
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells.
Topics: Adipose Tissue; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Epididymis; Forkhead Trans | 2012 |
Therapeutic effects of hydrogen saturated saline on rat diabetic model and insulin resistant model via reduction of oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Hydrogen; Hypoglycemic Agents; Insulin Resistance; Oxidati | 2012 |
A study on the short-term effect of cafeteria diet and pioglitazone on insulin resistance and serum levels of adiponectin and ghrelin.
Topics: Adiponectin; Animals; Body Weight; Dietary Carbohydrates; Dietary Fats; Energy Intake; Ghrelin; Insu | 2012 |
Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Grifola; Hypog | 2012 |
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subu | 2012 |
The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance.
Topics: Adiponectin; Adipose Tissue; Animals; Cerebrosides; Diet, High-Fat; Gene Expression; Gene Knockdown | 2012 |
Improvement of insulin sensitivity promotes extravillous trophoblast cell migration stimulated by insulin-like growth factor-I.
Topics: Cell Movement; Cells, Cultured; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2013 |
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Melli | 2013 |
Syndrome of extreme insulin resistance (Rabson-Mendenhall phenotype) with atrial septal defect: clinical presentation and treatment outcomes.
Topics: Adolescent; Donohue Syndrome; Female; Heart Septal Defects, Atrial; Humans; Hypoglycemic Agents; Ins | 2013 |
Hepatic steatosis with relation to increased expression of peroxisome proliferator-activated receptor-γ in insulin resistant mice.
Topics: Animals; Fatty Liver; Gene Expression; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistan | 2013 |
Gender differences in non-glycemic responses to improved insulin sensitivity by pioglitazone treatment in patients with type 2 diabetes.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hydrocortisone; Hypogly | 2014 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans | 2002 |
Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Topics: Acyl Coenzyme A; Adiponectin; Animals; Blood Glucose; Fat Emulsions, Intravenous; Fatty Acids, Nones | 2002 |
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deo | 2003 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Tes | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug T | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids | 2003 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; | 2003 |
[Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
Topics: Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Thera | 2003 |
A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Cells, Cultured; Glucose; Glucose Tolerance Test; Insulin; I | 2003 |
[Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
Topics: Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; H | 2003 |
[Insulin sensitizer improves lipid profile. Infarct prevention for type 2 diabetic patients?].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agent | 2002 |
[Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Drug Therapy, Combination; Germany; | 2003 |
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Topics: Adiponectin; Adipose Tissue; Blood Glucose; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Ty | 2004 |
Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Hormones, Ect | 2004 |
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Insulin Resistan | 2004 |
Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.
Topics: Aldehydes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucose; Heme Oxygenase (Decycli | 2004 |
Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
Topics: Adiponectin; Albumins; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agents; Infu | 2004 |
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch | 2004 |
Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Homeostasis; Humans; | 2004 |
Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Topics: Animals; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fenofibrate; Glycogen; Hypoglycemic Agent | 2004 |
Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients.
Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Human | 2004 |
Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
Topics: Animals; Benzimidazoles; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Hypoglycemic A | 2004 |
Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Piogli | 2004 |
Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans | 2003 |
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Topics: Adiponectin; Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Binding Proteins; | 2004 |
[Ameliorations of pioglitazone on insulin resistance in spontaneous IGT-OLETF rats].
Topics: Animals; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
[Warning signals insulin resistance. Insulin resistance causes not only diabetes].
Topics: Adolescent; Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Human | 2004 |
Pioglitazone treatment of insulin resistance in a patient with Werner's syndrome.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Middle Aged; Pioglitazone; T | 2004 |
[Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glyc | 2003 |
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, N | 2004 |
Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity.
Topics: Acromegaly; Adiponectin; Adult; Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Human | 2005 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy | 2005 |
Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Anti-Inflammatory Agents; C-Reactive Protein; Cell Size; Dose-Respon | 2005 |
[The impact of pioglitazone on plasma homocysteine high-fat diet-induced insulin resistance in rats].
Topics: Animals; Blood Glucose; Dietary Fats; Homocysteine; Hypoglycemic Agents; Insulin Resistance; Male; P | 2005 |
[Effect of pioglitazone, one of TZDs, on IGT-patients].
Topics: Adiponectin; Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gene Expression; | 2005 |
Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; Diabetes Mellitus, Type | 2005 |
Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Cholesterol, HDL; Dietary Fats; Female; Glucose Tr | 2005 |
Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.
Topics: Administration, Oral; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Hyperlipidemias; Hypoglyc | 2005 |
PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose.
Topics: Cell Culture Techniques; Cell Proliferation; Fibrosis; Glucose; Humans; Hyperglycemia; Hypoglycemic | 2005 |
[Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mid | 2005 |
Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity.
Topics: Adipocytes; Age Factors; Amino Acid Sequence; Animals; Base Sequence; Blood Glucose; Blotting, North | 2005 |
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Gluc | 2005 |
[In vitro study of the effects of pioglitazone on endothelial cell functions of human umbilical vein and the mechanisms involved].
Topics: Apoptosis; Cells, Cultured; Endothelium, Vascular; Glucose; Humans; Hypoglycemic Agents; Insulin Res | 2005 |
Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin.
Topics: Blood Glucose; Central Nervous System Cysts; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2005 |
Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance.
Topics: Animals; Carotid Arteries; Disease Models, Animal; Drug Evaluation, Preclinical; Glipizide; Insulin | 2005 |
[PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].
Topics: Albuminuria; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Glucose; Humans; Hypoglycemic | 2005 |
Commentary: the PROactive study--the glass is half full.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Hum | 2006 |
Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Midd | 2005 |
Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin.
Topics: Adiponectin; Animals; Drug Interactions; Fatty Acids, Nonesterified; Heparin; Insulin; Insulin Resis | 2006 |
Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
Topics: Adiponectin; Animals; Blood Glucose; Blotting, Western; Crosses, Genetic; Diabetes Mellitus; Dose-Re | 2006 |
Lipid metabolism.
Topics: Insulin Resistance; Lipid Metabolism; Lipid Mobilization; Pioglitazone; Receptors, Scavenger; Thiazo | 2006 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type | 2006 |
Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
Topics: Animals; Antioxidants; Aorta; Blood Pressure; Cells, Cultured; Gene Expression Regulation; Glucose; | 2006 |
Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
Topics: Adipose Tissue; Administration, Sublingual; Adult; Aged; Biomarkers; Blood Glucose; Brachial Artery; | 2006 |
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Benzimidazoles; Cell Differenti | 2006 |
Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Ghrelin; Glycated Hemoglobin; Humans; I | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combinatio | 2006 |
The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
Topics: Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Diet; Dose-Response Relationshi | 2006 |
Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Fatty Liver; Insul | 2006 |
Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 2; Fever; Glucose Tolerance Test; Glyburide; HSP | 2006 |
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Body Composition; Body Mass Index; Body Weight; Female; Glucose Tolerance Test; He | 2006 |
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Animals; Diacylglycerol O-Acyltransferase; Fatty Acid Synth | 2006 |
The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; C-Reactive Protein; Cross-Sectional Studie | 2006 |
A patient with extreme insulin resistance syndrome treated with pioglitazone.
Topics: Adolescent; Female; Gene Deletion; Humans; Insulin Resistance; Metabolic Syndrome; Pioglitazone; Rec | 2006 |
Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation.
Topics: Adipose Tissue; Adult; Aged; Female; Glucose Intolerance; Humans; Insulin Resistance; Male; Middle A | 2006 |
Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypogl | 2007 |
Pioglitazone increases gallbladder volume in insulin-resistant obese mice.
Topics: Acetylcholine; Age Factors; Animals; Blood Glucose; Cholecystokinin; Cholinergic Agents; Dietary Car | 2006 |
Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
Topics: Adiponectin; Ceramides; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Gluc | 2007 |
Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.
Topics: Animals; Blood Glucose; Disease Models, Animal; Fatty Liver; Female; Hepatitis, Chronic; Hypoglycemi | 2007 |
Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Glucose; Humans; Insulin; Insu | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats.
Topics: Animals; Endothelium, Vascular; Female; Hyperplasia; Hypoglycemic Agents; Insulin Resistance; Piogli | 2007 |
[Metabolic and hemodynamic effects of pioglitazone in obese patients with type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal | 2006 |
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Topics: Animal Feed; Animals; Choline; Collagen Type I; Collagen Type I, alpha 1 Chain; Diabetes Mellitus, T | 2007 |
Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles.
Topics: Amidohydrolases; Animals; Ceramidases; Ceramides; Dietary Fats; Fatty Acids; Hypoglycemic Agents; In | 2006 |
Impacts of long-term treatments with testosterone replacement and pioglitazone on glucose and lipid metabolism in male patients with Werner's syndrome.
Topics: Adult; Blood Glucose; Drug Therapy, Combination; Glucose; Hormone Replacement Therapy; Humans; Insul | 2007 |
Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Diabetes Mellitus; Dietary Fats; Epi | 2007 |
Pioglitazone in nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; H | 2007 |
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose | 2007 |
Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipocytes, White; Adipose Tissue; Administration, Oral; Animals; Benzimidazoles; | 2007 |
Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders?
Topics: Animals; Gene Expression; Hyperinsulinism; Insulin; Insulin Receptor Substrate Proteins; Insulin Res | 2007 |
Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats.
Topics: Acyl-CoA Oxidase; Animals; Blood Glucose; Fatty Acids; Gene Expression; Glucose Tolerance Test; Hypo | 2007 |
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis | 2007 |
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis | 2007 |
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis | 2007 |
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Female; Humans; Insulin Resis | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2007 |
Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol; Enzyme | 2007 |
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Topics: Abdominal Fat; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fe | 2007 |
Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exenatide; HIV Infections; Humans; Hypo | 2007 |
[The relationship between islet alpha cell insulin resistance and inflammatory pathway activation and its mechanism].
Topics: Animals; Fatty Acids, Nonesterified; Glucagon; Hypoglycemic Agents; Inflammation; Insulin; Insulin R | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance.
Topics: Animals; C-Peptide; Cell Line; Cell Movement; Chemotaxis, Leukocyte; Diet; Dietary Fats; Endothelium | 2008 |
[The mechanism of and relationship between lipid metabolism genes expression and insulin resistance in high fat-fed mice].
Topics: Acetyltransferases; Animals; Blood Glucose; Carnitine O-Palmitoyltransferase; Dietary Fats; Gene Exp | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate | 2007 |
Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone.
Topics: Biomarkers; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Male; | 2008 |
Effect of a polyphenol-rich extract from Aloe vera gel on experimentally induced insulin resistance in mice.
Topics: Aloe; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Eating; Flavonoids; Hypoglycemic | 2007 |
The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Techni | 2008 |
Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia.
Topics: Administration, Oral; Angiotensin II; Animals; Blood Glucose; Blood Pressure; Chronic Disease; Disea | 2008 |
High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects.
Topics: Adipose Tissue; Body Composition; Carrier Proteins; Diabetes Mellitus, Type 2; Female; Humans; Hypog | 2008 |
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Topics: Animals; Cells, Cultured; Chemokine CCL2; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Neph | 2008 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Melli | 2008 |
Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes.
Topics: Adipose Tissue; Animals; C-Peptide; Diabetes Mellitus, Experimental; Fatty Acids, Nonesterified; Glu | 2008 |
Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Topics: Adipokines; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Fe | 2008 |
Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.
Topics: Aminoisobutyric Acids; Animals; Biological Transport; Blotting, Western; Cell Line; Cytosol; Glucose | 1995 |
Polyunsaturated fatty acid-mediated suppression of insulin-dependent gene expression of lipogenic enzymes in rat liver.
Topics: Acetyl-CoA Carboxylase; Animals; ATP Citrate (pro-S)-Lyase; Corn Oil; Diabetes Mellitus, Experimenta | 1995 |
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
Topics: Aging; Amino Acids; Animals; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Hypoglycemi | 1995 |
Pioglitazone attenuates diet-induced hypertension in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Diet; Dietary Carbohydrates; Dietary Fats; Hypertension; Ins | 1995 |
Insulin sensitization in diabetic rat liver by an antihyperglycemic agent.
Topics: Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Gene Expression; Glucoki | 1995 |
Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats.
Topics: Animals; Chromans; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose; Gluco | 1993 |
Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol.
Topics: Animals; Blood; Diglycerides; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Liver; Male | 1994 |
Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gene Expression; Hypoglycemic Agents; | 1994 |
Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Eating; Fasting; Feeding Behavior; Female; Gluc | 1994 |
Pioglitazone inhibits the diabetogenic action of growth hormone, but not its ability to promote growth.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Feeding Behavior; Female; Growth Hormone; H | 1994 |
Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Electrophoresis, Polyacrylamide Gel; Hypoglycemic | 1993 |
Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity.
Topics: Animals; Cell Membrane; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; M | 1993 |
Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle.
Topics: Animals; Benzopyrans; Blood Glucose; Deoxyglucose; Dexamethasone; Glucocorticoids; Glucose Transport | 1993 |
Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone.
Topics: Adipose Tissue; Animals; Blood Glucose; Blood Pressure; Dietary Carbohydrates; Dietary Fats; Hyperin | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 1997 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1997 |
Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Catecholamines; Dietary | 1997 |
KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production.
Topics: Animals; Blood Glucose; Body Weight; Glycine; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Insuli | 1997 |
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.
Topics: Adipocytes; Animals; Body Weight; Cell Differentiation; Fatty Acid Synthases; Female; Gene Expressio | 1997 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 1997 |
Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats.
Topics: Animals; Blood Glucose; Blood Pressure; Disease Models, Animal; Drinking; Fructose; Hypertension; Hy | 1997 |
Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat.
Topics: Acetylcholine; Adipocytes; Animals; Blood Pressure; Fructose; Glucose; Insulin; Insulin Resistance; | 1997 |
Pioglitazone-reduced insulin resistance in patient with Werner syndrome.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thi | 1997 |
Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Imm | 1998 |
Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Hypoglycemic Agents; Hypolipidemic Agents; Insuli | 1999 |
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue; Animals; Blood Glucose; Cyclic Nucleotide Phosp | 1999 |
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cell Differentiation; Cell Size; Diet; Eating; Ener | 1999 |
Thiazolidinediones exert different effects on insulin resistance between dexamethasone-treated rats and wistar fatty rats.
Topics: Animals; Chromans; Dexamethasone; Drug Combinations; Glucocorticoids; Glucose; Glucose Clamp Techniq | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitaz | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2000 |
[30-year-old diabetic patients mostly have type 2 diabetes. "Mature" diabetics are becoming increasingly younger].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pio | 2001 |
Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
Topics: Administration, Oral; Blood Glucose; Chromans; Dexamethasone; Glucose Tolerance Test; Humans; Hypogl | 2001 |
Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Deoxyglucose; Humans; Hypoglycemic | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric | 2001 |
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
Topics: Adipocytes; Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Cell Division; Cell Size; | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitaz | 2001 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic | 2002 |
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; | 2002 |
Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertriglyceridemia; Hypoglycemic Age | 2002 |
Comparison of the extrapancreatic action of BRX-220 and pioglitazone in the high-fat diet-induced insulin resistance.
Topics: Animals; Dietary Fats; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Muscle, | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |
Pioglitazone increases insulin sensitivity by activating insulin receptor kinase.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrophoresis, Po | 1992 |
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resista | 1992 |
Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
Topics: Animals; Crosses, Genetic; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Hypoglycemic | 1992 |
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Te | 1990 |
Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Topics: Animals; Blood Glucose; Body Weight; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance | 1990 |
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Dogs; Glucose; Glucose Tolerance Test; Hyp | 1990 |